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Macrocycles are attractive scaffolds for the development of new bioactive 
compounds. Central to this behavior is the shape of a macrocycle; it is a fundamental 
parameter that makes a macrocycle able to bind its target. This thesis is geared at 
understanding the factors that dictate the shape and topology of macrocycles, 
especially the relationship between the configuration of individual stereogenic centers 
and planar chirality. We previously evaluated stereogenic centers associated with the 
ester units, both on the chain attached to the ester oxygen and the carbon α - to the 
carbonyl. Here we evaluate using X-ray crystallography the consequences of 
substitution at the positions allylic to the E-alkene.  
Acinetobacter baumanni, one of the ESKAPE multi drug resistant pathogens, is 
responsible for the rising outbreak infections in hospital settings around the world. Pre-
acinetobactin is one of the siderophores that A.baumannii produces during iron 
deficiency. It is a mixed siderophore containing a catecholate and hydroxamate moiety. 
It is unique and unlike many other siderophores, in that it can isomerize to acinetobactin 
when pH levels change, allowing it to be a more versatile iron chelator and in turn be 
transported down the BauA pathway. The overall goal of this project is to synthesize 
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pre-acinetobactin analogs that link the siderophore and a warhead through a covalent 
linker. We posit that the analogs will inhibit A. baumanii bacterial cells, thus killing the 
bacteria. 
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Part I: 
Chapter 1  
Origin, Context, and Features of [13]-Macrodilactones 
1  
1.1 Origin of Macrocycles and their impact on biological processes 
 
There are a plethora of types of small molecules, all of which come in various 
shapes and sizes. Cyclic, acyclic and aromatic are some types, to name but a few. 
Different types of molecules, such as porphyrins, crown ethers, and amino acids have 
particular properties that make them unique and also enable them to perform a certain 
function. For instance, therapeutic drugs have their own distinct characteristics that 
enable them to be effective medicines. Following Lipinski’s “rule of 5”, many drugs tend 
to have a molecular weight less than 500, fewer than 5 H-bond donors, a log P that is 
≤5, and fewer than 10 H-bond acceptors.1 One class of molecules in particular that 
tends to have activity and is frequently put on the drug market but go beyond the limits 
of the rule of 5 are macrocycles.1–3 Macrocycles are molecules containing at least one 
large ring of 12 or more atoms.2,4 They are a class of compounds that play a major role 
in medicinal chemistry, material science, and chemical biology.5,6 Due to their particular 
shapes and sizes, many macrocycles have the potential to affect biological systems.7 
There are many well-known natural product macrocycles that demonstrate antifungal, 
anticancer and antibiotic activities.6 Examples of such macrocyclic natural products 
include rapamycin (1), epothilone B (2), amphotericin (3), and erythromycin (4) (Figure 
1.1).6 Due to the beneficial characteristics of these compounds, there is a high interest 
in understanding macrocycles and developing analogs. 
 2 
There are various trends that macrocyclic natural products tend to follow. Ring size, 
number of isolated double bonds, and heteroatoms are among some of them. Most 
natural products contain 13 or more covalently connected atoms in a ring. In general, as 
the ring size increases, the number of natural compounds decreases. According to 
Wessjohann et al, fourteen-membered ring macrocycles are the most abundant in 
nature (based off the analysis of the 132,522 compounds that are in the Beilstein 
database), followed by 13-, 16-, 18-, 19-, 21-, 24-, and 25-membered rings 
respectively.8 A majority of natural 14 membered rings are made up of only carbon with 
no heteroatoms followed by some that contain oxygen atoms. Thirteen membered rings 
are also among the abundant natural products but the majority of rings contain oxygen 
atoms while only few contain only carbon. Both thirteen and fourteen membered rings 
have the highest number of isolated double bonds. These trends for natural product 
macrocyles informed and inspired our investigation for new macrocycle design. 8  
 3 
 
Figure 1.1 Macrocyclic natural products 
Many of the trends in macrocycle are based on chemical databases that collect 
information on various natural products.8 However, they tend to be biased and 
overrepresent many types of compounds based on importance and history. 
Erythromycin is a well-known antibiotic drug and therefore, a lot of research is done on 
related macrocyclic analogs. On the other hand, there are not many well-known drugs 
that are 13 membered and are thus less studied. Although it is important to follow the 
trends of popular natural products in the databases (such as erythromycin and other 14 
membered rings), it is also important to investigate other less popular macrocyclic 
natural products. 
The shape of a macrocycle plays an important role in its biological activity.6 Activity 
depends on how well the molecule is able to interact with its target protein; in turn, if it is 
able to bind to a particular site depends on the shape. Figure 1.2 illustrates how the 
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correct shape is an important part of binding. The square will fit into a square-shaped 
concave surface, but the same surface will not fit a triangle properly. This concept is 
illustrated by the mechanisms of action of rapamycin and erythromycin. Rapamycin is 
an immunosuppressant for organ transplant patients. Its shape allowed it to 
concurrently bind to two different proteins (FKBP and mTOR(FRB) enabling them to 
come together.9 Erythromycin is a macrolide antibiotic that is used for treatment of 
upper/lower respiratory tract infections, skin infections, and acute pelvic inflammatory 
disease. It works by binding reversibly to the 50s subunit of the bacterial ribosome.10 
However, it does not inhibit protein translation like many macrocycles by binding in the 
protein translation center, but instead inhibits protein elongation by provoking 
dissociation of the peptidyl-tRNAs from the ribosome Erythromycin binds at the 
entrance of the exit tunnel (away from the protein translation center), constricting the 
space accessible to the tunnel and therefore blocking the elongation or growth of the 
peptide.11 Its shape allowed it to fit and block the tunnel. 
 
 
 
Figure 1.2 Comparison of A and B; how shape determines if binding is possible9 
+
+
A.
B.
 5 
1.2 Sigma Elements  
Understanding sigma elements is important in macrocycle research, especially 
when trying to learn more about what drives the overall topology. Differences in 
topology (molecular structure) can influence the way macrocycles interact with 
biomacromolecules.12 In 2003, some interesting reports from the Schreiber group13 
showed that a single stereocenter on a macromolecule dictates which reaction pathway 
a starting material will follow and ultimately what molecular shape it will take up (Figure 
1.3). These key atoms, which are typically stereogenic centers, are, also known as 
sigma elements. Sigma elements determine how a molecule will fold from its acyclic 
precursor.7,13 They pre-encode information into the molecular skeleton, dictating the 
reaction pathway it will take. The stereochemistry, and not the type of substituent 
dictates the course and determines the outcome of the reaction.14 Understanding sigma 
elements is important in macrocycle research because they pre-determine the shape 
that the acyclic structure will take on when the cyclic structure is formed. 
 
Figure 1.3 Sigma elements producing skeletal diversity down to two different reaction pathways 
(Reprinted with permission from Sello, J.K.; Andreana, P.R.; Lee, D.; Schreiber, S. L. Org. Lett. 
2003, 5, 4125-4127. 2018. American Chemical Society.) 
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Many studies have been done on macrocyclic molecules to explore how these 
stereocenters and chemical diversity impact its future pathway,12–15 which has potential 
to play a huge role in drug discovery. The activity of a compound greatly depends upon 
the shape (conformation) of the molecule. Due to restricted internal bond rotations, 
macrocycles are conformationally more restricted than their acyclic counterparts.4,5 By 
influencing the conformation of an acyclic precursor, sigma elements pre-determine the 
shape (and identitiy) of the cyclic structure  formed, therefore the rigidity does not form 
until the ring is formed. This cyclization reduces the number of available conformations 
of the molecule, lowering the entropy before it even binds to the target biomolecule. 
While retaining the conformational restriction, they have the ability to span large surface 
areas, making them suitable for targets that contain shallow surfaces.4 Although they 
are conformationally restricted, there is still sufficient flexibility within the ring to allow 
interactions and binding with proteins.5 This restriction or rigidity could possibly 
influence higher selectivity and target binding, leading to interaction with biological 
macromolecules.4 In addition, its been mentioned that rings are made up of multi atom 
planar units that also aid in the rigidity of the macrocycle.15 
Many have questioned how particular factors like the location of stereocenters 
and planar units affect the overall shape of the macrocycle. By evaluating the nature of 
key atoms, we can begin to design and synthesize potential biologically active 
compounds as well as having the ability to predict the shape of natural products without 
the assistance of any other useful tools.16,17  
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1.3  [13]-Macrodilactones 
[13]-membered macrocycles have been discovered in many various natural 
products, but unfortunately are minimally explored. [13]-macrodilatones in particular 
have been used to learn more about the topology of macrocycles and is of particular 
interest to the Peczuh group.7,18–20 From previous work, we know that the number of 
atoms, the location of planar units and stereogenic centers all play an important role in 
the overall topology of the macrocycle.20 When determining the overall topology of 
macrocycles, we are not exactly talking about shape. The shape of the macrocycle and 
topology are related, but the shape is the geometry that is adopted by the skeleton, 
while the topology involves the planar chirality and its functionalities in a three-
dimensional space.21 
The structure of [13]-macrodilactones consists of a hinge atom, three planar 
units, and an asymmetric stereocenter (Table 1.1).7,18,19 The esters, for example, 
organize four ring atoms each. These atoms are the alkyl carbon, the ester oxygen, the 
carbonyl carbon, and the α-carbon (e.g., atoms 4–7 in Table 1.1). Four atoms are also 
rigidified by the alkene (atoms 8–12). Twelve of the thirteen atoms in the macrocycle, 
therefore, are present in planar units. The connections between the planar units are 
of two varieties. A bond between the α-carbon atom of each ester and the 
corresponding allylic carbon on either end of the alkene unit constitutes one type of 
connection. Alternatively the two esters are linked to each other through a 
bridging atom, the only atom of the macrocycle that is not involved in a planar unit.22 
Numbering of [13]-macrodilactones can be found in Table 1.1, where we start with 1 
being the oxygen on the ester moiety (in red) and following the ring in a 
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counterclockwise motion. This numbering system will be referenced and used going 
forward.  
Table 1.1 Planar units and numbering of [13]-macrodilactone 
                            Planar Units 
C4-O5-C6-C7 Ester (green) 
C8-C9-C10-C11 Alkene (blue) 
C12-C13-O1-C2 Ester (red) 
C3 Hinge atom (black) 
 
The structure obtained from X-ray diffraction data for the unsubstituted [13]-
macrodilactone that has previously been synthesized is shown in Figure 1.4.21 Data 
from the solid state has been valuable to our understanding of how the functional 
groups and their connections translate into conformations in this family of macrocycles. 
The unsubstituted macrocyle contains a pair of enantiomers in the crystal structure (pR 
and pS planar chiralities), both adopting the same shape. The conformation of the 
macrocycle, which we dubbed the “ribbon”, is shown with the alkene planar unit defining 
the top edge of a loosely triangle-shaped structure. The pi bond of the alkene is oriented 
perpendicular to the mean plane of the ring; consequently, one face of the alkene points 
outwards and the other inwards. The ester units, with their carbonyl groups pointing in 
opposite directions, are the other edges of the triangle. The hinge atom allows them to 
twist relative to each other about an axis that goes through the center of the macrocyclic 
ring. The twisting of the planar units is handed. The chirality of the molecule, therefore, 
is based on the asymmetry of the wrapping of the ester arms around the double bond 
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and is analogous to the chirality of the enantiomers of (E)-cyclooctene. It was 
discovered through the investigation of (E)-cyclooctene that the alkene becomes twisted 
when the saturated segments of the ring are shorter (Figure 1.5). The rigidity and lack of 
rotation about the alkene actually forces the remaining segments of the ring to be out of 
plane, creating the ring to twist.23 Two main types of chirality, planar (helical) chirality 
and point chirality, make up these macrodilactones. Planar chirality refers to the twist of 
the macrocycle (left-handedness or right-handedness), whereas point chirality refers to 
the key atom (stereocenter).19 The point chirality (R or S) determines the fold of planar 
chirality around the double bond. Because the planar chirality is the only stereogenic 
element in the molecule, the macrocycle exists as a racemate.22   
 
 
Figure 1.4 Crystal stuctures of both enantiomers of the unsubstituted [13]-macrodilactone 
system, as well as 1D visual of [13]-macrodilactone with numbering of atoms. Graphic showing 
the twist about the alkene in (E)-cyclooctene and the unsubstituted macrocycle. 
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Figure 1.5 Alkene forces rest of ring to twist for trans-cycloalkenes 
 
Our group recently discovered that there are certain key atoms that have an 
influence on the way the ring folds.19 Substituents on either the C2 or C4 atom are 
stereogenic centers that can dictate the shape of the backbone skeleton into one of its 
enantiomeric configurations.19 By incorporating a substituent, even as simple as a 
methyl group, at the C2 or C4 position, the configuration of the alkene facial selectivity 
is altered due to the unsymmetrical diene precursor. The substituent does not 
necessarily matter, but rather where the substituent is placed within the ring, which 
determines its planar chirality.12,14 It was found that when there is one substituent at 
either the C2 or C4 atom, the macrocycle adopts a ribbon, or helical shape. In Figure 
1.6, the planar units are displayed in three different colors, red, black, and blue. Sighting 
through the center of the alkene moiety in blue, the twist is clearly visible. There is a 
propensity for sterically demanding substituents to be located on the outside of the 
macrocycle, orienting themselves farther away from the rest of the atoms on the ring. 
Because of this, it takes on a particular shape and creates the handedness of the 
backbone twist.19 
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Figure 1.6 Chemdraw (A) and Crystal Structure (B) of C2-methyl (green) substituted [13]-
macrodilactone 5. 
 
On the other hand, when a substituent was placed at both the C2 and C4 
positions, the two stereogenic centers either worked together or against each other. In 
theory one would assume that four products would be isolated since there are two 
stereocenters, two diastereomers and their enantiomers (one being a meso compound). 
When RCM was performed, the two diastereomers could be isolated, but the 
enatiomeric pair was not. One product was the racemate of the 2,4-trans-macrocycle 
and the other was the meso 2,4-cis macrocycle. The racemate, as expected, expressed 
the ribbon topology both right-handed and left-handed, whereas the meso product had a 
new cup shape (Figure 1.7). The trans- racemic products are due to the two methyl 
groups working together in the same direction. This partnership allows the macrocycle 
to form the observable ribbon shape. Methyl groups being in the cis position, though, 
are working in opposite directions forming a new cup (alternate) type of topology.7  
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Figure 1.7 A. Ribbon shape of trans-dimethyl 6 and B. Cup shape of cis-dimethyl 7 at C2,C4 
positions. 
 
Thirteen membered rings are of particular interest for different reasons, the main 
reason being that they are under-represented in the biochemical field. Though a high 
number of natural products are 13 membered macrocycles8, they are still under-
explored and little research has been done to find how they can play a role in drug 
discovery. Macrocycles can in fact have different shapes, as proven by previous 
studies. Although in our group some work has been done on what kind of shapes will 
arise, as well as what causes those shapes, it is still not fully understood as to what 
substituents on the rest of a [13]-macrodilactone key atoms can do to the overall 
topology.  
1.4 α-Monosubstituted macrodilactones 
We have seen in previous studies with the C2/C4 model that if a substituent at any 
key atom results in ring strain (primarily due to transannular interactions), then the 
planar units are forced to reorganize driving the macrocycle to assume a different 
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shape. Integrating various substituents at other key atoms around the ring tested this 
hypothesis. Either one or two stereogenic centers were implemented (other than just C2 
or C4) to see how the interplay between the planar units alters themselves depending 
on the placement. This led to a general model proposed by our group that attempts to 
explain various factors that govern the overall topology. 
 Previously in our group, the α-substituted [13]-macrodilactones were explored 
and compared to the unsubstituted macrocycle. Various size substituents were placed 
at either the C7 or C12, or at both C7 (or C12)/C2 positions. By implementing just one 
stereocenter or two stereocenters, we were curious to see if we would find the same 
overall topology as the unsubstituted and C2 methyl. In doing so we needed a way to 
really compare shapes and planar chiralities between our [13]-macrodilactones. 
Therefore, we adapted a 2D graphical representation previously used for porphyrin 
systems.24 
The representation is a type of conformational map that exhibits the three-
dimensional shape of the macrocycle in two dimensions, by plotting deviations from the 
molecular plane for each ring atom. Using the pS enantiomer of [13]-macrodilactone 1 
as an example (Figure 1.8), the molecular plane is represented by three atoms, C3, 
C13, and C6 (coded in black). In order to make the crystal structure into a two-
dimensional structure, the macrocycle is first placed with the C3 atom nearest to the 
viewer and the alkene of the macrocycle farther away. Then, the ring is virtually cut 
through the C3 atom and opened up to give an acyclic representation. Numbers along 
the y-axis of the map correlate to the relative distances of each atom with respect to the 
molecular plane (Å). Positive or negative deviations indicate whether the atoms are 
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above (+) or below (-) the molecular plane. The x-axis positions the atoms of the ring 
skeleton along with the bonds that connect them. Note that C3 is itself shown twice on 
the map (at each end of the map) so that the C2-C3 and the C3-C4 bonds may both be 
shown. This two-dimensional map technique was implemented to graphically represent 
all the [13]-macrodilactone crystal structures obtained (not all are shown). 
 
Figure 1.8 3D conformational map of unsubstituted macrodilactone (1). a) Blue plane going 
through three points, two ester carbons and the C3 carbon; b) crystal structure of unsubstituted 
macrocycle, arrows indicating which way to cut; c) graphical representation of the unsubstitued 
macrocycle with 0 being the three points that the plane goes though (black points).25 
 
In using these maps to describe three-dimenisional space in a two-dimensional graph, 
we can help ease the comparison of the shape and planar chirality between various 
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[13]-macrodilactones that would otherwise require multiple figures to illustrate the 
different perspectives.25  
Various α-macrodilactones were synthesized and subjected to X-ray 
crystallographic analysis. From these crystal structures, we were able to compare the 
overall topology to C2/C4 and unsubstituted macrocycles that were already explored. 
The C7-phenyl substituted macrocycle contains a racemic mixture since the starting 
pentenoic acid was racemic. The C7 stereogenic center of R configuration gave rise to 
a pS planar chirality while the S configuration gave rise to a pR planar chirality (Figure 
1.9).  At first glance, the point and planar chirality do not seem to correlate for the C7-
phenyl and C2-methyl mono substituted [13]-macrodilctones. The C2-methyl with a 2R 
stereocenter gave rise to a pR planar chirality while the C7-phenyl (8) with a 7R 
stereocenter gave rise to a pS planar chirality. However, if the substituent on the 7-
phenyl [13]-macrodilactone becomes the third priority, then the 7S-phenyl becomes 7R. 
With that, the R stereocenter now correlates to the pR chirality and the S correlates to 
pS. This implies that the geometry of substituents (in this case, both C2-methyl and C7-
phenyl adopted a pseudo-equatorial positions), not just R/S, substituent type or location, 
sets the planar chirality of the macrocycle. Even though the stereocenter may vary in 
relation to the planar chirality, both monosubstituted C2 (5) and C7 (8) macrocycles 
adopted the same ribbon shape as the unsubstituted macrocycle seen in the overlay in 
Figure 1.9. 
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Figure 1.9 a. Structures of C7-phenyl-[13]-macrodilactone 8 from X-ray crystallographic data. b. 
Conformation map showing both C7 enantiomers c. overlay of unsubstituted, C3 methyl, and C7 
phenyl macrodilactones d. Conformational map of unsubstituted, C3 methyl and C7 phenyl 
macrodilactones 25 
 
1.5 α-Disubstituted macrodilactones 
 Since altering the stereochemistry at one specific carbon in a molecule can affect 
its biological activity26, our group was interested in understanding how the interplay 
between multiple stereocenters can work together or against one another in determining 
its shape and topology. Various α-disubstituted macrodilactones were synthesized by 
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previous group members, analyzed through X-ray crystallography and compared to 
previously explored disubstituted [13]-macrodilactones.  
There were 3 new compounds synthesized which were compared to the 
previously synthesized C2/C4 dimethyl macrodilactone (2 and 4). The alpha substituted 
compounds were C7/C12 (9 and 10), C2/C7 (13 and 14), and C2/C12 (11 and 12); each 
containing two diastereomers (one cis and the other trans) with its enantiomer 
counterpart. In all ribbon shaped compounds (9, 11, 13, and 15) the substituents occupy 
the pseudo-equatorial positions based on the stereogenic configuration. The 
configuration of the stereogenic centers work constructively with each other to obtain 
the global, low-energy ribbon conformation.25 The preference for cis in compound 13 is 
similar to cis 1,3-di-substituted cyclohexane stability comparative to trans 1,3-di-
substituted diastereomer, while the trans 9, 11, and 15 are similar to trans 1,2 and 1,4-
di-substituted cyclohexanes. Since there are a pair of diastereomers (and pair of 
enantiomers) that came from the ring closing metathesis of the dienes, the result was 
not one, but two isolatable products. One of the products adopted the lowest energy 
preferred conformation (the ribbon shape) while the other adopted a different family of 
conformers, which we refer to as the “alternate” shapes (Figure 1.10- 10, 12, 14, 16). 
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Figure 1.10  Various crystal structures of α- disubstituted [13]-macrodilactones 
Based on the family of [13]-macrodilactones synthesized so far, our group has 
developed a set of rules that can be applicable to macrocycles with 12-16 atoms within 
their ring.25 They are as follows: 
1) In order to minimize intramolecular (transannular) interactions, an unsubstituted 
macrocycle will assume either one conformation or a small number of 
conformations.  
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2) The conformation of the unsubstituted macrocycle is governed by: a) the number of 
atoms within the ring, b) rigidifying elemets such as fused rings and/or multi-atom 
planar units (amides, esters, alkenes, etc); c) sp3 hybridized atoms that allow planar 
untis to reorient themselves one relative to another (e.g., “hinge” atoms); d) the 
vicinity or sequence of the structural units described in b) and c). 
3) The three-dimensional shape/topology is specified by the number, placement, and 
absolute configuration of the stereogenic centers on the macrocyclic backbone. Not 
only does the stereochemistry at that center rigidify the ring through non-bonding 
interactions, but it also generates a chiral compound with a particular handedness. 
By placing a stereogenic center at the termini of planar units, complete portions of 
the macrocycle can be adjusted. In addition, there is a correlation between point 
chirality and planar chirality. This means that the absolute configuration of one 
stereogenic center presents planar chirality, which will determine the handedness of 
the planar chirality. When more than one stereocenter is present, there can be a 
constructive relationship which reinforces the low energy conformation shown by 
the unsubstituted macrocycle or the stereogenic centers can compete with each 
other yielding a different shape or conformation. The preference of a substituent to 
inhabit a pseudo-equatorial position guides the effect of stereogenic centres in both 
planar chirality and shape. 25 
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1.6 Conclusion  
Due to the importance of macrocycles in biological environments, it is necessary to 
explore structural features more in depth. By obtaining and observing the crystal 
structure of the unsubstituted [13]-macrodilactone, we have been able to compare alpha 
substituted macrocycles in order to try and have a better understanding of the lowest, 
global energy conformation (the ribbon). By developing a set of rules for [13]-
macrodilactones, we now have a more insight of how the shape and topology of 
macrocycles are affected by outside elements. There are still other positions that have 
not been explored on our [13]-macrodilactone, which will be further investigated in later 
work. 
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Chapter 2  
Structural and functional consequences of an allylic stereogenic 
center in a family of [13]-macrodilactones 
2  
2.1 Understanding the shape and topology of [13]-Macrodilactones 
Structural features that guide molecular conformations are important 
design elements that underpin the development of de novo bioactive 
macrocycles. Their utilization, however, requires an understanding of how a 
given feature actually influences conformations. Macrocycles have engendered 
enthusiasm as leads for drug development because they can be broken down 
into smaller domains that can modulate functions, affinity, specificity, and 
physicochemical properties.1–9 Active compounds frequently fall outside of the 
typical Lipinski rule of five parameters;8 this has been rationalized by classifying 
macrocycles separately from other small molecules or by invoking the ability of 
specific macrocycles to adopt different conformations based on the local 
environment (e.g., the dielectric of the surrounding medium). This is because, 
among their special features, macrocycles balance domains that can make a 
molecule locally flexible while still being relatively rigid overall.9–11 Macrocyclic 
conformations have been correlated with their bioactivity, particularly with respect 
to natural products and their analogs.5,9,10,12–16  The point is not that a macrocycle 
limits the conformational space of a compound to only one conformation and thus 
reaps an enthalpic benefit upon binding. Rather, the macrocycle occupies a small 
number of low-energy conformers, one of which will likely be the bound 
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conformer. The ability to access multiple conformations likely assists in binding 
and also in tuning physical properties. As part of a project that aims to 
characterize the interplay between stereogenic centers at key positions in a 
model [13]-macrodilactone and the planar chirality of the ring, we have 
discovered the effects of substitutions at the allylic positions. 
A particular family of [13]-macrodilactones, typified by the macrocycle 
depicted in Figure 2.1, has provided a model system for the investigation of 
parameters that drive to the structure and conformation of macrocycles.17–22  As 
previously explained, several factors contribute to the rigidification of this family 
of macrocycles. The primary ones are the two ester units and the alkene. 
The esters, for example, organize four ring atoms each. These atoms are the 
alkyl carbon, the ester oxygen, the carbonyl carbon, and the α-carbon (e.g., 
atoms 4–7 in Figure 2.1). Four atoms are also rigidified by the alkene (atoms 8–
12). Twelve of the thirteen atoms in the macrocycle, therefore, are present 
in planar units. The connections between the planar units are of two varieties. A 
bond between the α-carbon atom of each ester and the corresponding allylic 
carbon on either end of the alkene unit constitutes one type of connection. 
Alternatively,  the two esters are linked to each other through a bridging atom - 
the only atom of the macrocycle that is not involved in a planar unit. The planar 
units and their connectivity are intimately linked with the conformation adopted by 
the macrocycle.  
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Figure 2.1 The [13]-macrodilactone motif as illustrated using the unsubstituted 
macrocycle. a) The connectivity of the ring. b) Schematic showing the three planar units 
and numbering of key atoms. c) Structure from X-ray crystallographic data; shown is the 
pS enantiomer of the racemate present in the crystal. 
Our earliest investigations on the [13]-macrodilactones used chiral diol 
templates, such as 4,6-O-acylated pyranose sugars.20 Subsequently, we have 
identified several key atoms (i.e. C2, C4, C7, C12; see Figure 2.1) along the 
backbone of the macrocycle, the absolute stereochemistry of which will dictate 
the planar chirality of the macrocycle when there is only one substituent on the 
ring.17–19, 21 The commonality between these key centers is that they are at the 
terminus of a planar unit. Consider, for example, C4 and C7; these two atoms are 
at either end of one of the ester units in the [13]-macrodilactones. The interplay 
between a point of asymmetry and a plane or axis of asymmetry is an important 
way to dictate the handedness of macrocycles and it has implications for the 
design of desired shapes for a particular application. The principle seems to be 
relatively general, with instances in both natural products and de novo 
compounds.18,23,24 Studies of other macrocycle motifs have shown that 
substitution at the allylic position could either have an effect on the overall 
conformation or have no effect at all, as in (-)-exiguolide and dictyostatin.25,26 
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Given that atoms C8 and C11 are at the termini of the alkene planar unit of our 
[13]-macrodilactone, we wanted to know if substitution there would similarly 
influence the planar chirality of the macrocycle, and consequently affect its low-
energy conformations. As with previous investigations of this macrocycle, we 
aimed to characterize the conformation in solid state, and further understand 
what principles explain the observed conformations. The modularity of 
macrocycles, in terms of both their assembly27–31 and conformational 
behavior,9,10 provided additional impetus for our investigation.  
[13]-Macrodilactones could potentially become drugs for target molecules 
in the future. For this to happen, though, it is crucial to understand what factors 
affect its overall shape, or topology, as well as to determine the diversity of 
macrocyclic shapes that are possible. In order to develop new potential drugs, 
the question of how the shapes of macrocycles are affected by substituents at 
various key atoms is very important and needs to be answered. By adding 
substituents at the allylic positions (position β to an ester carbonyl), will a 
different type of topology be obtained or will it adopt shapes that are similar to the 
[13]-macrodilactones of our previous studies? By building upon our recent 
research of [13]-macrodilactones, we plan to attain an important trend among the 
topology of this particular class of macrocycles, specifically at the allylic position. 
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2.2 Synthesis of [13]-Macrodilactones 
2.2.1 Retrosynthesis 
 The [13]-macrodilactone consists of three planar units, as previously 
described (Figure 2.1;Figure 2.2).  There are two ester units (C7-C6-O5-C4 and 
C2-O1-C13-C12) and an alkene unit (C8-C9-C10-C11). The C8 and C11 atoms 
can be referred to as either beta or allylic carbons interchangeably. Beta is used 
in reference to the ester unit, whereas allylic is in reference to the alkene. 
Previous work has prepared [13]-macrodilactones with substituents on the C7, 
C12, C2, and C4 atoms where the substituents were found to guide the twist 
shape of the macrocycle either left handed or right handed. Since the allylic 
carbons C8 and C11 are at the terminal carbons of the unit like the atoms 
previously explored, we wondered whether the same shape would be observed. 
Therefore, a synthetic approach to make new monosubstituted [13]-
macrodilactones at the β-positions was taken to address this question. 
 
Figure 2.2 Planar units of [13]-macrodilactone. The (C7-C6-O5-C4) unit is in green, (C2-
O1-C13-C12) unit is in red, and the alkene (C8-C9-C10-C11) unit is in blue. 
Retrosynthetically, the first disconnection was at the alkene by ring closing 
metathesis transform, which gives a diene (Scheme 2.1B). The diene is, 
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4
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conveniently, a diester where one or both of the two acyl groups could be 
substituted at the position beta to the ester carbonyl. For disubstituted 
compounds, this can be of two types: symmetrical (Figure 2.3a) or unsymmetrical 
(Figure 2.3b). Symmetrical dienes use the same pentenoic acid for each 
acylation but for the unsymmetrical dienes, two different pentenoic acids were 
used — one which is readily available and the other which is not. Since some of 
the acids that will be used are not readily available, they must be synthesized. An 
acid will first be used to monoacylate a diol followed by a second acylation using 
a different acid to give the unsymmetrical diene. The diene can then be 
disconnected at the C6-O5 ester, giving the monoacylated product (Scheme 
2.1C), which can then be followed by a disconnection at the other ester, C13-O1 
to give the starting diol and acid (Scheme 2.1.D). 
Scheme 2.1 Retrosynthesis of β–substituted [13]-Macrodilactones 
 
 
  
Figure 2.3 Symmetrical a and unsymmetrical b diene 
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2.2.2  Synthesis of 3-substituted-4-pentenoic acids 
 There were four acids used in the process of synthesizing the [13]-
macrodilactones. Since 4-pentenoic acid 17 is commercially available, we only 
had to synthesize 18, 19, and 20 using various procedures (Figure 2.4).32 All 
three started from racemic starting materials. Both 3-methyl-4-pentenoic acid 18 
and 3-phenyl-4-pentenoic acid 19 were made from its allylic alcohol starting 
material (21 or 22) (Scheme 2.2) via a Johnson-orthoester Claisen 
rearrangement. Triethylorthoacetate 23 was added to the allylic alcohol to 
undergo the rearrangement affording an γ,δ-unsaturated ester. The ester was 
then hydrolyzed using potassium hydroxide in methanol to yield the desired 3-
substituted-4-pentenoic acid, 18 in 40% crude yield and 19 in 64% crude yield. 
The 3-(4-bromophenyl)-4-pentenoic acid 20 had a few more steps involved 
(Scheme 2.3). Since the allylic alcohol was not readily available, we needed to 
make it. Starting from aldehyde 24, (carbethoxymethylene)triphenylphosphorane 
25 was added to give ester 26. Then 26 was reduced using DIBAL-H to yield 4-
bromophenyl allylic alcohol 27 and then subjected to 28 to undergo the Johnson-
orthoester Claisen rearrangment to give the final desired carboxylic acid 20. 
 
Figure 2.4 3-substituted-4-pentenoic acids used in synthesis of [13]-macrodilactones. 
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Scheme 2.2 Synthesis of 3-substituted-4-pentenoic acids 
 
  
 
Scheme 2.3 Synthesis of 3-(4-bromophenyl)-4-pentenoic acid 
 
  
2.2.3 Acylations to Form Dienes  
In the synthesis of the dienes, there were two acylation reactions that 
were used. The first was a dicyclohexylcarbodiimide (DCC) mediated coupling of 
the carboxylic acid and alcohol and the second was through the use of acid 
chlorides with the alcohol. DCC couplings produce a side product, DCU, which is 
somewhat difficult to remove from the monoacylated products but is easily 
separated from the diene. Acid chlorides, on the other hand, are much easier to 
purify, but have an unpleasant odor. Due to the unpleasant odor, it was decided 
to use the DCC coupling method for acylations in the synthesis. The [13]-
macrodilactones varied the bis-functionalized diols, using either 1,3 propanediol 
29 or racemic 1,3 butanediol 30 as starting materials (Figure 2.5). Each end of 
the diol was acylated using the assortment of 4-pentenoic acids (Figure 2.4). 
Both monoacylations and diacylations were performed using the coupling 
reagent dicyclohexylcarbodiimide (DCC) and N,N-dimethylaminopyridine (DMAP) 
R1 OH +       MeC(OEt)3
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as an acylating catalyst (Scheme 2.4; Scheme 2.5).  
  
Figure 2.5 Readily available diols used in synthesis of [13]-macrodilactones 
 
There are several possible products of the acylation process overall. 
Among these include mixed acylation (unsymmetrical diene/diester) consisting of 
two different acids and diacylations (symmetrical diene/diester) consisting of the 
same acid. The acid is acylated using either diol 29 or 30. When diol 29 is used, 
there is no chemoselectivity, but rather just the number of equivalents of 
acylating agent. On the other hand diol 30 does have chemoselectivity. If 1,3-
butanediol 30 was used (Figure 2.5), the primary alcohol reacted faster than the 
secondary alcohol leading to the substituent being on the C2 atom (31= 67%, 
33= 47%) (Scheme 2.4). If 1,3-propanediol 29 was used instead, either alcohol 
will react since it is symmetrical and both are primary alcohols giving 32 (84%). 
Scheme 2.4 Mono-acylation using two different diols 
 
  
The first acylation gave a mono-acylated product (Scheme 2.4), which 
also produced a side product of DCU. Since the DCU is very difficult to isolate 
from our desired product, it was originally removed as best as possible through 
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 32 
both celite pad filtration and silica chromatography, but DCU was still present in 
the mono-acylated compounds. It was then discovered that if you dissolve your 
crude material in cold ether, most of the DCU precipitate, allowing you to filter 
through celite and leaving only minor impurities. A column was still performed to 
obtain pure products. The second acylation used a 3-substituted-4-pentenoic 
acid, which reacted with the remaining hydroxyl group present on the 
monoacylated product (Scheme 2.5). Even though minor amounts of DCU were 
still present in the monoacylated product, it was removed during the purification 
process of the diene and was not a problem during the RCM.  
Scheme 2.5 Second acylation 
  
 
  
Figure 2.6 Dienes of mixed acylations 
For diacylation, only one acid is used for the entire process, allowing the 
use of a one-pot synthesis (Scheme 2.6). Two equivalents of the acid permits 
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both ends of diol 29 to be acylated at the same time during the reaction giving 
the diene in a one-pot process. 
Scheme 2.6 Diacylation 
  
2.2.4 Ring Closing Metathesis 
 Olefin metathesis is an extremely popular and powerful way to form 
olefinic carbon-carbon bonds. Metathesis consists of many different methods 
such as ring-opening metathesis (ROM), cross metathesis (CM), and ring closing 
metathesis (RCM).33 Ring Closing metathesis is very common and has been 
used extensively for macrocyclization reactions, especially in the synthesis of 
natural products.33,34 There are various possible pathways that can occur during 
RCM, such as intermolecular oligimerization and intramolcular ring closing 
reactions, which are determined by different factors. Some include temperature, 
dilution, nature of the substrate, and reactivity of catalyst.35 High temperatures 
and dilute diene concentration have been proven to yield higher macrocyclic 
products. In addition, if a substrate has a sterically hindered olefin, dimerization 
can occur, and depending on the catalyst being used, it may be insufficient for 
RCM to occur.35 There are many types of catalysts that have been explored and 
experimented on RCM procedures. Most catalysts that have been found to be 
the most influential on RCM reactions are metal-based. Two of the main ones are 
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 34 
Schrock’s molybdenum-based catalyst and Grubb’s, ruthenium-based catalyst. 
Numerous groups have made variations of both. Schrock’s catalyst is sensitive to 
air and moisture, has thermal instability, and has moderate to poor functional 
group tolerance36–38 Grubbs’, on the other hand, has little sensitivity to air and 
moisture, has robust reactivity and great tolerance toward many functional 
groups.  Therefore, we opted to use Grubbs’ catalyst for RCM reactions of the 
dienes. Due to its availability in our lab, Grubbs’ second-generation was our 
catalyst of choice. Therefore, RCM is one of the key reactions (Scheme 2.7) 
used in concluding our [13]-macrodilactone final products 42-49 (Figure 2.7). 
Scheme 2.7 Ring closing metathesis of various dienes 
  
We were interested to see not only how the overall topology is affected by 
substituents placed at the allylic position, but also how ring-closing metathesis is 
affected. Fürstner et al. have shown that by placing something as small as a 
methyl group at the allylic position can decrease the yield dramatically compared 
to no substituent at all.39 Although it has been exhibited that allylic substituents 
can impact the ring-closing metathesis yields, there still hasn’t been much 
reported literature on the affect of steric hindrance.39–41 
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Figure 2.7 Macrocyclic products. 
 So we tried to see if we could find a trend among the percent yields. The goal 
was to run three RCM trials on 50mg scale of various mono and disubstituted 
dienes. Unfortunately as RCMs were conducted, there became a problem with 
grease getting into the samples. Due to the trials being on such small scale and 
having low yields as it is, it was very difficult to obtain accurate isolated percent 
yields. Therefore, the two trials were done on each and the graph below can only 
support non-definitive data (Figure 2.8). We can see that both the disubstituted at 
the allylic positions (48 and 49) have much lower yields, which could very well be 
due to the steric hindrance, especially those two bulky phenyl groups. They may 
not be able to orient themselves in a way that is favorable to obtain the 
macrocyclic product due to not only the sterics, but possibly at these conditions. 
In addition, one can notice that the unsubstituted 42, mono-methyl C11 43, and 
disubstituted methyl C2/C11 45, all had relatively close yields to one another 
(Figure 2.8;Table 2.1). This could imply that the less sterics around the double 
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bond has a lower energy for ring closing metathesis than if you have bulkier 
groups such as a bromophenyl. If comparing to the literature, the trend seems to 
make sense seeing that the two largest bulky groups around the alkene has the 
lowest yield and no substituent around the alkene has the highest yield.  
Unfortunately, we cannot say for sure that there is a trend here among the 
compounds tested, but it can be used as a place to start and build upon. 
 
                                 
Figure 2.8 RCM yields for various substituted  macrocycles. 
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Table 2.1 RCM yields for various macrocycles 
Compound Trial 1 % Trial 2 % Avg % 
49 10 8 9 
48 16 17 16.5 
44 34 29 31.5 
46 44 23 33.5 
45 45 49 47 
43 48 49 48.5 
42 48 50 49 
 
2.3 Overall topology of various disubstituted β-[13]-macrodilactones 
One important question that has driven much of this project deals with how 
the overall topology of our macrocycles is affected by the addition of substituents. 
We have been successful in growing various crystals and obtaining X-ray 
diffraction data on them to observe how the [13]-macrodilactones behave in the 
solid state.  
Since disubstituted [13]-macrodilactones yield a pair of diastereomers (as 
racemates), we obtained two different isolatable products from RCM reactions. 
We have seen from previous studies in our group with the α-series that one of 
the diastereomers tends to be the ribbon shape, while the other diastereomer is 
an alternate, non-ribbon shape. One would assume that the β-substitution would 
be similar to that of the alpha, so we tried to prove it. Unfortunately, due to the 
small scale (50 mg) that these macrocycles were performed on (and low yields 
as it is for some), the crystal structures we obtained were all the major 
diastereomer (higher yielding product) and we were not able to obtain the minor 
(alternate shape).  
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Table 2.2 Macrocycles and their relationships 
Compound Cis Trans 
2,4 Alt* Ribbon* 
2,7 Ribbon* Alt* 
2,8 Alt Ribbon* 
2,11 Ribbon *(for both 45 & 46) Alt 
2,12 Alt* Ribbon* 
7,12 Alt Ribbon* 
8,11 Alt Ribbon* 
      * = have crystal 
 As shown in Figure 2.9, the C2/C8 trans (47), C2/C11 cis (45 and 46), and 
the C8/C11 trans (48) all take the ribbon shape, which we have proven to be the 
lowest global energy conformation in the alpha series (Table 2.2). However, it is 
difficult to determine what the major diastereomer is for 48 since the isolated 
yields between both diastereomers are very close to each other (isolated yield for 
47 was higher for the more polar product (10%; no crystal structure) and not the 
ribbon (8%; with crystal structure)) and there was grease present in the samples. 
The other compounds 45-47, though, do have the ribbon being the major 
diastereomer. It must be noted, though, that the crystal structure of 45 is a rough 
estimate of what it looks like in crystal form since the crystal gave the 
crystallographer multiple red flag alerts. Therefore, it can only be used as a 
preliminary result. However, we can still obtain some data from it, resulting in 
what seems to be the ribbon shape. It is interesting to observe the minor 
diastereomer to be the ribbon shape and the major diastereomer in the 
macrocycle 48 to be the alternate (if we do take into account the isolated yields) 
since the substituents are allylic to the alkene. Due to the sterics around the 
alkene, it would make sense for the macrocycle to have to rearrange itself to get 
in the lowest energy conformation. It would be intriguing to see what the alternate 
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diastereomer looks like, but unfortunately we were not able to obtain crystal 
structure data. It is also interesting to see that the major diastereomers for the 
46-C2/C11 and 47-C2/C8 macrocycles are also ribbon.  
   
   
Figure 2.9 Disubstituted crystal structures (one diastereomer) with corresponding 
conformational map (overlay with unsubstituted). 
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Once again, since one bulky substituent is so close to the alkene, it would not 
have been shocking to see the two substituents working against each other 
instead of constructively.  
As seen in the crystal structures and the conformational maps (Figure 2.9), 
we can safely say that the rules we have put together for macrocycles based on 
the alpha series, also applies to the beta series. The major topology that the 
macrocycles take up is the ribbon shape. When each crystal structure was 
overlayed in the conformational map with the unsubstituted macrocycle, one can 
see that there is slight deviation, but it still embodies the ribbon shape.   
 
2.4  p-BrPh Substitution at C8 [13]-macrodilactone42 
 As with the disubstituted macrocycles, we were able to obtain a crystal 
structure for our C8 monosubstituted p-bromophenyl-[13]-macrodilactone as well. 
Upon inspection of the data we noticed something unusual. There was not one, 
but two structures in the crystal cell unit, which is something that we have not 
seen in our previous investigations. We aimed to characterize the conformation 
in both the solid state and solution, and further understand what principles 
explain the observed conformations. The modularity of macrocycles, in terms of 
both their assembly27–31 and conformational behavior9,10 provided additional 
impetus for our investigation. Here we describe the synthesis and 
characterization of a new [13]- macrodilactone substituted at C8, the position β- 
to an ester carbonyl. Through a combination of spectroscopy, reactivity studies, 
and computational chemistry, a clearer picture of the low energy conformers of 
the macrocycle emerged. Further, potential energy surfaces for their 
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interconversion and their epoxidation are also described.  
2.4.1 Solid state conformation 
To our delight, [13]-macrodilactone 44 was a crystalline solid. We have 
previously relied on X-ray crystallography to understand how planar units and 
stereogenic centers at key centers affect the solid-state conformations of these 
macrocycles.17–21 We expected that the carbon bearing the aryl ring was at the 
terminus of the alkene planar unit would guide the adoption of a ribbon 
conformation by the macrocyclic backbone as we had observed for other mono- 
substituted [13]-macrodilactones. Because 20 was racemic (Figure 2.10), we 
further anticipated that two complementary enantiomers would be in the unit cell 
for 44; each configuration of the stereogenic carbon (R or S) would dictate the 
planar chirality (pR or pS) of the macrocycle. The X-ray structure of 44 we 
obtained, therefore, allowed us to compare it to our previously studied ring 
systems, specifically α-pBrPh-[13]-macrodilactone (52) (Figure 2.10).  
 
 
Figure 2.10 Synthesis of macrocycles 44 (β) and 52 (α) 
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The unit cell of the crystals of 44 shows that the macrocycle took up the 
ribbon conformation as we had predicted based on the earlier compounds 
(Figure 2.11a). In this conformation were enantiomers of 44 where the 
configuration at C8 and the alkene were matched – the 8R,pR and the 8S,pS 
isomers. The planar chirality of these conformers was guided by the configuration 
at the key C8 atom, as expected. What was not anticipated, though, was to find 
an additional pair of macrocycle conformers in the same unit cell. This new 
conformer was characterized by a partial rotation of the alkene unit (C8-C11) that 
switches its planar chirality for a given stereogenic center. The consequence of 
the partial bond rotation formally converts the 8R,pR ribbon conformer to the 
8R,pS and similarly the 8S,pS becomes 8S,pR. When the new conformer is 
viewed from the (planar) axis of chirality, a kink in the backbone is apparent 
(Figure 2.11a); we dub this the “heart” conformer based on its resemblance to a 
cartoon heart.  
A conformational map in Figure 2.11b graphically illustrates the alkene 
shifting from pS to pR planar chirality for the 8R isomer of 44. The unit cell is 
populated by a 1:1 mixture of the two macrocycle conformers, as well as their 
corresponding enantiomers. Figure 2.11c is a stylized version of the unit cell that 
shows both the conformers. Additional copies of C9 and C10 for each conformer 
demonstrate that the sites within the unit cell are degenerate – any of the four 
conformers can be present in a given spot. It became apparent that the 
conformations observed in the crystal structure were also likely to be present in 
solution. Efforts to get information about solution conformations of 44 were 
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therefore undertaken. 
 
 
a.       
b.     
c.   
 
Figure 2.11  (a) Ribbon (blue) and heart (pink) conformers of 8R configured 44. (b) A 
conformational map displaying a visual difference of the alkene in the ribbon (8R,pR) 
and heart (8R,pS) conformers; blue represents the ribbon, while pink represents the 
heart. Arrows drawn show placement of alkene in each conformer. (c) Unit cell showing 
the skeletal versions of both the ribbon (8S, pS) and heart (8R, pS) conformers being 
present. Enantiomers of each were omitted (8R, pR for ribbon and 8S, pR for heart), for 
visual purposes, but all four isomers do exist in the unit cell. 
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2.4.2 Solution conformations by NMR and molecular modeling 
Since the crystal structures of previously synthesized [13]-
macrodilactones led us to believe that there was only the ribbon conformer 
present in the unit cell, we decided to investigate two macrocycles: 44 as the test 
system and 52 as a control. A strategy that leveraged NMR data in conjunction 
with quantum chemical conformational energies was adopted to gain a better 
understanding of the behavior of 44 in solution. Versions of this same strategy 
are well precedented for macrocycle conformational analysis.43,44 Coupling 
constants predictably play an important role in the technique. Guided by the 
crystal structure data for 44, we opted to focus on 3Js in the region of the 
molecule where the change in conformation was most pronounced between the 
ribbon and heart conformers. Specifically, the alkene and the surrounding 
carbons from the carbonyl carbon C6 to carbonyl C13 (I in Scheme 2.8), partially 
flipped over the course of the transition. This rotation had a significant effect on 
several dihedral angles between atoms in this part of the macrocycle (see 
Supplementary info for charts). By using both 44 and 52, then, it was expected 
that 1H signals for the allylic (C8, C11) and alkenyl protons (C9, C10) would 
harbor important coupling constants. The appearance of the 1H NMR spectrum 
suggested that average signals were being observed and that the two 
conformers, if both present, were not in slow exchange. Table 2.3 organizes 
coupling constants collected from NMR data for the allylic and alkenyl protons. 
Couplings are depicted with double-headed arrows in the table. Experimental 
values were compared to those calculated with a Karplus equation45 and density 
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functional theory (DFT) calculations at the ZORA-B3LYP/QZ4P//BLYP-
D3(BJ)/TZ2P level. These couplings provided important information about 
dihedral angles in this fragment of the molecule. The calculated coupling 
constants were based on low energy conformations that were likely to be the 
primary contributors to the overall ensemble of conformers available in solution.  
Table 2.3 Select 3JH,H values (Hz) for compounds 44 and 52 
 
 
                                              Karplus                        DFT 
3J coupling observed ribbon heart ribbon heart 
compound 44      
H10-C10-C11-H11a 10.4 11.35 3.02 11.39 3.57 
H10-C10-C11-H11b 7.6 4.06 11.28 4.72 12.10 
H8b-C8-C9-H9 7.8 11.44 4.76 11.40 4.50 
compound 52      
H8b-C8-C9-H9 8.7 10.79 - 11.27 4.54 
H10-C10-C11-H11a 9.6 10.89 - 11.60 3.15 
 
Scheme 2.8 Rendition of the C6-C13 fragment (I) of 44 
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The observed 3JH,H values in Table 2.3 were collected in a multi-step 
process and provided values that could be compared to Karplus computed and 
DFT calculated coupling constants. Signals of the 1H NMR spectra were 
assigned for 44 and 52 from spectra collected in both CDCl3 and C6D6. Deutero- 
benzene (C6D6) gave better overall dispersion of signals but some from the 
CDCl3 spectra were resolved where there was overlap in the C6D6 spectra. Due 
to the similarity of the dielectric constants of both solvents, we used data from 
each spectrum interchangeably. Three main H-H relationships were used to 
characterize the conformers of macrocycle 44 in solution: H10-H11a, H10-H11b, 
and H8-H9b. The H10- H11a 3J has an observed value of 10.4 Hz, which is 
closer to the computed/calculated ribbon value for this dihedral than to the heart 
conformer (~11 Hz for ribbon versus ~3.5 Hz for heart). On the other hand, both 
the H10-H11b 3J (7.6 Hz) and the H8-H9b 3J (7.8 Hz) are between the values 
calculated for the ribbon and heart conformations. In fact, they are nearly the 
average value between the two (the average values would be 8.4 and 7.9 Hz, 
respectively), suggesting that there may be equal populations of both conformers 
in solution. The H10-H11a and H8-H9b 3J values for compound 52 gave similar 
information about the conformations of this macrocycle. The H10-H11a displays 
a coupling constant of 9.6 Hz in NMR, a value between the average of the two 
conformers (7.38 Hz) and the ribbon computational value (11.60 Hz). Also, the 3J 
of H8-H9b is 8.7 Hz, which is also intermediate between the values for the ribbon 
and heart conformers. The data are interpreted as an indication of a dynamic 
conformational profile for this segment of the molecule for both 44 and 52. 
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Values of several C-H 3Js were also evaluated for macrocycles 44 and 52 (see 
Supplementary Information). There was less agreement between the measured, 
computed, and calculated values for these coupling constants, however. Part of 
the reason behind the discrepancies may be related to the measurement of the 
values themselves. The difficulty stemmed from the overlap of signals that 
prevented the accurate measurements, even at high field (700 MHz). 
Consequently, they did not provide us sufficient confidence about the 
conformations of the macrocycles to be interpretable.  
Although the NMR solution study suggested that the ribbon and heart 
conformers were populated for both macrocycles, the data were at least partially 
equivocal. Computational studies were carried out, therefore, in order to better 
understand the conformational preferences of 44 and 52. Using density 
functional calculations, we calculated the potential energy surfaces (PES) 
associated with isomerization of the 7S enantiomer of 52 and the 8R enantiomer 
of 44 (Figure 2.12). The rationale was that the absolute configuration of each 
position (7S and 8R) corresponded to the R configured planar chirality. We had 
previously shown that the configuration of key atoms dictates the planar chirality 
associated with the [13]-macrodilactones. Figure 2.12 places the heart 
conformers on the left-hand side, the ribbons on the right-hand side, and the 
structure associated with the transition state between the two. It should be noted 
that when the alkene unit of each macrocycle flips, the planar configuration also 
flips (i.e from pR to pS).  
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Figure 2.12 Computed reaction profiles (ΔG) for the isomerization between the ribbon 
and heart shaped macrocycles 44 and 52. All data were computed at the BLYP-
D3(BJ)/TZ2P level in the gas phase and in toluene with relative energies in kcal/mol. 
Inspection of the PES of 44 reveals that at ambient temperature, the two 
conformers, heart 44 and ribbon 44, are of similar energies with the overall 
exergonicity associated with the formation of the ribbon structure from the heart 
being small, (ΔGrxn = –1.9 and –0.4 kcal/mol in gas phase and toluene, 
respectively). This result is consistent with the idea that the heart and ribbon 
conformers can exist in both solid state and solution, likely to a similar extent. 
Further, there is a nominal barrier of inversion around the double bond of 3.9 and 
4.4 kcal/mol in the gas phase and toluene, respectively. The vinylic CHs of the 
alkene in the ribbon conformation are orthogonal to the plane of the ring, while in 
the heart conformation they are in the plane (H-C9 out of the ring H-C10 inside 
the ring). The transition states involved in conversion between heart and ribbon 
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shapes of both 44 and 52 were located by scanning the potential energy surface 
associated with rotation of the vinylic CH with respect to the plane of the 
macrocycle. Starting from the heart shape, this motion can be thought of as the 
H-C10 moving through the center of the ring. Rotation in the opposite direction is 
energetically unfavorable and requires more degrees of rotation.  
Analysis of the PES for isomerization of 52 reveals key similarities and 
differences with respect to the PES of 44. First, the barrier of isomerization is 
slightly less than for 44, although it is more or less the same. The reaction in 
toluene is exergonic by –4.4 kcal/mol, with the reverse barrier increasing to 7.7 
kcal/mol. Taken together, it is reasonable that, while ribbon 52 is 4 kcal/mol more 
stable than ribbon 44, there is a relatively low barrier associated to 
interconversion between ribbon and heart conformers for both of them. The fact 
that the heart conformer of 52 is not observed in the crystal structure of related α- 
substituted [13]-macrodilactones18 may simply be related to crystal packing 
forces.  
What remained necessary was to put our observations into the context of 
a physical model that could rationalize the conformations and the dynamics of 
the [13]-macrodilactones. Specifically, we wanted to explain why, in the case of 
44, both the ribbon and the heart conformers were adopted in nearly equal 
populations. The main difference between the two conformers is in the 
orientation of the double bond. Both have the aryl ring in a pseudo-equatorial 
disposition relative to the macrocycle, likely to minimize transannular interactions. 
The rotamer about the C-aryl, C8 bond, present in the crystal structure and 
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computational structures, puts the aryl ring in an eclipsing orientation relative to 
the benzylic CH (“aryl parallel”). This has been shown to be the preferred rotamer 
for equatorial aryl groups in cyclohexanes,46 1,3-dioxanes, and 
tetrahydropyrans.47 In the six membered-ring cases this preference is adopted 
because steric interactions between ortho-hydrogens of the aryl ring and 
equatorial hydrogens on the saturated ring are avoided. It is likely that a similar 
effect is at play for the [13]-macrodilactones. The benzylic carbon in 44 is flanked 
by a saturated methylene on the one side (the carbon α− to the ester carbonyl, 
C7) and a vinyl group on the other. The ortho hydrogen of the aryl ring is some 
distance from the pseudo-equatorial hydrogen of the methylene (3.118 Å) but it is 
close to the proximal vinyl proton (2.482 Å). In the heart conformation, the 
proximal vinyl is significantly farther away from the ortho hydrogen (3.948 Å). The 
main driver between this subtle difference in conformations is, therefore, this 
steric interaction. While it is speculative, the close proximity and geometry of a 
vinylic CH bond to the carbonyl oxygen of an ester in the heart conformation is 
also noteworthy. One thing that becomes clear from the analysis of the solid 
state and computational structures of both 44 and 52, though, is that the 
conformational dynamics are primarily localized around the alkene portion of the 
molecule. It does not seem that the other planar units (the two esters) are 
oscillating in a similar way.  
2.4.3 Macrocyclic diastereocontrol as a readout of solution 
conformation 
In an attempt to better understand the solution conformations of the [13]-
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macrodilactones, epoxidation reactions were performed. There is no internal 
cavity of the [13]-macrodilactones so, based on the planar chirality, only one face 
– the outer face of the alkene is available to react with electrophiles. The planar 
chirality of the ring, therefore, controls the diastereoselectivity of epoxidation of 
the [13]-macrodilactones, which is an example of macrocyclic diastereocontrol.48–
52 Macrocycles 44 and 52 were both epoxidized under established reaction 
conditions that involved either in situ generation of dimethyl dioxirane (DMDO) in 
the presence of the substrate or addition of a solution of DMDO to a solution of 
the substrate.16,53,54 When α-substituted [13]-macrodilactone 52 was the 
substrate, two diastereomeric epoxides, 54 and 55 (Figure 2.13), were obtained 
in an approximately 1:3 ratio. This result initially seemed inconsistent with results 
obtained of epoxidation on the related compound, α-phenyl substituted [13]-
macrodilactone 53.18 When the reaction was revisited, however, we found that 53 
does, in fact, provide two diastereomeric epoxide products in an approximately 
1:3 ratio (56:57). These results suggest that both sides of the alkene are 
reacting. A model where reaction occurs through both the heart and the ribbon 
conformations is consistent with, or even required by, the observed products. 
Epoxidation of β-substituted macrodilactone 44 was also conducted; in this case, 
two products that we ascribe as diastereomeric epoxides 58 and 59 came about 
in an approximately 1:7 ratio. Upon initial consideration, an explanation for these 
results was not obvious so we once again resorted to computational chemistry in 
the hope of gaining insight into the reaction.  
 52 
  
 
Figure 2.13  [13]-Macrodilactones 44, 52, 53 and the products of their epoxidation, 
organized by the conformer that gives rise to each diastereomer: 54, 56, 58 are the 
major isomers via the heart conformers; 55, 57, and 59 are the minor isomers via the 
ribbon.   
 
The objective of the computational investigation was to determine whether 
the observed epoxide product distributions could be qualitatively rationalized 
when considering the conformational equilibria of macrocycles 44 and 52 and the 
transition states associated with each. Toward that goal, the stationary points on 
the potential energy surface (PES) for the DMDO mediated epoxidation of 44 and 
52 were found. Extensive conformational searches for transition states have 
been conducted, and only the lowest energy conformers are shown in this work. 
Even though the ring closing metathesis reaction is carried out in toluene, when 
the macrocycle is epoxidized in DCM, the equilibrium between the two topologies 
(ribbon and heart) will be shifted and we then computed the entire PES, that is, 
isomerization as well as epoxidation, in DCM. The β - and α -substituted p-Br 
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conformations in DCM, the new solvent. These conformers served as the starting 
point for modeling the epoxidation reaction. At this point the transition state (TS) 
was located using initial structures derived from Houk's and Jorgensen’s 
published coordinates, which involved epoxidation of cis- and trans-2-butene by 
DMDO.55 Moving along the reaction coordinate, the final epoxide product was 
then also located. During the epoxidation, DMDO is converted to acetone. 
Computed energies that represent the PES of isomerization and epoxidation in 
DCM for macrocycles 44 and 52 are collected in Table 2.4; figures showing the 
PES for each compound are provided in the Supporting Information.  
A number of observations become apparent when considering the relative 
energetic values in Table 2.4. First, the isomerization of ground state 
macrocycles between heart and ribbon conformers in DCM is reminiscent of the 
surface calculated in toluene earlier. The ribbon conformers for both 44 and 52 
are preferred, and that preference is more pronounced (by 0.6 kcal/mol) for α-
substituted macrocycle 52. Similarly, conversion from the ribbon to the heart 
conformer requires 4.6 and 6.8 kcal/mol for 44 and 52, respectively. This 
suggests that interconversion of the conformers occurs readily under the reaction 
conditions. Second, the products that are the result of epoxidation of the ribbon 
conformer are more stable (by ~5 kcal/mol) than those that arise from the heart 
conformer. Third, activation barriers for epoxidation of the heart conformers are 
higher in both cases compared to the ribbon conformers. Epoxidation of the 
ribbon conformer of 44 and 52 is the preferred pathway in terms of energetics 
and, based on the Curtin-Hammett Principle, should deliver the major product 
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diastereomer. Amongst the four transition states, the one with ribbon configured, 
8R,pR β-macrocycle 44 and DMDO is the most stable at 8.5 kcal/mol relative to 
reactants. Fourth, the barrier for epoxidation of the 7S,pS heart structure of α-
macrocycle 52 is 2.1 kcal/mol higher than that of the 7S,pR ribbon. For 44 the 
8R,pS heart is 4.4 kcal/mol higher than the 8R,pR ribbon. There is a greater 
preference, therefore, for epoxidation of 44 to proceed via the ribbon conformer 
than there is for 52. There is strong qualitative agreement, therefore, between the 
picture painted by the analysis of the PES and the higher diastereoselectivity in 
epoxidation of β-macrocycle 44.  
Table 2.4 Computed reaction energies (kcal/mol) for the isomerization between the 
ribbon and heart conformers of 44 and 52 and epoxidation reactions leading to adducts 
11 - 14.a 
  
Conformer/Compound 
52 
Energy 
[kcal mol-1] 
 
Conformer/Compound 
44 
 
α β 
 
heart 
7S,pS – epoxide (56) -53.3 -53.4 8R,pS – epoxide (58)  
heart 7S,pS – epoxidation TS‡ 13.9 13.5 8R,pS – epoxidation TS‡ 
7S,pS – g.s. heart-52 0.0 0.0 8R,pS – g.s. heart-44 
 7S TS‡ (52) 5.7 4.1 8R TS‡ (44)  
 
ribbo
n 
7S,pR – g.s. ribbon-52 -1.1 -0.5 8R,pR – g.s. ribbon-44  
ribbon 7S,pR – epoxidation TS‡ 10.7 8.5 8R,pR – epoxidation TS‡ 
7S,pR – epoxide (57) -58.9 -58.4 8R,pR – epoxide (59) 
[a] Computed at the BLYP-D3(BJ)/TZ2P level in DCM; g.s.=ground state; epox = epoxidation 
 
Inspection of the geometries and associated energies of the transition 
states in the epoxidation reaction reveals additional insights. The computed TS 
geometries confirmed that epoxidation is a concerted asynchronous process; that 
is, the newly forming C–O bond distances are not equal (Figure 2.14). The 
extreme case being for 7S,pR ribbon, where the difference in bond distance is 
0.9 Å. This is at variance with the previous accounts on the very simple model 
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reaction involving (E/Z)-but-2-ene.55 Apparently, the p-bromophenyl group and 
other geometric features in the [13]-macrodilactones prohibit a synchronous 
process.  
 
Figure 2.14 Structures (in Å) of the TSs and relative activation free energies 
∆∆G‡DCM,298K (in kcal/mol) computed at the BLYP-D3(BJ)/TZ2P level. 
Next, the activation strain model (ASM),56–60 also known as the 
distortion/interaction model61–63 was applied to understand the factors giving rise 
to the activation barriers associated with the epoxidation reaction in the gas 
phase. This analysis is based on the “electronic energy (E)” that constitutes the 
multidimensional PES of a system and thus its state function, which determines 
all thermal and statistical effects leading to H or G. The activation barrier results 
from the interplay between the strain ΔEstrain and interaction ΔEint energies, as 
shown in Equation 1:  
ΔE‡ = ΔE‡strain + ΔE‡int 
 
In this framework, each transition state structure is separated into two fragments, 
namely the distorted macrocycle and the distorted DMDO, followed by single-
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point energy calculations on each fragment. The difference in energy between 
the optimized energy minimum structure for a given species and geometry it 
adopts in the transition state is the strain, ΔE‡strain, while the ΔE‡int is the 
interaction between the deformed reactants. 
It is difficult to attribute the difference in reactivity between the different 
conformations of the macrocycle to either the ΔE‡strain or the ΔE‡int exclusively. 
Trends, however, do emerge as demonstrated in Figure 2.15. The total strain 
energy, for example, is primarily due to distortion of the DMDO molecule. 
Furthermore, we find that the strain associated with epoxidation of the ribbon 
macrocycles is lower compared to that of the heart macrocycles (ΔΔE‡strain = 
3.2 – 4.5 kcal/mol). This, along with a favorable interaction, leads to markedly 
lower barriers for epoxidation of the ribbon macrocycles. Comparison of the 
ribbon conformers reveals that the ΔE‡strain term is nearly equivalent, but the 
more favorable interaction for the ribbon 44 leads to a lower barrier (ΔΔE‡ = 1.8 
kcal/mol). Additionally, we see that the greater distortion energies associated 
with epoxidation of the heart shaped macrocycles overtakes their more favorable 
interaction energies, thereby resulting in higher activation barriers compared to 
the ribbon conformations.  
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Figure 2.15 Graph of interaction, strain, and activation energies for the epoxidation 
reactions of ribbon 44, heart 44, ribbon 52, and heart 52. Energies (in kcal/mol) 
computed at the BLYP-D3(BJ)/TZ2P level in the gas phase. 
 
2.5 Conclusion 
The main insight gained from this project is that substituents at the allylic 
position behave similarly to that of the unsubstituted and alpha substituted [13]-
macrodilactones. The lowest global energy conformation is the “ribbon” shape as 
seen in both beta monosubstituted and disubstituted [13]-macrodilactones, but 
with proof that the alkene itself is not as rigid as we once thought.  The p-
bromophenyl substituent at the allylic position (C8) of our [13]-macrodilactone 
motif engenders flexibility in the macrocycle that is observable in both the solid 
state and in solution, which we never originally observed in the alpha position. 
Two essentially equi-energetic conformers, the ribbon and the heart, are 
populated by compound 44. This conformational effect is in contrast to other 
studies on natural product macrocycles where an allylic substituent either had 
little effect on the conformational dynamics or it helped to rigidify it. The results 
also support the contention that the flexibility is a local effect. That is, of the two 
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esters and the alkene units in the macrocycle, it is only the alkene moiety that 
shows evidence of fluctuating. Epoxidation reactions of the alkene unit revealed 
additional differences between C7 and C8 substituted [13]-macrodilactones. 
Specifically, there was a greater difference in the transition state energies for the 
ribbon and heart conformers for 44 than there was for a-substituted macrocycle 
52. The consequence was that 44 showed a qualitatively higher macrocyclic 
diastereoselectivity. Throughout the experimental investigation, computational 
chemistry guided the explanation of our observations. This fact underscores the 
significant impact that computational chemistry had on the project. Finally, the 
conformational and reactivity patterns observed underscore the natural product-
like properties of this family of [13]-macrodilactones.  
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2.6 Experimental 
2.6.1  General Methods 
 Unless stated otherwise, all acylations were conducted at 0°C and then 
left overnight at room temperature. Reactions were monitored using TLC.  UV 
light and p-anisaldehyde or CAM were used for visualization. Chromatography 
was performed on silica gel and solvent systems were based on the Rf values. 
Both 1HNMR spectra referenced to CDCl3 (δ H 7.27 ppm) using 300 and 400 
MHz and 13CNMR spectra referenced to CDCl3 (δ C 77.23 ppm) using 100 MHz 
were collected. 
2.6.2 Diene through stepwise acylations: General method  
Method  A: 
 To a 25 mL round bottom flask was added DCM (7 mL), 
dicyclohexylcarbodiimide (DCC) (1.08 eq.) and N,N-dimethylaminopyridine 
(DMAP) (0.3 eq.) were added and cooled to 0 °C. 4-pentenoic acid (1.0 eq.) was 
added and the mixture was stirred at the same temperature for 30 minutes until a 
white suspension was observed in the flask. 1,3-Propanediol or 1,3-butanediol 
(1.0 eq.) in DCM (3 mL) was then added to the reaction mixture and it was stirred 
overnight at room temperature. After, the reaction mixture was filtered through a 
prewashed (DCM) short pad of celite, rinsed with DCM and the filtrate was 
removed under reduced pressure. The material was then dissolved in cold ether, 
allowing the DCU to precipitate out, and filtered again through a prewashed (cold 
ether) short pad of celite followed by an ether rinse. The crude residue was 
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purified by silica gel column chromatography (15 % EtOAc: hexanes) to give the 
monoacylated product. 
Method B: 
 In a 25 mL round bottom flask, DCC (1.08 eq.) and DMAP (0.3 eq.) were 
added in DCM (7 mL) and cooled to 0°C. Acid of choice (1.0 eq.) was added to 
the solution and stirred at room temperature for 30 minutes until a white 
suspension was observed. A monoacylated diol (1.0 eq.) dissolved in 3mL of 
DCM was then added to the mixture as a solution and stirred overnight at room 
temperature. The reaction mixture was filtered through a prewashed (DCM) short 
pad of celite, rinsed with small amount of DCM and then the solvent was 
removed under reduced pressure. The material was re-dissolved in cold ether 
allowing the DCU to precipitate out, filtered again through a prewashed (cold 
ether) pad of celite, which was then rinsed by a small amount of cold ether. The 
solvent was removed under reduced pressure and the crude residue was purified 
by silica gel column chromatography (hexanes: EtOAc 70:30) to give the diene. 
2.6.3 Diene through diacylation: General method 
In a 25 mL round bottom flask, DCC (1.08 eq.) and DMAP (0.3 eq.) were 
dissolved in DCM (7mL), and the solution was cooled to 0°C. Then acid of choice 
(1.0 eq.) was added and stirred at the same temperature for 30 minutes until a 
white suspension formed. A solution of 1,3-butanediol (0.5 eq.) in DCM (3 mL) 
was then added to the mixture and it was stirred overnight at room temperature. 
The mixture was then filtered through a prewashed (DCM) short pad of celite, 
which was then washed with cold DCM. The DCM was removed under reduced 
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pressure and the residue was purified by silica gel column chromatography to 
dive the desired diene. 
2.6.4 RCM General Method 
 Under an atmosphere of dry N2, the appropriate ring closing metathesis 
catalyst – Grubbs’ second-generation or Hoveyda Grubbs’ second generation- 
(0.05 – 0.105 mmol) was added to a solution of the diene in toluene (100 mL). 
The mixture was heated to reflux at 110 °C for 18 hrs. After, the toluene was 
removed under reduced pressure to give a residue that was purified by column 
chromatography. 
2.6.5 General procedure for DMDO epoxidation of macrocycle 
In an eight-dram dry vial containing 4Å sieves and a stir bar, macrocycle 
(0.109 mmol, 1 eq) was dissolved in dry DCM (0.1 mL) and parafilmed with a 
septum. DMDO-acetone in DCM (3 mL, 0.094 M, 2.5 eq) was then added to the 
vial and stirred at r.t for 3 hours. Crude material was concentrated under reduced 
pressure followed by a crude NMR. 
 
  
 62 
2.6.6 Synthesis of DMDO 
 
 
 
NAHCO3 (240g, 2.86 mol), H2O (350mL), and acetone (260mL) were 
added in a 3L 3-knecked flask at 0°C. KHSO4 was then added slowly while 
stirring. Vacuum was applied and DMDO-acetone was distilled out over 1hr into 2 
connected receiving flasks (500mL and 250mL) while temperature of those flasks 
were kept at -78°C. After an hour DMDO-acetone was distilled out with cold H2O 
(same volume of DMDO-acetone mixture). 10 mL of DCM were added and 
aqueous layer was separated. Organic layer was washed with phosphate buffer 
(pH-7- 100mL). It was then extracted with DCM (10 mL), dried with Na2SO4 and a 
yellow solution was obtained. It was stored in a dry flask with activated 4Å 
molecular sieves and stored in freezer.  
Calibration: Citronellic acid (0.16g, 0.940 mmol) was dissolved in 1 mL 
DMDO-acetone in DCM and left to stir for at least 10 minutes at r.t. DCM was 
evaporated, dissolved in CDCl3 (0.6 mL) and the NMR was taken. The NMR is 
calibrated using the alkene of citronellic acid, which is a dd at 5.05 ppm. Once 
calibrated, the epoxidation signal was found to be a dd between 2-3ppm 
(2.7ppm). The signal’s integration (0.29) was then used to calculate the molarity.  
Molarity Calculation= (citronellic acid (g)/ MW) x (epoxide integration/alkene 
integration) x 1000; Molarity = 0.09M (day 7)  - 0.273M (day 1).  
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2.6.7 3-methyl-4-pentenoic acid  (18) 
 
 
 
A mixture of crotyl alcohol (d= 0.845 g/mL; 7.08 mL, 83.0 mmol), triethyl 
orthoacetate (d= 0.885 g/mL; 15.22mL, 83.0 mmol) and acetic acid (d= 1.05 
g/mL; 63 µL, 0.5 mmol) were placed in a 50 mL flask with a Claisen head 
adapter, condenser, and thermometer and heated on an oil bath. After 1.5 h, the 
temperature reached 150 °C10 mL of ethanol had distilled from the mixture. 
When distillation slowed another 63 µL of acetic acid was added and continued 
distilling for another half an hour. It was then taken off the oil bath, allowed to 
cool to rt, and transferred into a 200 mL round bottom flask. Potassium hydroxide 
(6.56 g, 0.117 mol) was added to 50 mL ethanol and the mixture was heated 
under reflux for 2.5 h. It was allowed to cool to rt and then the ethanol was 
evaporated under vacuum. The crude material was dissolved in 50 mL of water 
and acidified to pH 1 using concentrated HCl. The reaction mixture was washed 
with Et2O (3 x 25 mL) and the combined organic layers were dried over Na2SO4. 
The solution was filtered and concentrated under reduced pressure. The crude 
material was then purified by distillation with toluene (25 mL) to give a yellow oil. 
Not pure based on NMR impurities (mostly triethyl orthoacetate) and comparing 
to the literature, but carried on for use in acylation (40% crude). Rf 0.59 (hexanes: 
EtOAc 80:20); 1HNMR (CDCl3) 400 MHz correlates to literature.64 
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2.6.8 3-Phenyl-4-pentenoic acid (19) 
 
 
 
 Followed procedure by Bartlett et. al.32 Cinnamyl alcohol (16.85 g, 0.125 
mol), triethyl orthoacetate (23.05 mL, 0.125 mol) and hexanoic acid (95 µL , 0.75 
mol) were placed in a 100 mL round bottom flask with a Claisen head adapter, a 
condenser, and a thermometer. The mixture was heated on an oil bath (slowly to 
reach 150 °C). After 3 h, the distillation slowed down and 50 µL of additional 
hexanoic acid was added. Further additions of 50 µL hexanoic acid were made at 
3.5 h and 4.5 h. After 6 h the oil bath temperature reached 150 °C and 23.5 mL 
of ethanol has been distilled from the mixture. The reaction was cooled to rt and 
a solution of potassium hydroxide (9.85 g, 0.175 mol) in 12.5 mL water and 37.5 
mL methanol were then added to it. This mixture was refluxed for 1 h under 
nitrogen. The solution was allowed to cool to rt, and then washed with ether (3 x 
50 mL). The aqueous layer was then acidified with concentrated HCl to pH 1 and 
extracted with Et2O (3 x 50 mL). The combined organic layers were dried over 
MgSO4, filtered and concentrated under reduced pressure. The crude material 
(64%) was carried on for use in acylation. Rf 0.25 (hexanes: EtOAc 80:20); 
1HNMR (CDCl3) 400 MHz correlates to literature.65  
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2.6.9 3-bromo-phenyl-4-pentenoic acid (20)66–68 
 
 
 
To a solution of commercially available (carbethoxymethylene)-
triphenylphosphorane 25 (13.9 g, 40 mmol) in toluene (50 mL) in a 150 mL round 
bottom flask was added 4-bromobenzaldehyde 24  (16.2 g, 33 mmol). The 
mixture was stirred at rt for 30 minutes. The reaction mixture was concentrated 
under reduced pressure and the residue was purified via silica gel 
chromatography (5-15% EtOAc/Hexanes) to give the ester product 26 in 97% 
yield (with trace of Z isomer). Rf  0.51 (E isomer), Rf  0.58 (Z isomer) (10%  
EtOAc:Hex). 
 To a solution of ethyl-trans-4-bromocinnamate 26 (1.7g, 6.86 mmol) in 
anhydrous DCM (30 mL) under N2, 1.0 M DIBAL-H (14.41 mL, 14.41 mmol) in 
hexanes was added dropwise over 1 hour min at -78 °C. It was stirred for 3 h at -
78 °C and then slowly warmed to 0 °C.  The mixture was quenched by the slow 
addition of isopropanol (5 mL) and then the mixture was warmed to rt. Then 5 
drops of water was slowly added, followed by addition of another 15mL of water. 
The aqueous phase was separated and the extracted with DCM (3 x 15 mL). The 
organic fractions were combined, dried with Na2SO4 and filtered through fluted 
filter paper. The obtained solution was concentrated under reduced pressure 
giving you crude 27 as a white solid in 73% yield (1.07g). 
Ph3P=CHCO2Et
Br
O
Toluene
   97% Br
O
OEt
Br
OH
DIBAL-H
DCM
 73%
1. Triethylortho Acetate, 
        Hexanoic Acid
2. KOH, Me/MeOH/H2O
                 78%
O
OH
Br
24                                                                   26                                                         27                                                                          20
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The crude 3-(4-bromophenyl)-2-propen-1-ol 27 (0.621 g, 2.92 mmol) was 
placed in a 10 mL flask containing triethyl orthoacetate (2.67 mL, 14.58 mmol) 
and hexanoic acid (22 µL, 0.175 mmol) with a condenser and thermometer. The 
mixture was heated in an oil bath (138°C) for 3h, adding an additional 10 µL of 
hexanoic acid after 1 h and 2 h reaction time. After 3 h, external temperature was 
raised to 170°C to distill excess triethyl orthoacetate for 2 hours and then cooled. 
Potassium hydroxide (0.229 g, 4.08 mmol) in water (292 µL) and methanol (875 
µL) were added and the mixture was then refluxed overnight and cooled. Water 
and ether were then added to the cooled reaction mixture (10mL each), 
separated, and the aqueous layer was acidified to pH 1 with concentrated HCl. It 
was then extracted with ether (3 x 10 mL). The combined organic layers were 
dried with Na2SO4 and filtered through fluted filter paper. The solution was then 
concentrated under reduced pressure and the crude product was purified through 
column chromatography with a 78% yield (580mg) as a tan solid. Rf  0.23 
(Hexanes:EtOAc 80:20); 1HNMR (CDCl3) 400 MHz δ 10.7 (s, 1H), 7.4 (d, J = 8.4 
Hz, 2H), 7.1 (d, J = 8.4 Hz, 2H), 6.0 (ddd, J  = 17.3, 10.5, 6.8 Hz, 1H), 5.1 (dd, J 
=16.3, 9.8 Hz, 2H), 3.8 (ddd or dt, J = 7.3, 7.3, 7.3 Hz, 1H), 2.8 (ddd, J = 11.9, 
7.8, 0 Hz, 2H); 13C NMR (CDCl3) 100 MHz δ 177.3, 141.3, 139.6, 132.0, 129.6, 
120.9, 115.7, 44.8, 39.8; DART-TOF HRMS  m/z calcd for C11H11O2Br  [M+H]+ 
236.9915, obs. 236.9911 
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2.6.10 2-p-bromophenyl-4-pentenoic acid (52) 
 
 
 
 Followed the literature procedure.69 To a solution of 4-bromophenylacetic 
acid (1g) in methanol (50 mL) at 0 °C, concentrated H2SO4 (5 mL) was added 
dropwise. It was heated under reflux for 3 hours, cooled to 25 °C and diluted with 
ethyl acetate (350 mL). The solution was washed with water (3 x 60 mL), the 
combined fractions were dried over Na2SO4 and concentrated under reduced 
pressure to give the methyl ester 61. 
 To a solution of diisopropylamine (9.63 mmol) in dry THF (46 mL) at 0 °C 
under a flow of nitrogen, butyllithium (10.1 mmol) was added. After 10 minutes at 
0 °C, the LDA solution was cooled to -60 °C and a solution of methyl(4-
bromophenyl)acetate 61 (9.17 mmol) in THF (5 mL) was added. Temperature of 
the reaction mixture was maintained at -60°C for 30 minutes and the allyl 
bromide (9.63 mmol) was added dropwise. The reaction mixture was slowly 
warmed to room temperature over 1 hour. The solution was then diluted with 
ethyl acetate (100 mL), washed with saturated aqueous NH4Cl, dried over 
Na2SO4, and concentrated under reduced pressure. The crude ester was purified 
using column chromatography to give pure 62 in 72% yield.  
 The methyl ester of the 2-p-bromophenyl-4-pentenoic acid (6.4 mmol) 
was dissolved in a mixture of MeOH/H2O 3:1 (32 mL) and NaOH (8.3 mmol) was 
added to the solution. After 20 hours at room temperature the reaction mixture 
Br O
OH
Br O
OMeOH, H2SO4
80°C, 3hr
    85% Br O
O
Br O
OH
LDA, THF NaOH
MeOH/H2O
      96%
Br
72%
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was concentrated under reduced pressure. It was diluted with H2O and acidified 
with concentrated HCl to pH 1. The mixture was extracted with ethyl acetate (3x) 
and the combined extracts were dried over Na2SO4. The solvent was 
concentrated under reduced pressure to afford the crude pentenoic acid. 1HNMR 
(CDCl3) 400 MHz correlates to literature.70  
 
2.6.11 3-Methyl-3-hydroxypropyl-4-pentenoate 31 
 
 
Followed the diene through stepwise acylations general method to give 31 
as a colorless oil (84 %). Rf = 0.26 (hexanes:EtOAc 70:30); 
1
H NMR (CDCl3) 400 
MHz δ 5.82 (dddd/dq, J = 16.8, 11.2, 6.2, 6.2 Hz, 1H), 5.07 (dd, J = 17.2, 1.5 Hz, 
1H), 5.01 (dd, J = 10.3, 1.3 Hz, 1H), 4.34 (ddd, J = 11.3, 8.3, 5.3 Hz, 1H), 4.15 
(ddd/dt, J = 11.4, 5.7, 5.7 Hz, 1H), 3.81 (m, 1H), 2.40 (m, 4H), 2.07 (s, 1H), 1.74 
(m, 2H), 1.22 (d, J = 6.31 Hz, 3H); 13CNMR (CDCl3) 100 MHz δ 173.4, 136.6, 
115.6, 64.9, 61.7, 38.1, 33.5, 28.9, 23.5; TOF HRMS (DART) m/z calcd for 
C9H17O3 [M+H]
+ 
173.1177, found 173.1161.  
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2.6.12 3-Hydroxypropyl-4-pentenoate (32)  
 
 
Followed the diene through stepwise acylations general method to give 32 
in 67% yield as a clear, colorless oil. Rf 0.2 (hexanes: EtOAc 70:30); 1HNMR 
(CDCl3) 400 MHz. δ 5.82 (ddd, J = 10.4, 6.3, 6.3, 6.3 Hz, 1H), 5.08 (dd, J = 16.6, 
16.6, 0 Hz, 1H), 5.02 (dd, J = 10.2, 10.2, 0 Hz, 1H), 4.25 (ddd, J = 6.1, 6.1, 0 Hz, 
2H), 3.69 (ddd, J = 6.1, 6.1, 0 Hz, 2H), 2.41 (m, 4H), 1.88 (dddd or tt, J = 6.1, 6.1, 
6.1, 6.1 Hz, 2H), 1.72 (s, 1H); 13C NMR (CDCl3) 100 MHz δ 173.6, 136.6, 115.6, 
61.5, 59.0, 33.6, 31.7, 28.9; TOF HRMS (ESI) m/z calcd for C8H14O3 (M+Na)+ 
181.0841, found 181.0838  
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2.6.13  Compound 34 
 
  
 
Followed general method of dienes through monoacylation (method A and 
then method B) in 81% yield and as a colorless oil. Rf 0.55 (hexanes: EtOAc 
80:20); 1H NMR (CDCl3) 400 MHz δ 5.84 (ddd, J = 16.5, 10.9, 6.0 Hz, 1H), 5.7 
(dddd (or dtd), J = 10.0, 7.0, 7.0, 3.0 Hz, 1H), 5.05 (m, 5H), 4.1 (ddd (or dt), J = 
11.0, 4.82 Hz, 2H), 2.66 (ddd, J = 20.6, 13.5, 6.7 Hz, 1H), 2.38 (m, 4H), 2.30 (dd, 
J = 7.3, 2.9 Hz, 1H), 2.23 (dd, J = 18.9, 7.3 Hz, 1H), 1.87 (m, 2H), 1.24 (d, J = 
6.25 Hz, 3H), 1.05 (d, J = 7.18 Hz, 3H); 13C NMR (CDCl3) 100 MHz δ 172.9, 
171.9, 142.4, 136.6, 115.5, 113.4, 67.8, 60.6, 41.6, 34.8, 34.6, 33.5, 28.8, 20.1, 
19.7 TOF HRMS (DART)  m/z calcd for C15H24O4 [MH]
+, calc. 269.1753, found 
269.1744 
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2.6.14   Compound 35 
 
    
 
Followed general method of dienes through monoacylation (method A and 
then method B) in 70% yield and as a colorless oil. Rf 0.56 (hexanes: EtOAc 
80:20); 1H NMR (CDCl3) 400 MHz δ 7.42 (d, J = 8.31 Hz, 2H), 7.09 (d, J = 8.3 
Hz, 2H), 5.93 (dddd, J = 16.8, 10.3, 6.5, 1.7 Hz, 1H), 5.8 (m, 1H), 5.01 (m, 5H), 
4.02 (m, 2H), 3.81 (ddd, J = 7.5, 7.5, 7.5 Hz, 1H), 2.73 (m, 1H), 2.64 (ddd, J = 
15.3, 7.9, 0 Hz, 1H) 2.38 (m, 4H), 1.81 (m, 2H), 1.17 (d, J = 6.3 Hz, 2H), 1.12 (d, 
J = 6.3 Hz, 1H); 13C NMR (CDCl3) 100 MHz δ 173.1, 171.2, 141.5, 139.9, 136.8, 
131.8, 129.6, 120.8, 115.7, 115.4, 68.3, 60.7, 45.3, 40.4, 34.9, 33.7, 29.0, 20.1 
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2.6.15   Compound 36  
 
Followed general method of dienes through monoacylation (method A and 
then method B) in 74% yield and as a yellow oil. Rf 0.22 (hexanes: EtOAc 95:5); 
1H NMR (CDCl3) 400 MHz δ 7.32 (m, 2H), 7.21 (m, 3H), 5.98 (ddd, J = 18.2, 
10.14, 7.8 Hz, 1H), 5.81 (m, 1H), 5.0 (m, 5H), 4.21 (m, 2H), 3.86 (ddd (or dt), J = 
7.4, 7.4, 7.4 Hz, 1H), 2.80 (dd, J = 15.1, 8.12 Hz, 1H), 2.70 (dd, J = 15.1, 7.4 Hz, 
1H), 2.40 (m, 4H), 1.78 (m, 2H) 1.21 (d, 3H, J = 5.6 Hz); 13C NMR (CDCl3) 100 
MHz δ 172.6, 171.8, 142.5, 140.4, 136.8, 128.7, 127.7, 126.8, 115.7, 115.0, 67.9, 
60.9, 45.7, 40.3, 34.9, 33.9, 29.0, 20.2 
2.6.16   Compound  37 
 
 
 Followed the general method of dienes through monoacylation (method A 
and then method B) in 53% yield and colorless oil. Rf 0.45 (hexanes: EtOAc 
90:10); 1HNMR (CDCl3) 400 MHz. δ 5.76 (m, 2H), 4.98 (m, 4H), 4.13 (ddd or dt, J 
= 6.4, 6.4, 1.8 Hz, 4H), 2.66 (s, J = 7.0, 7.0, 7.0, 7.0, 7.0, 7.0, 7.0 Hz, 1H), 2.34 
(m, 6H), 1.95 (dddd or dq, J = 6.3, 6.3, 6.3, 6.3 Hz, 2H), 1.03 (d, J = 6.7 Hz, 3H); 
13C NMR (CDCl3) 100 MHz δ 172.9, 172.4, 142.3, 136.6, 115.5, 113.4, 60.9, 
60.8, 41.2, 34.4, 33.4, 28.8, 28.0, 19.7; TOF HRMS (DART) m/z calcd for 
C14H22O4 [MH]
+ 255.1596, found 255.161 
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2.6.17  Compound 38 
 
  
Followed general method of dienes through monoacylation (method A and 
then method B) in 87% yield and as a colorless oil. Rf 0.43 (hexanes: EtOAc 
90:10); 1H NMR (CDCl3) 400 MHz δ 7.43 (d, J = 8.3 Hz, 2H), 7.10 (d, J = 8.3 Hz, 
2H), 5.93 (ddd, J = 17.2, 10.4, 6.8 Hz, 1H), 5.82 (ddd or dt, J = 10.4, 10.4, 4.6 
Hz, 1H), 5.09 (d, J = 7.8 Hz, 2H), 5.01 (d, J = 10.9 Hz, 2H), 4.08 (ddd, J = 6.2, 
6.2, 6.2 Hz, 4H), 3.83 (ddd, J = 7.5, 7.5, 7.5 Hz, 1H), 2.72 (dddd or dq, J = 15.3, 
15.3, 15.3, 7.8 Hz, 2H), 2.40 (ddd, J = 15.0 11.0, 4.3 Hz, 4H), 1.88 (ddd or dt, J = 
12.4, 6.2, 6.2 Hz, 2H); 13C NMR (CDCl3) 100 MHz δ 173.1, 171.6, 141.5, 139.9, 
136.8, 131.9, 129.5, 115.8, 115.5, 61.3, 61.0, 53.6, 45.2, 40.2, 33.7, 29.0, 28.2; 
TOF HRMS (DART)  m/z calcd for C19H23O4Br  [M+H]+ 395.0858, found. 
395.0827. 
 
 
 
 
 
 
 
O
O
O
OBrPh
 74 
2.6.18 1,3-Propane diol di-(4-pentenoate) (39) 
 
 
Followed the general procedure of diene through diacylation in 96% as 
colourless oil. Rf = 0.58 (hexanes:EtOAc 80:20); 
1H NMR (CDCl3) 400 MHz δ  
5.83 (dddd/dq, J = 16.6, 10.3, 6.2, 6.2 Hz, 2H), 5.08 (dd, J = 17.2, 1.5 Hz, 2H), 
5.02 (dd, J =10.3, 1.5 Hz, 2H) 4.17 (t, J =6.42 Hz, 4H), 2.42 (m, 8H), 1.98 ppm 
(quin, J=6.3 Hz, 2H);
 13C NMR (CDCl3) 100 MHz δ 173.2, 136.8, 115.8, 61.2, 
33.7, 29.1, 28.2ppm; TOF HRMS (DART) m/z calcd for C13H21O4 [M+H]
+ 
241.1439, found 241.1425  
2.6.19  1,3-Propane diol di-(3-methyl-4-pentenoate) (40) 
 
 
Followed the general procedure of diene through diacylation in 43% yield 
and colorless oil. Rf 0.47 (hexanes: EtOAc 90:10); 1H NMR (CDCl3) 400 MHz δ 
5.73 (ddd, J = 17.2, 10.2, 7.3 Hz, 2H), 4.96 (dd, J = 22.3, 17.2 Hz, 4H), 4.13 (dd, 
J = 6.33, 6.33 Hz, 4H), 2.65 (s, J = 7.0, 7.0, 7.0, 7.0, 7.0, 7.0, 7.0 Hz, 2H), 2.29 
(dddd or dq, J = 22.1, 14.8, 14.8, 14.8 Hz, 4H), 1.94 (dddd or dq, J = 12.5, 6.2, 
6.2, 6.2 Hz, 2H), 1.03 (d, J = 6.6 Hz, 6H); 13C NMR (CDCl3) 100 MHz δ 172.4, 
142.5, 113.5, 61.0, 41.4, 34.6, 28.2, 19.9; TOF HRMS (DART) m/z calcd for 
C15H24O4 [MH]
+ calc. 269.1753, found 269.1749 
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2.6.20  1,3-Propane diol di-(3-bromophenyl-4-pentenoate) (41) 
 
  
 
Followed general method of dienes through monoacylation (method A and 
then method B) in 86% yield and as a colorless oil. Rf 0.57 (hexanes: EtOAc 
80:20); 1H NMR (CDCl3) 400 MHz δ 7.43 (d, J = 8.4 Hz, 4H), 7.10 (d, J = 8.4 Hz, 
4H), 5.93 (ddd, J = 17.1, 10.3, 17.0 Hz, 2H), 5.10 (m, 4H), 4.00 (ddd, J = 6.4, 6.4, 
0 Hz, 4H), 3.84 (ddd, J = 7.6, 7.6, 7.6 Hz, 2H), 2.76 (dd, J = 15.1, 7.4 Hz, 2H), 
2.67 (dd, J = 15.3, 7.4 Hz, 2H), 1.79 (m, 2H) 13C NMR (CDCl3) 100 MHz δ 171.4, 
141.3, 139.6, 131.7, 129.4, 120.6, 115.3, 60.9, 45.0, 39.9, 27.9 
2.6.21  Compound 42 
 
 
Followed the general method of RCM in 54% yield and as a white 
crystalline solid; m.p. 61.2– 61.7 °C; Rf 0.34 (hexanes: EtOAc, 80:20);
 1H NMR 
(CDCl3) 400 MHz δ 5.44 (m, 2H), 4.18 (dd, J =5.7, 5.7 Hz, 4H), 2.33 (m, 8H), 
2.02 ppm (ddd, J =11.8, 5.9, 5.9 Hz, 2H); 13C NMR (CDCl3) 100 MHz δ 173.9, 
130.0, 60.7, 34.4, 28.7, 26.1 ppm; TOF HRMS (DART) m/z calcd for C11H16O4 
[M+H]
+ 213.1127, found 213.1158.  
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2.6.22  Compound 43  
 
 
Followed the general method of RCM in 46% yield and as a clear oil. Rf  
0.38 (hexanes: EtOAc 80:20); 1H NMR (CDCl3) 400 MHz δ 5.40 (m, 1H), 5.24 
(dd, J = 15.4, 8.5 Hz, 1H), 4.34 (dddd or dq, J = 11.2, 8.1, 8.1, 8.1 Hz, 2H), 3.98 
(ddd or dt, J = 8.3, 4.6, 4.6 Hz, 1H) , 3.93 (ddd or dt, J = 8.9, 4.6, 4.6 Hz, 1H), 
2.60 (m, 1H), 2.30 (m, 5H), 2.13 (dd, J = 12.3, 12.3 Hz, 1H), 1.99 (dddd or tt, J = 
8.6, 8.6, 4.3, 4.3 Hz, 2H), 1.01 (d, J = 6.9 Hz, 3H); 13C NMR (CDCl3) 100 MHz δ 
173.8, 173.2, 135.9, 129.9, 127.8, 60.51, 42.4, 35.6, 34.2, 28.5, 26.0, 21.3 
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2.6.23  Compound 44 
 
 
Followed the general procedure for RCM on diene (38) to give the product 
as a white crystalline solid in 74% yield. M.p. 115.3-116.8°C, Rf 0.36 (hexanes: 
EtOAc 90:10); 1H NMR (C6D6) 500 MHz δ 7.18 (d, J = 8.7 Hz, 2H), 6.53 (d, J = 
8.3 Hz, 2H), 5.39 (m, 2H), 4.38 (ddd, J = 11.0, 11.0, 6.2 Hz, 2H), 3.69 (ddd, J = 
15.3, 4.1, 4.1 Hz, 1H), 3.65 (ddd, J = 15.0, 4.1, 4.1 Hz, 1H), 3.60 (ddd or dt, J = 
11.1, 4.2, 4.2 Hz, 1H), 2.37 (dd, J = 13.3, 12.4 Hz, 1H), 2.26 (dd, J = 13.6, 3.1 
Hz, 1H), 2.20 (dddd, J = 10.6, 7.6, 5.0, 2.9 Hz, 1H), 2.06 (ddd, J = 13.8, 7.1, 3.2 
Hz, 1H), 1.99 (ddd, J = 13.9, 10.9, 3.0 Hz, 1H), 1.87 (dddd, J = 13.9, 10.5, 7.0, 
3.4 Hz, 1H), 1.43 (m, 2H); 13C NMR (C6D6) 100 MHz δ 173.0, 171.2, 142.8, 
133.7, 132.3, 130.2, 129.5, 121.0, 60.9, 60.6, 46.2, 41.6, 34.4, 28.9, 26.3; TOF 
HRMS (DART) m/z calcd for C17H19O4Br  [M+H]+ 367.0545, found. 367.0531 
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2.6.24  Compound 45 
 
 
Followed the general method of RCM in 89% overall yield and as a white solid.  
Spot 1 (cis) 
m.p 47-50°C; Rf 0.35 (hexanes: EtOAc 80:20); 1H NMR (CDCl3) 400 MHz δ 5.45 
(ddd, J = 13.9, 8.4, 5.3 Hz, 1H), 5.18 (dd, J = 15.2, 8.9 Hz, 1H), 5.05 (m, 1H), 
4.29 (ddd, J = 11.7, 11.7, 3.7 Hz, 1H), 3.92 (ddd, J = 11.2, 5.3, 2.2 Hz, 1H), 2.71 
(m, 1H), 2.30 (m, 5H), 2.08 (m, 1H), 1.77 (m, 1H), 1.28 (d, J = 6.45 Hz, 3H), 1.02 
(d, J = 6.45 Hz, 3H); 13C NMR (CDCl3) 100 MHz δ 173.9, 172.3, 135.9, 128.4, 
66.8, 60.17, 42.5, 35.0, 34.3, 33.3, 28.8, 20.9, 20.5; TOF HRMS (DART) m/z 
[M+H]+ calcd for C13H21O4, calc. 240.1429, found 241.1420 
Spot 2 (trans) 
 Rf 0.29 (hexanes: EtOAc 80:20); 1H NMR (CDCl3) 400 MHz δ 5.47 (m, 2H), 5.10 
(m, 1H), 4.15 (ddd, J = 11.2, 11.2, 3.7 Hz, 1H), 4.08 (ddd, J = 16.5, 11.4, 4.6 Hz, 
1H), 2.62 (m, 1H), 2.32 (m, 5H), 1.93 (m, 3H), 1.28 (d, J = 6.0 Hz, 3H), 1.08 (d, J 
= 6.8 Hz, 3H); 13C NMR (CDCl3) 100 MHz δ 173.9, 172.0, 135.6, 126.2, 68.4, 
60.8, 41.5, 34.9, 33.7, 32.6, 29.7, 28.8, 20.7  
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2.6.25  Compound 46 
 
 
Followed the general method of RCM in overall 44% yield and as a white 
solid.  
 
Spot 1 (cis) 
m.p 97-101°C; Rf 0.46 (hexanes: EtOAc 80:20); 1H NMR (CDCl3) 400 
MHz δ 7.43 (d, J = 8.5 Hz, 2H), 7.10 (d, J = 8.5 Hz, 2H), 5.59 (ddd, J = 15.0, 8.7, 
5.4 Hz, 1H), 5.44 (dd, J = 15.2, 9.0 Hz, 1H), 5.11 (m, 1H), 4.35 (ddd, J = 11.9, 
11.9, 3.7 Hz, 1H), 3.95 (ddd, J = 11.3, 5.2, 2.4 Hz, 1H), 3.81 (ddd, J = 8.3, 8.3, 
8.3 Hz, 1H), 2.55 (m, 2H), 2.32 (m, 4H), 2.04 (m, 1H), 1.81 (dddd or ddt, J = 14.6, 
6.0, 3.3, 3.3 Hz, 1H), 1.30 (d, J = 6.2 Hz, 3H); 13C NMR (CDCl3) 100 MHz δ 
174.0, 171.7, 142.2, 133.2, 132.0, 130.3, 129.0, 67.5, 60.5, 45.5, 41.5, 34.5, 
33.5, 29.0, 20.7 
Spot 2 (trans) 
Rf 0.41 (hexanes: EtOAc 80:20); 1H NMR (CDCl3) 400 MHz δ 7.45 (d, J = 8.7 Hz, 
2H), 7.09 (d, J = 8.7 Hz, 2H), 5.63 (ddd, J = 11.7, 6.1, 0 Hz, 1H), 5.21 (m, 2H), 
4.13 (m, 2H), 3.80 (m, 1H), 2.71 (dd, J = 7.7, 0 Hz, 1H), 2.70 (ddd, J = 3.0, 3.0, 0 
Hz, 1H), 2.40 (m, 4H), 2.2 (m, 2H), 1.33 (d, J = 6.3 Hz, 3H); 13C NMR (CDCl3) 
100 MHz δ Not available. 
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2.6.26  Compound 47 
 
Followed the general method of RCM in 89% overall yield and as a yellow 
solid.  
Spot 1 (trans) 
m.p 86-89°C; Rf  0.45 (hexanes: EtOAc 80:20); 1H NMR (CDCl3) 400 MHz δ 7.33 
(m, 2H), 7.24 (m, 3H), 5.59 (dd, J = 15.5, 8.5 Hz, 1H), 5.53 (ddd, J = 15.9, 8.7, 
5.1 Hz, 1H), 5.14 (m, 1H), 4.35 (ddd, J = 14.9, 11.4, 3.5 Hz, 1H), 3.94 (ddd, J = 
12.4, 7.3, 1.3 Hz, 1H), 3.74 (ddd, J = 11.9, 8.8, 3.8, 1H), 2.61 (dd, J = 12.9, 12.9 
Hz, 1H), 2.56 (dd, J = 12.6, 4.0 Hz, 1H), 2.42 (m, 2H), 2.29 (m, 1H), 2.20 (m, 1H), 
2.1 (dddd, J = 18.6, 9.5, 5.7, 4.1 Hz, 1H), 1.8 (m, 1H), 1.31 (d, J = 6.19 Hz, 3H); 
13C NMR (CDCl3) 100 MHz δ 173.0, 172.9, 143.3, 134.5, 129.0, 128.9, 127.1, 
126.9, 66.8, 60.6, 47.1, 41.9, 34.3, 33.4, 28.1, 20.7 
Spot 2  (cis) 
Rf 0.32 (hexanes: EtOAc 80:20); 1H NMR (CDCl3) 400 MHz δ 7.33 (m, 2H), 7.24 
(m, 3H), 5.75 (dd, J = 15.9, 7.2,Hz, 1H), 5.67 (ddd, J = 15.8, 4.9, 4.9 Hz, 1H), 
5.13 (m, 1H), 4.29 (ddd, J = 10.6, 7.5, 3.1 Hz, 1H), 4.21 (ddd, J = 10.6, 7.2, 2.8 
Hz, 1H), 3.80 (ddd, J = 11.2, 7.2, 3.9 Hz, 1H), 2.76 (dd, J = 13.8, 13.8 Hz, 1H), 
2.64 (dd, J = 13.8, 3.4 HZ, 1H), 2.39 (m, 5H), 2.03 (m, 1H), 1.33 (d, J = 6.4 Hz, 3 
H); 13C NMR (CDCl3) 100 MHz δ 173.1, 172.4, 143.4, 133.2, 128.7, 128.5, 127.1, 
126.7, 69.8, 62.4, 44.8, 41.5, 34.6, 34.1, 27.1, 20.7 
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2.6.27 Compound 48 
 
 
Spot 1 (trans)  
 Followed the general method of RCM in 8% yield and as a white solid. Rf 
0.45 (hexanes: EtOAc 80:20); 1HNMR (CDCl3) 400 MHz δ 5.80 (dd, J = 5.9, 2.6 
Hz, 2H), 4.43 (ddd, J = 11.1, 8.8, 6.8 Hz, 2H), 3.91 (dd, J = 4.0, 4.0 Hz, 1H), 3.88 
(dd, J = 4.0, 4.0 Hz, 1H), 2.61 (m, 2H), 2.30 (dd, J = 13.4, 3.2 Hz, 2H), 2.11 (dd, 
J = 12.7, 12.7 Hz, 2H), 2.00 (dddd, J = 9.5, 9.5, 4.0, 4.0 Hz, 2H), 1.03 (d, J = 6.9 
Hz, 6H); 13C NMR (CDCl3) 100 MHz δ 173.2, 134.3, 59.8, 42.5, 35.9, 25.6, 21.6; 
TOF HRMS (DART) m/z [M+H]+ calcd for C13H21O4, calc. 241.1440, found 
241.1440. 
 
Spot 2 (cis) 
Followed the general method of RCM in 13% yield and white solid. Rf 0.39 
(hexanes: EtOAc 80:20); 1HNMR (CDCl3) 400 MHz δ 5.40 (dd, J = 3.8, 1.7 Hz, 
2H), 4.17 (dddd, J = 22.7, 11.3, 5.7 Hz, 4H), 2.62 (m, 2H), 2.39 (dd, J = 13.9 3.8 
Hz, 2H), 2.27 (dd, J = 11.1, 2.69 Hz, 2H), 2.01 (dddd or dq, J = 5.7, 5.7, 5.7, 5.7 
Hz, 2H), 1.03 (d, J = 6.9 Hz, 6H); 13C NMR (CDCl3) 100 MHz δ 173.1, 132.8, 
61.9, 41.9, 34.1, 26.7, 21.3;  
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2.6.28  Compound 49 
 
 
 
Spot 1  
 Followed the general method of RCM in 10% yield and white solid. Rf 0.5 
(hexanes: EtOAc 80:20); 1HNMR (CDCl3) 400 MHz δ 7.42 (d, J = 8.23 Hz, 4H), 
7.02 (d, J = 8.23 Hz, 4H), 5.62 (m, 2H), 4.10 (ddd, J = 10.0, 5.7, 5.7 Hz, 4H), 
3.83 (m, 2H), 2.67 (m, 4H), 1.88 (m, 2H); 13C NMR (CDCl3) 100 MHz δ 171.4, 
141.5, 132.0, 129.4, 120.9, 61.2, 44.1, 40.6, 30.0, 28.2; TOF HRMS (DART) m/z 
[M+H]+ calcd for C23H24Br2O4 [MH]+, calc. 522.9944, found 522.9962 
 
** Spot 2 not determined by NMR. Rf= 0.44 
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2.6.29  Compounds 54 and 55 
 
  
            
 
Compounds 54 and 55 were prepared by using the general procedure for 
the epoxidation of macrocycles. The products, as a 1:3 mixture of diastereomers, 
were analyzed without separation. Rf 0.27, 0.19 (hexanes/EtOAc 80:20); 
1
H 
NMR (CDCl3) 400 MHz δ 7.44 (d, J =8.3 Hz, 7H), 7.19 (d, J =7.8 Hz, 2H), 7.15 (d, 
J =8.1 Hz, 5H), 4.77 (m, 5H), 4.60 (ddd, J =11.5, 8.2, 3.0 Hz, 1H), 4.48 (ddd, J = 
12.1, 9.6, 3.3 Hz, 1 H), 4.21 (ddd, J = 9.0, 5.4, 3.6 Hz, 1 H), 3.97 (m, 1H), 3.91 
(m, 2.5H), 3.69 (m, 5H), 3.51 (m, 1H), 2.99 (m, 1H), 2.84 (m, 7H), 2.46 (m, 7H), 
2.25 (m, 5H), 2.05 (m, 7H), 1.95 (m, 3H), 1.68 (m, 1 H), 1.58 (m, 3 H), 1.46 ppm 
(m, 1 H); 
13
C NMR (CDCl3) 100 MHz δ 173.1, 173.0, 172.8, 138.0, 137.5, 132.2, 
132.1, 129.5, 129.3, 121.8, 64.6, 64.0, 60.4, 59.5, 58.5, 57.4, 56.6, 55.8, 48.3, 
47.2, 36.5, 36.3, 30.1, 29.6, 28.1, 26.9, 26.5, 26.3 ppm; TOF HRMS (DART) m/z 
calcd for C17H20O5Br [M+H]
+
 383.0494; found 383.0484.  
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2.6.30  Compound 56 and 57 
 
Compounds 56 and 57 were prepared by using the general procedure for the 
epoxidation of macrocycles starting with 52. 
 
 
 
Compound 56 (minor): 1HNMR (CDCl3) 400 MHz δ 7.30 (m, 5H), 4.61 
(ddd, J = 11.2, 7.9, 3.1 Hz, 1H), 4.49 (ddd, J =11.6, 8.9, 2.9 Hz, 1H), 4.20 (ddd, J 
= 11.4, 6.2, 3.9 Hz, 1H), 3.96 (ddd, J = 10.2, 6.6, 3.3 Hz, 1H), 3.55 (dd, J = 12.4, 
2.9 Hz, 1H), 3.00 (ddd, J = 6.2, 3.5, 2.7 Hz), 1H, 2.85 (m, 2H), 2.48 (m, 2H), 2.26 
(m, 1H), 2.06 (m, 2H), 1.67 (m, 1H), 1.49 (ddd, J = 13.9, 7.2, 3.1 Hz, 1H); 13C 
NMR (CDCl3) 100 MHz δ 173.5, 173.2, 138.5, 129.0, 127.8, 64.4, 64.1, 56.6, 
48.8, 36.4, 30.1, 28.1, 26.6  
 
Compound 57 (major): 1HNMR (CDCl3) 400 MHz δ 7.30 (m, 5H), 4.82 (m, 
2H), 3.91 (ddd/dt, J = 8.1, 3.7, 3.7Hz, 1H), 3.72 (m, 2H), 2.87 (ddd, J = 8.8, 8.8, 
2.6 Hz, 2H), 2.47 (dd, J = 8.24, 5.04 Hz, 2H), 2.24 (m, 2H), 2.03 (m, 3H), 1.60 
(m, 1H); 13C NMR (CDCl3) 100 MHz δ 173.4, 172.9, 139.1, 129.0, 127.7, 127.6, 
60.2, 59.5, 58.5, 57.6, 47.8, 36.7, 29.6, 26.9, 26.3  
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2.6.31  Compound 44 (diastereomers 58 and 59) 
 
         
Compounds 58 and 59 were prepared using the general procedure for 
epoxidation of macrocycles using 44 as starting material. The products, as a 1:7 
mixture of diastereomers, were analyzed without separation. Rf 0.24, 0.16 
(hexanes: EtOAc 80:20); 1HNMR (CDCl3) 400 MHz δ 7.46 (d, J = 8.5 Hz, 14H), 
7.15 (d, J = 8.2 Hz, 14H), 4.80 (m, 14H), 4.44 (ddd or dt, J= 11.4, 5.2, 5.2 Hz, 
1H), 4.32 (m, 2H), 4.23 (ddd, J = 11.7, 5.4, 5.4Hz, 1H) 3.96 (ddd, J = 8.26, 4.3, 
4.3 Hz, 7H), 3.86 (ddd, J = 7.4, 3.7, 3.7 Hz, 7H), 3.61 (ddd, J = 11.2, 3.1, 3.1 Hz, 
1H), 3.04 (dd, J = 2.5, 2.5 Hz, 1H), 2.99 (m, 8H), 2.76-2.89 (m, 21H), 2.60 (m, 
8H), 2.43 (m, 16H), 2.23 (m, 8H), 2.13 (m, 2H), 2.08 (m, 14H), 1.55 (m, 11H); 13C 
NMR (CDCl3) 100 MHz δ 172.8, 171.6, 140.4, 132.0, 131.9, 129.8, 129.3, 121.2, 
63.8, 63.6, 61.9, 60.4, 59.9, 59.1, 54.6, 43.6, 37.1, 29.9, 29.6, 27.3, 27.0, 26.9, 
26.7; TOF HRMS (DART) m/z calcd for C17H20O5Br [M+H]
+ 383.0494, found 
383.0477. 
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2.6.32  C11- phenyl diene  
 
 
 
 
 
Followed general method of dienes through monoacylation (method A and 
then method B) in 44% yield and yellow oil. Rf 0.43 (Hexanes: EtOAc 90:10); 
1HNMR (CDCl3) 400 MHz δ 7.30 (m, 2H), 7.2 (m, 3H), 6.00 (ddd, J = 17.5, 10.1, 
7.1 H, 1H), 5.83 (dddd or dq, J = 10.2, 6.0., 6.0, 6.0. Hz, 1H), 5.06 (m, 4H), 4.09 
(ddd, J = 12.7, 6.4, 6.4 Hz, 4H), 3.88 (ddd, J =7.5, 7.5, 7.5 Hz, 1H), 2.76 (dddd, J 
= 15.0, 15.0, 15.0, 8.1 Hz, 2H), 2.4 (ddd, J = 15.2, 10.8, 4.2 HZ, 4H), 1.88 (ddd or 
dt, J = 12.7, 6.4, 6.4 Hz, 2H); 13C NMR (CDCl3) 100 MHz δ 173.1, 172.0, 142.5, 
140.5, 136.8, 128.8, 127.8, 127.0, 115.8, 115.1, 61.2, 61.1, 45.9, 40.5, 33.7, 
29.1, 28.2  
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2.6.33 C2-methyl, C11-phenyl diene  
 
 
 
Followed the general method of dienes through monoacylation (method A 
and then B) in 72% yield and yellow oil. Rf 0.45 (hexanes: EtOAc 95:5); 1HNMR 
(CDCl3) 400 MHz δ 7.3 (m, 2H), 7.22, (m 3H), 5.9 (m, 1H), 5.80 (m, 1H), 5.07 (m, 
5H), 4.03 (m, 2H), 3.87 (ddd or dt, 1 H, J = 7.4, 7.4, 7.4 Hz), 2.72 (dt, 2H, J = 8.0. 
8.0, 2.9 Hz), 2.38 (dddd or dq, 4H, J = 4.5, 4.5, 4.5, 0 Hz), 1.8 (m, 2H), 1.19 (d, J 
= 6.3 Hz, 2H), 1.13 (d, J = 6.3 Hz, 1H); 13C NMR (CDCl3) 100 MHz δ 173.1, 
171.6, 142.5, 140.5, 136.9, 128.8, 127.8, 127.0, 115.8, 115.0, 68.2, 60.9, 46.0, 
40.7, 35.0, 33.7, 29.1, 20.2 
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2.6.34  C11-phenyl [13]-macrodilactone  
 
Followed the general method of RCM in 28.3%(Grubbs’), 62.4%(Hoveyda-
Grubbs’) and yellow solid. Rf 0.35 (hexanes: EtOAc 80:20); 1HNMR (CDCl3) 400 
MHz. δ 7.30 (m, 2H) 7.22 (m, 3H), 5.57 (dddd, J = 2.3, 2.3, 2.3, 0 Hz, 2H), 4.46 
(dddd or ddt, J = 20.1, 8.0, 6.8, 6.8 Hz, 2H), 4.02 (dddd or ddt, J = 15.3, 8.6, 4.3, 
4.3 Hz, 2H), 3.77 (ddd, J = 11.4, 7.7, 3.7 Hz, 1H), 2.67 (dd, J = 11.9, 11.9 Hz, 
1H), 2.60 (dd, J = 13.6, 3.8 Hz, 1H), 2.36 (m, 4H), 2.07 (ddd, J = 12.4, 8.4, 4.3 
Hz, 2H); 13C NMR (CDCl3) 100 MHz δ 173.7, 172.7, 143.3, 133.6, 129.1, 128.9, 
127.2, 126.8, 60.8, 60.5, 46.4, 41.6, 34.3, 28.6, 26.0; TOF HRMS (DART) m/z 
[M+H]+ calcd for  C17H21O4, 289.1440, found 289.1451 
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2.6.35 C2-methyl, C11-phenyl [13]-macrodilactone 
 
 
Trans- 
 Followed the general method of RCM in 41% yield and yellow solid. Rf 0.30 
(hexanes: EtOAc 95:5); 1HNMR (CDCl3) 400 MHz δ 7.30 (dd, J = 7.59, 7.59 Hz, 
2H), 7.22 (dd, J =7.59, 7.59 Hz, 3H), 5.57 (m, 2H), 5.13 (ddd, J = 10.55, 6.19, 
4.13 Hz, 1H), 4.35 (ddd or dt, J = 11.7, 11.7, 3.67 Hz, 1H), 3.96 (ddd, J = 11.24, 
5.28, 2.06 Hz, 1H), 3.85 (ddd or dt, J = 7.80, 7.80, 7.80, 7.80 Hz, 1H), 2.59 (dd, J 
= 7.80, 7.80, 0 Hz, 2H), 2.32 (m, 3H), 2.05 (m, 1H), 1.82 (m, 2H), 1.30 (d, J = 
6.21 Hz, 3H); 13C NMR (CDCl3) 100 MHz δ 174.03, 171.51, 143.19, 133.47, 
128.84, 127.58, 127.46, 126.88, 68.92, 60.89, 43.85, 41.81, 35.44, 33.86, 29.69, 
21.04; TOF HRMS (DART) m/z [M+H]+ calcd for C18H23O4 calc. 303.1596, found 
303.1590. 
Cis- 
 Followed the general method of RCM in 28% yield and yellow solid. Rf .0.22 
(hexanes: EtOAc 95:5); 1HNMR (CDCl3) 400 MHz. δ 7.30 (dd, J = 7.59, 7.59 Hz, 
2H), 7.20 (dd, J = 11.66, 7.05 Hz, 3H), 5.63 (m, 2H), 5.18 (ddd, J = 9.76, 6.24, 
3.80 Hz, 1H), 4.13 (m, 2H), 3.81 (m, 1H), 2.72 (dd, J = 5.29, 5.29 Hz, 2H), 2.38 
(ddd or dt, J = 8.36, 8.36, 8.36 Hz, 4H), 1.98 (m, 2H), 1.31 (d, J = 6.35 Hz, 3H); 
13C NMR (CDCl3) 100 MHz δ 174.01, 171.92, 143.22, 133.78, 129.76, 128.86, 
127.17, 126.78, 67.35, 60.46, 45.99, 41.59, 34.46, 33.46, 28.98, 20.68; TOF 
HRMS (DART) m/z [M+H]+ calcd for C18H23O4 calc. 303.1596, found 303.1587  
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entary Inform
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2.7.1 
C
hem
ical Shifts C
ouplings, and A
ssignm
ent for [13]-M
acrodilactone 44 
  
carbon # 
δ (ppm
) 2 
δ (ppm
) 3 
6 
172.3 
172.3 
13 
171.2 
171.2 
arom
. 
142.2, 133.0,128.8, 120.3 
142.1, 133.0, 128.8, 120.2 
10 
131.6 
131.5 
9 
129.2 
129.2 
2 &
 4 
60.2, 59.9 
60.2, 59.8 
7 
40.9 
40.9 
8 
45.5 
45.5 
11 
28.2 
28.2 
12 
33.7 
33.7 
3 
25.7 
25.6 
  
hydrogen 
δ (ppm
) 2 
δ (ppm
) 3 
m
ult. 4 
obs. 3J
H,H  (Hz)1
1,2 
obs. 3J
H,H  (Hz) 1,3 
2a  
4.40 
4.40 
ddd (Jy >>Jx ) D 
11.0, 11.0, 6.2 
11.0,11.0,5.5 
4b 
4.34 
4.34 
11.1, 11.1,5.4 
4a  
3.65 
? 
ddd (Jy =Jx ) A 
Overlapping w/H8 
(15.0, 4.1, 4.1)? 
? 
2b  
3.60 
3.59 
ddd/dt  (Jy =Jx ) C
2   
11.1, 4.2, 4.2 
11.1, 4.2, 4.2 
3a & 3b 
1.43 
1.43 
m
 
m
 
 m
 
7a  
2.37 
2.36 
dd 
13.3, 12.4 
12.9, 12.9 
7b 
2.26 
2.24 
dd 
13.6, 3.1 
13.5,3.1 
8b 
3.69 
3.69 
ddd (Jy >>Jx ) L 
Overlapping H4 
(15.3, 4.1, 4.1)? 
- 
3.77 
ddd (Jy =Jx )I (400) 
11.6, 7.8, 3.7 
9 & 10 
5.39 
 
m
 
m
 
m
 
11a or 11b 
2.20 
2.20 
dddd (Jy =Jx =Jw ) J 
10.6, 7.6, 5.0 (11-10 3J), 2.9 
13.9, 10.8, 7.6, 3.3 
11a or 11b 
1.87 
1.88 
dddd ( Jy =Jx =Jw ) H 
13.9 (11-10 3J), 10.5, 7.0, 3.4 
13.6,10.4,6.9,3.2 
 
 
91 
12a  
2.06 
2.06 
ddd (Jy >Jx ) B 
13.8, 7.1, 3.2 
13.9, 7.3, 3.2 
12b 
1.99 
1.99 
ddd (Jy =Jx ) I 
13.9, 10.9, 3.0 
14.0, 11.1,3.1 
1 R
T, [X
] = 5 m
M
 in benzene-d
6  
2 500 M
H
z 1H
, 125 M
H
z 13C
 
3 700 M
H
z 1H
, 175 M
H
z 13C
 
4 m
ultiplicities characterized using Hoye, J. Org. Chem
., 1994, 59 (15), 4096–4103 
  green highlight is 400 data in chloroform
 
  
2.7.2 
C
hem
ical Shifts C
ouplings, and A
ssignm
ent for [13]-M
acrodilactone 52 
 
 
atom
 
δ (ppm
) 2 
δ (ppm
) 3 
carbons 
 
N
/A
 
13 &
 6 
172.8, 172.4 
 
arom
atics 
138.0, 131.6, 129.4, 121.3 
 
9 &
 10 
131.1, 128.5 
 
2 &
 4 
60.2,59.6 
 
7 
33.7 
 
8 
28.4 
 
11 
37.8 
 
12 
51.2 
 
3 
25.5 
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atom
 
δ (ppm
) 2 
δ (ppm
) 5 
δ 
(ppm
) 3 
m
ult. 4 
obs. 3J
H
,H  (H
z) 1,2 
obs. 3J
H
,H  (H
z) 1,5 
hydrogens 
 
 
 
 
 
 
2a or 2b or  
4a or 4b 
4.44 
4.49 
N
A
 
m
 
m
 
m
 
2a or 2b or 
4a or 4b 
4.35 
4.49 
N
A
 
m
 
m
 
m
 
2a or 2b or 
4a or 4b 
3.65 
4.02 
N
A
 
ddd (app dt) C
 
11.4, 3.9, 3.9 
11.2, 4.0, 4.0 
2a or 2b or 
4a or 4b 
3.36 
3.85 
N
A
 
 ddd (app dt) C
 
m
 
11.2, 3.9, 3.9 
3a & 3b 
1.36 
2.04 
N
A
 
m
 
m
 
m
 
7a 
3.36 
3.55 
N
A
 
dd 
12.2, 2.9  
12.4, 2.9 
8a or 8b 
2.69 
? 
N
A
 
ddd (app dt) K 
12.9, 12.9, 8.7 (to 9?) 
? 
8a or 8b 
1.95 
? 
N
A
 
m
 
m
 
? 
9 &
 10 
5.43 
5.54 
N
A
 
m
 
m
 
m
 
11a or 11b 
2.27 
? 
N
A
 
dddd (e) ? 
18.0, 9.6, 9.6, 3.1 
? 
11a or 11b 
1.95 
? 
N
A
 
m
 
m
 
? 
12a or 12b 
2.06 
? 
N
A
 
m
 
m
 
? 
12a or 12b 
2.03 
? 
N
A
 
m
 
m
 
? 
1 R
T, [Y
] = 5 m
M
 in benzene-d
6  
2 500 M
H
z 1H
, 125 M
H
z 13C
 
3 700 M
H
z 1H
, 175 M
H
z 13C
 
4 m
ultiplicities characterized using Hoye, J. Org. Chem
., 1994, 59 (15), 4096–4103 
5 400 M
Hz 1H
, C
D
C
l3 
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2.7.3 
H
,H
 D
ihedral A
ngles for X-ray conform
ers of [13]-M
acrodilactones 44 and 52 
     
 
  diol 
ester 1 
 
 
 
ester 2 
 
 
 
dihedral  
pR 
b-rib 
b-heart 
dihedral 
pR 
b-rib 
b-heart 
dihedral 
pR 
b-rib 
b-heart 
2a-C
2 -C
3 -3a 
-52.11 
-46.84 
-46.84 
7a-C
7 -C
8 -8a 
-73.34 
-67.71 
-67.71 
10H-C
10 -C
11 -11a 
163.7 
170.45 
-71.19 
2a-C
2 -C
3 -3b 
-169.69 
-164.17 
-164.17 
7a-C
7 -C
8 -8b 
168.28 
168.19 
-177.38 
10H-C
10 -C
11 -11b 
45.69 
52.84 
169.17 
2b-C
2 -C
3 -3a 
67.6 
72.79 
72.79 
7b-C
7 -C
8 -8a 
48.15 
50.00 
50.00 
11a-C
11 -C
12 -12a 
-66.44 
-82.73 
-47.6 
2b-C
2 -C
3 -3b 
49.6 
-44.54 
-44.54 
7b-C
7 -C
8 -8b 
-70.22 
-74.10 
-59.67 
11a-C
11 -C
12 -12b 
175.25 
158.18 
-166.69 
3a-C
3 -C
4 -4a 
-46.94 
-50.74 
-50.74 
8a-C
8 -C
9 -9H 
44.16 
49.78 
-67.02 
11b-C
11 -C
12 -12a 
51.56 
34.87 
72.05 
3a-C
3 -C
4 -4b 
-166.88 
-170.57 
-170.57 
8b-C
8 -C
9 -9H 
162.49 
172.33 
42.73 
11b-C
11 -C
12 -12b 
-66.75 
-84.22 
-47.04 
3b-C
3 -C
4 -4a 
70.55 
66.53 
66.53 
 
 
 
 
 
 
 
 
3b-C
3 -C
4 -4b 
-49.37 
-53.29 
-53.29 
 
 
 
 
 
 
 
 
  pR (α)=  
Alpha-phenyl 8 =  007_13133.cif  (7S-pR) 
rib-7=   
Beta Heart =     8R,pS-B_007_14033 
heart-7=  
Beta Ribbon =  8R,pR_A_007_14033 
   
C
10C
9
O
5
O
1
O
O
H
H
7a
4a 3a
2a
12a
11a
7b
4b 3b
2b
12b
11b8a8b
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2.7.4 
C
,H
 D
ihedral A
ngles for X-ray conform
ers of [13]-M
acrodilactones 44 and 52 
      
 
 diol 
 
 
 
ester 1 
 
 
 
ester 2 
 
 
 
dihedral  
pR 
b-rib 
b-heart 
dihedral 
pR 
b-rib 
b-heart 
dihedral 
pR 
b-rib 
b-heart 
 
H
7a -C
7 -C
8 -C
9  
47.49 
49.24 
67.89 
H
9 -C
9 -C
10 -C
11  
4.75 
1.23 
-5.04 
H
7b -C
7 -C
8 -C
9  
- 
166.95 
-174.41 
H
10 -C
10 -C
11 -C
12  
-75.33 
-68.39 
48.98 
H
8a -C
8 -C
9 -C
10  
-135.83 
- 
- 
H
11a -C
11 -C
10 -C
9  
-16.32 
-9.55 
108.78 
H
8b -C
8 -C
9 -C
10  
-17.50 
-7.8 
-137.11 
H
11b -C
11 -C
10 -C
9  
-134.34 
-127.16 
-10.87 
H
9 -C
9 -C
8 -C
7  
-76.71 
-68.78 
157.47 
 
 
 
 
H
10 -C
10 -C
9 -C
8  
4.72 
1.36 
-5.23 
 
 
 
 
  pR (α)=  
Alpha-phenyl 8 =  007_13133.cif  (7S-pR) 
rib-7=   
Beta Heart =     8R,pS-B_007_14033 
heart-7=  
Beta Ribbon =  8R,pR_A_007_14033 
     
C
10C
9
O
5
O
1
O
O
H
H
7a
4a 3a
2a
12a
11a
7b
4b 3b
2b
12b
11b8a8b
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2.7.5 
D
ihedral A
ngles and 3J C
oupling C
onstant Values for [13]-M
acrodilactone 44 
 a. H,H Dihedrals  
  diol 
 
dihedral  
b-rib 
3J (calc.) 
b-heart 
3J (calc.) 
2a-C
2 -C
3 -3a 
-46.84 
 
-46.84 
 
2a-C
2 -C
3 -3b 
-164.17 
 
-164.17 
 
2b-C
2 -C
3 -3a 
72.79 
 
72.79 
 
2b-C
2 -C
3 -3b 
-44.54 
 
-44.54 
 
3a-C
3 -C
4 -4a 
-50.74 
 
-50.74 
 
3a-C
3 -C
4 -4b 
-170.57 
 
-170.57 
 
3b-C
3 -C
4 -4a 
66.53 
 
66.53 
 
3b-C
3 -C
4 -4b 
-53.29 
 
-53.29 
 
       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ester 1 
 
 
3J (Com
putational) 
dihedral 
b-rib 
3J (calc.) 
b-heart 
3J (calc.) 
3J (obs.) 
b-rib 
b-heart 
7a-C
7 -C
8 -8b 
168.19 
8.82 
-177.38 
9.2 
 
 
7b-C
7 -C
8 -8b 
-74.10 
0.36 
-59.67 
1.89 
 
 
8b-C
8 -C
9 -9H 
172.33 
11.44 
42.73 
4.76 
7.8  
(400 Hz) 
11.386 
4.497 
 ester 2 
 
 
3J (Com
putational) 
dihedral 
b-rib  
3J (calc.) 
b-heart 
3J (calc.) 
3J (obs.) 
b-rib 
b-heart 
10H-C
10 -C
11 -11a 
170.45 
11.35 
-71.19 
3.02 
10.4 
(500 Hz) 
11.386 
3.570 
10H-C
10 -C
11 -11b 
52.84 
4.06 
169.17 
11.28 
7.6  
(500) 
4.723 
12.096 
11a-C
11 -C
12 -12a 
-82.73 
-0.14 
-47.6 
3.58 
 
 
 
11a-C
11 -C
12 -12b 
158.18 
7.91 
-166.69 
8.72 
 
 
11b-C
11 -C
12 -12a 
34.87 
5.44 
72.05 
0.53 
 
 
11b-C
11 -C
12 -12b 
-84.22 
-0.19 
-47.04 
3.67 
 
 
 
C
10
C
9
O
5
O
1
O
O
H H
7a
4a
3a
2a
12a
11a
7b
4b
3b
2b
12b
11b
R
8b
R=
Br
7 10
1112
9
2
O
5
6 7
8
13O1
O
O
3
4
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Equation for calculating allylic H-H values: 
 
 
6.6cos 2 Φ + 2.6sin
2 Φ  (0< x <90°) 
 
 
11.6cos 2 Φ + 2.6sin
2 Φ  (90°<) 
Equation for calculating other H-H: 
 
 
8.5cos 2 Φ - 0.28 (0< x <90°) 
 
 
9.5cos 2 Φ - 0.28 (90°<) 
  b. C,H Dihedrals 
 ester 1 
 
 
3J (Com
putational) 
dihedral 
b-rib 
3J (calc.) 
b-heart 
3J (calc.) 
3J (obs.) 
b-rib 
b-heart 
H
7a -C
7 -C
8 -C
9  
67.89 
 
49.24 
 
0.7(2.26ppm
) (very weak) 
 
 
H
7b -C
7 -C
8 -C
9  
-174.41 
 
166.95 
 
0.7(2.26ppm
) (very weak) 
 
 
H
8b -C
8 -C
9 -C
10  
-137.11 
 
-7.8 
 
5.5 
 
 
H
9 -C
9 -C
8 -C
7  
157.47 
 
-68.78 
 
7.5 (negative peak) 
0.922 
5.424 
H
10 -C
10 -C
9 -C
8  
-5.23 
 
1.36 
 
4.5 
5.340 
4.524 
H
9 -C
9 -C
8 -C
8a  
49.78 
 
-67.02 
 
 
2.692 
1.366 
  ester 2 
 
 
3J (Com
putational) 
dihedral 
b-rib 
3J (calc.) 
b-heart 
3J (calc.) 
3J (obs.) 
b-rib 
b-heart 
H
9 -C
9 -C
10 -C
11  
1.23 
 
-5.04 
 
5.2 
5.344 
6.023 
H
10 -C
10 -C
11 -C
12  
-68.93 
 
48.98 
 
0.8 
0.519 
2.134 
H
11a -C
11 -C
10 -C
9  
-9.55 
 
108.78 
 
6.0 (2.2ppm
), 3.7Hz (1.87ppm
) 
 
 
H
11b -C
11 -C
10 -C
9  
-127.16 
 
-10.87 
 
6.0 (2.2ppm
), 3.7Hz (1.87ppm
) 
 
 
H
9 -C
9 -C
10 -C
(aryl120)  
? 
 
 
 
No correlation 
 
 
H
9 -C
9 -C
10 -C
(aryl128)  
? 
 
 
 
2.0 
 
 
H
9 -C
9 -C
10 -C
(aryl133)  
? 
 
 
 
-1.9 
 
 
H
9 -C
9 -C
10 -C
(aryl142)  
49.78 
 
 
 
2.8 (negative correlation) 
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2.7.6 
D
ihedral A
ngles and 3J C
oupling C
onstant Values for [13]-M
acrodilactone 52 
  
a. 
H,H Dihedrals  
 
diol 
 
 
dihedral  
pR 
3J (calc.) 
2a-C
2 -C
3 -3a 
-52.11 
 
2a-C
2 -C
3 -3b 
-169.69 
 
2b-C
2 -C
3 -3a 
67.6 
 
2b-C
2 -C
3 -3b 
49.6 
 
3a-C
3 -C
4 -4a 
-46.94 
 
3a-C
3 -C
4 -4b 
-166.88 
 
3b-C
3 -C
4 -4a 
70.55 
 
3b-C
3 -C
4 -4b 
-49.37 
 
        
 
 
 
 
 
 
 
 
 
 
 
ester 1 
 
 
 
3J  
(Com
putational) 
dihedral 
pR 
3J (calc.)-rib 
3J (obs.) 
a-rib 
a-heart 
7a-C
7 -C
8 -8a 
-73.34 
0.42 
 
 
7a-C
7 -C
8 -8b 
168.28 
8.83 
 
 
8a-C
8 -C
9 -9H 
44.16 
4.09 
 
4.472 
2.627 
8b-C
8 -C
9 -9H 
162.49 
10.79 
 8.7 
11.267 
4.539 
 ester 2 
 
 
 
3J (Com
putational) 
dihedral 
pR 
3J (calc.)-rib 
3J (obs.) 
a-rib 
a-heart 
10H-C
10 -C
11 -11a 
163.7 
10.89 
9.6 
11.603 
3.149 
10H-C
10 -C
11 -11b 
45.69 
4.55 
 
4.470 
12.274 
11a-C
11 -C
12 -12a 
-66.44 
1.08 
 
 
11a-C
11 -C
12 -12b 
175.25 
9.15 
 
 
11b-C
11 -C
12 -12a 
51.56 
3.01 
 
 
11b-C
11 -C
12 -12b 
-66.75 
1.04 
 
 
  
C
10
C
9
O
5
O
1
O
O
H H
7a
4a
3a
2a
12a
11a
R
4b
3b
2b
12b
11b
8a
8b
R=
Br
6 10
1112
9
2
O
5
6 7
8
13O1
O
O
3
4
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b. C,H Dihedrals 
  ester 1 
3J (Com
putational) 
dihedral 
p-R 
3J (calc.) 
3J (obs.) 
a-rib 
a-heart 
H
7a -C
7 -C
8 -C
9  
 47.49 
 
3.3Hz (3.36ppm
, 128.5ppm
 - H2 or H4?) 
0Hz (3.36ppm
, 131.1ppm
 - H2 OR H4?) 
 
 
H
8a -C
8 -C
9 -C
10  
-135.83 
 
5.3Hz (2.69ppm
, 128.5ppm
)/ 6.6Hz (dispersive 
peak) (1.95ppm
, 128.5ppm
 - H11?) 
 
 
H
8b -C
8 -C
9 -C
10  
-17.50 
 
5.8Hz (2.69ppm
, 131.1ppm
)/ 6.1Hz (dispersive 
peak) (1.95ppm
, 131.1ppm
 - H11?) 
 
 
H
9 -C
9 -C
8 -C
7  
-76.71 
 
Signal has opposite sign in 2 spectra 
0.460 
6.306 
H
10 -C
10 -C
9 -C
8  
4.72 
 
5.7Hz (rhs of 5.43ppm
/28.4ppm
) 
5.266 
4.743 
H
8a -C
8 -C
7 -C
7b  
48.15 
 
 
 
 
H
8b -C
8 -C
7 -C
7b  
-70.22 
 
 
 
 
   ester 2 
3J (Com
putational) 
dihedral 
p-R 
3J (calc.) 
3J (obs.) 
Rib 
Heart 
H
9 -C
9 -C
10 -C
11  
4.75 
 
5.0Hz (rhs of 5.43ppm
, 37.79ppm
) 
5.483 
6.188 
H
10 -C
10 -C
11 -C
12  
-75.33 
 
2.6Hz (difficult to overlay) 
0.629 
2.243 
H
11a -C
11 -C
10 -C
9  
-16.32 
 
4.6Hz (hard to overlay exactly 2.27ppm
, 128.5ppm
)/ 
6.6Hz (dispersive peak) (1.95ppm
, 128.5ppm
 - H8?) 
(either or) 
 
 
H
11b -C
11 -C
10 -C
9  
-134.34 
 
2..3Hz (hard to overlay exactly 2.27ppm
/131ppm
)/ 
6.1Hz (dispersive peak) (1.95ppm
, 131.1ppm
 - H8?) 
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2.7.7 Crystallographic Data for Compound 46a 
Low-temperature diffraction data (ω-scans) were collected on a Rigaku 
MicroMax-007HF diffractometer coupled to a Saturn994+ CCD detector with Cu 
Kα (λ = 1.54178 Å) for the structure of 007-16012. The diffraction images were 
processed and scaled using the Rigaku Oxford Diffraction software (CrysAlisPro; 
Rigaku OD: The Woodlands, TX, 2015). The structure was solved with SHELXT 
and was refined against F2 on all data by full-matrix least squares with SHELXL 
(Sheldrick, G. M. Acta Cryst. 2008, A64, 112–122). All non-hydrogen atoms were 
refined anisotropically. Hydrogen atoms were included in the model at 
geometrically calculated positions and refined using a riding model. The isotropic 
displacement parameters of all hydrogen atoms were fixed to 1.2 times the U 
value of the atoms to which they are linked (1.5 times for methyl groups). The full 
numbering scheme of compound 007-16012 can be found in the full details of the 
X-ray structure determination (CIF), which is included as Supporting Information. 
CCDC number XXXXXX (007-16012) contains the supplementary 
crystallographic data for this paper. These data can be obtained free of charge 
from The Cambridge Crystallographic Data Center via 
www.ccdc.cam.ac.uk/data_request/cif.  
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Figure 1. The complete numbering scheme of 007-16012 with 50% thermal 
ellipsoid probability levels.  The hydrogen atoms are shown as circles for clarity. 
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  Table 1.  Crystal data and structure refinement for 007-16012. 
Identification code  007-16012 
Empirical formula  C18 H21 Br O4 
Formula weight  381.26 
Temperature  93(2) K 
Wavelength  1.54184 Å 
Crystal system  Monoclinic 
Space group  P21/n 
Unit cell dimensions a = 15.3128(3) Å a= 90°. 
 b = 5.55594(11) Å b= 95.7658(18)°. 
 c = 20.5689(4) Å g = 90°. 
Volume 1741.08(6) Å3 
Z 4 
Density (calculated) 1.454 Mg/m3 
Absorption coefficient 3.365 mm-1 
F(000) 784 
Crystal size 0.200 x 0.190 x 0.100 mm3 
Theta range for data collection 3.438 to 66.830°. 
Index ranges -18<=h<=18, -6<=k<=6, -24<=l<=24 
Reflections collected 59208 
Independent reflections 3075 [R(int) = 0.0398] 
Completeness to theta = 66.830° 99.1 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.00000 and 0.82281 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3075 / 0 / 209 
Goodness-of-fit on F2 1.100 
Final R indices [I>2sigma(I)] R1 = 0.0268, wR2 = 0.0614 
R indices (all data) R1 = 0.0273, wR2 = 0.0616 
Extinction coefficient n/a 
Largest diff. peak and hole 0.513 and -0.522 e.Å-3 
 102 
 Table 2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement 
parameters (Å2x 103) for 007-16012.  U(eq) is defined as one third of  the trace 
of the orthogonalized Uij tensor. 
________________________________________________________________  
 x y z U(eq) 
________________________________________________________________ 
Br(1) 3201(1) -2511(1) 7306(1) 27(1) 
O(1) 7252(1) 4330(2) 4770(1) 22(1) 
O(5) 9138(1) 3563(3) 5452(1) 30(1) 
O(14) 9129(1) -133(3) 5904(1) 47(1) 
O(15) 6753(1) 7207(3) 5407(1) 36(1) 
C(2) 7917(1) 6004(4) 4573(1) 23(1) 
C(3) 8637(1) 4450(4) 4339(1) 28(1) 
C(4) 8952(1) 2471(4) 4810(1) 31(1) 
C(6) 9183(1) 2041(4) 5961(1) 32(1) 
C(7) 9297(1) 3365(5) 6603(1) 34(1) 
C(8) 8576(1) 2637(4) 7035(1) 33(1) 
C(9) 7692(1) 3597(4) 6773(1) 31(1) 
C(10) 7053(1) 2259(4) 6474(1) 27(1) 
C(11) 6180(1) 3232(4) 6186(1) 24(1) 
C(12) 6140(1) 3223(4) 5432(1) 25(1) 
C(13) 6737(1) 5153(4) 5210(1) 25(1) 
C(16) 5426(1) 1846(4) 6434(1) 21(1) 
C(17) 5111(1) -298(4) 6146(1) 24(1) 
C(18) 4444(1) -1589(4) 6398(1) 24(1) 
C(19) 4095(1) -712(4) 6946(1) 22(1) 
C(20) 4382(1) 1415(4) 7240(1) 24(1) 
C(21) 5047(1) 2677(4) 6982(1) 24(1) 
C(22) 7504(1) 7680(4) 4048(1) 29(1) 
________________________________________________________________ 
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 Table 3.   Bond lengths [Å] and angles [°] for  007-16012. 
_____________________________________________________  
Br(1)-C(19)  1.9053(19) 
O(1)-C(13)  1.338(2) 
O(1)-C(2)  1.466(2) 
O(5)-C(6)  1.343(3) 
O(5)-C(4)  1.454(2) 
O(14)-C(6)  1.216(3) 
O(15)-C(13)  1.210(3) 
C(2)-C(22)  1.515(3) 
C(2)-C(3)  1.516(3) 
C(2)-H(2)  1.0000 
C(3)-C(4)  1.513(3) 
C(3)-H(3A)  0.9900 
C(3)-H(3B)  0.9900 
C(4)-H(4A)  0.9900 
C(4)-H(4B)  0.9900 
C(6)-C(7)  1.506(3) 
C(7)-C(8)  1.540(3) 
C(7)-H(7A)  0.9900 
C(7)-H(7B)  0.9900 
C(8)-C(9)  1.503(3) 
C(8)-H(8A)  0.9900 
C(8)-H(8B)  0.9900 
C(9)-C(10)  1.329(3) 
C(9)-H(9)  0.9500 
C(10)-C(11)  1.508(3) 
C(10)-H(10)  0.9500 
C(11)-C(16)  1.519(3) 
C(11)-C(12)  1.546(3) 
C(11)-H(11)  1.0000 
C(12)-C(13)  1.509(3) 
C(12)-H(12A)  0.9900 
C(12)-H(12B)  0.9900 
C(16)-C(17)  1.395(3) 
C(16)-C(21)  1.397(3) 
 104 
C(17)-C(18)  1.390(3) 
C(17)-H(17)  0.9500 
C(18)-C(19)  1.384(3) 
C(18)-H(18)  0.9500 
C(19)-C(20)  1.379(3) 
C(20)-C(21)  1.385(3) 
C(20)-H(20)  0.9500 
C(21)-H(21)  0.9500 
C(22)-H(22A)  0.9800 
C(22)-H(22B)  0.9800 
C(22)-H(22C)  0.9800 
 
C(13)-O(1)-C(2) 116.31(15) 
C(6)-O(5)-C(4) 115.81(18) 
O(1)-C(2)-C(22) 109.62(15) 
O(1)-C(2)-C(3) 105.93(16) 
C(22)-C(2)-C(3) 112.85(16) 
O(1)-C(2)-H(2) 109.5 
C(22)-C(2)-H(2) 109.5 
C(3)-C(2)-H(2) 109.5 
C(4)-C(3)-C(2) 113.90(16) 
C(4)-C(3)-H(3A) 108.8 
C(2)-C(3)-H(3A) 108.8 
C(4)-C(3)-H(3B) 108.8 
C(2)-C(3)-H(3B) 108.8 
H(3A)-C(3)-H(3B) 107.7 
O(5)-C(4)-C(3) 107.42(17) 
O(5)-C(4)-H(4A) 110.2 
C(3)-C(4)-H(4A) 110.2 
O(5)-C(4)-H(4B) 110.2 
C(3)-C(4)-H(4B) 110.2 
H(4A)-C(4)-H(4B) 108.5 
O(14)-C(6)-O(5) 123.5(2) 
O(14)-C(6)-C(7) 124.8(2) 
O(5)-C(6)-C(7) 111.6(2) 
C(6)-C(7)-C(8) 110.59(18) 
 105 
C(6)-C(7)-H(7A) 109.5 
C(8)-C(7)-H(7A) 109.5 
C(6)-C(7)-H(7B) 109.5 
C(8)-C(7)-H(7B) 109.5 
H(7A)-C(7)-H(7B) 108.1 
C(9)-C(8)-C(7) 111.78(18) 
C(9)-C(8)-H(8A) 109.3 
C(7)-C(8)-H(8A) 109.3 
C(9)-C(8)-H(8B) 109.3 
C(7)-C(8)-H(8B) 109.3 
H(8A)-C(8)-H(8B) 107.9 
C(10)-C(9)-C(8) 124.2(2) 
C(10)-C(9)-H(9) 117.9 
C(8)-C(9)-H(9) 117.9 
C(9)-C(10)-C(11) 124.3(2) 
C(9)-C(10)-H(10) 117.8 
C(11)-C(10)-H(10) 117.8 
C(10)-C(11)-C(16) 111.08(17) 
C(10)-C(11)-C(12) 109.77(16) 
C(16)-C(11)-C(12) 112.43(16) 
C(10)-C(11)-H(11) 107.8 
C(16)-C(11)-H(11) 107.8 
C(12)-C(11)-H(11) 107.8 
C(13)-C(12)-C(11) 109.70(17) 
C(13)-C(12)-H(12A) 109.7 
C(11)-C(12)-H(12A) 109.7 
C(13)-C(12)-H(12B) 109.7 
C(11)-C(12)-H(12B) 109.7 
H(12A)-C(12)-H(12B) 108.2 
O(15)-C(13)-O(1) 123.73(19) 
O(15)-C(13)-C(12) 124.10(18) 
O(1)-C(13)-C(12) 112.16(17) 
C(17)-C(16)-C(21) 118.13(18) 
C(17)-C(16)-C(11) 122.13(17) 
C(21)-C(16)-C(11) 119.71(18) 
C(18)-C(17)-C(16) 121.21(18) 
 106 
C(18)-C(17)-H(17) 119.4 
C(16)-C(17)-H(17) 119.4 
C(19)-C(18)-C(17) 118.67(19) 
C(19)-C(18)-H(18) 120.7 
C(17)-C(18)-H(18) 120.7 
C(20)-C(19)-C(18) 121.85(18) 
C(20)-C(19)-Br(1) 119.21(14) 
C(18)-C(19)-Br(1) 118.94(15) 
C(19)-C(20)-C(21) 118.62(18) 
C(19)-C(20)-H(20) 120.7 
C(21)-C(20)-H(20) 120.7 
C(20)-C(21)-C(16) 121.52(19) 
C(20)-C(21)-H(21) 119.2 
C(16)-C(21)-H(21) 119.2 
C(2)-C(22)-H(22A) 109.5 
C(2)-C(22)-H(22B) 109.5 
H(22A)-C(22)-H(22B) 109.5 
C(2)-C(22)-H(22C) 109.5 
H(22A)-C(22)-H(22C) 109.5 
H(22B)-C(22)-H(22C) 109.5 
_____________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
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 Table 4.   Anisotropic displacement parameters  (Å2x 103) for 007-16012.  The 
anisotropic displacement factor exponent takes the form:  -2p2[ h2 a*2U11 + ...  
+ 2 h k a* b* U12 ] 
________________________________________________________________ 
 U11 U22  U33 U23 U13 U12 
________________________________________________________________ 
Br(1) 24(1)  28(1) 30(1)  1(1) 10(1)  -2(1) 
O(1) 22(1)  22(1) 23(1)  0(1) 5(1)  -2(1) 
O(5) 27(1)  36(1) 26(1)  -1(1) -3(1)  -2(1) 
O(14) 66(1)  35(1) 40(1)  0(1) 6(1)  9(1) 
O(15) 44(1)  25(1) 43(1)  0(1) 22(1)  3(1) 
C(2) 24(1)  24(1) 21(1)  0(1) 3(1)  -6(1) 
C(3) 24(1)  35(1) 24(1)  -3(1) 5(1)  -1(1) 
C(4) 30(1)  36(1) 28(1)  -7(1) 2(1)  7(1) 
C(6) 22(1)  41(1) 32(1)  2(1) 3(1)  6(1) 
C(7) 24(1)  48(1) 29(1)  -1(1) -4(1)  -4(1) 
C(8) 30(1)  42(1) 27(1)  -1(1) -3(1)  -2(1) 
C(9) 33(1)  34(1) 26(1)  -2(1) 4(1)  2(1) 
C(10) 23(1)  34(1) 24(1)  3(1) 3(1)  2(1) 
C(11) 23(1)  27(1) 24(1)  1(1) 4(1)  0(1) 
C(12) 22(1)  29(1) 25(1)  4(1) 4(1)  0(1) 
C(13) 25(1)  26(1) 24(1)  2(1) 5(1)  4(1) 
C(16) 19(1)  23(1) 22(1)  4(1) 1(1)  2(1) 
C(17) 23(1)  26(1) 23(1)  -2(1) 6(1)  2(1) 
C(18) 25(1)  22(1) 25(1)  -2(1) 2(1)  0(1) 
C(19) 18(1)  24(1) 23(1)  4(1) 2(1)  2(1) 
C(20) 26(1)  26(1) 21(1)  0(1) 5(1)  4(1) 
C(21) 27(1)  22(1) 22(1)  -1(1) 1(1)  0(1) 
C(22) 36(1)  29(1) 22(1)  3(1) 2(1)  -1(1) 
________________________________________________________________ 
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 Table 5.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters 
(Å2x 10 3) for 007-16012. 
________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________  
  
H(2) 8160 6969 4959 28 
H(3A) 8418 3714 3915 33 
H(3B) 9142 5490 4263 33 
H(4A) 8494 1218 4822 38 
H(4B) 9488 1711 4672 38 
H(7A) 9269 5121 6522 41 
H(7B) 9880 2989 6833 41 
H(8A) 8548 860 7060 40 
H(8B) 8728 3260 7483 40 
H(9) 7584 5267 6823 37 
H(10) 7153 578 6441 32 
H(11) 6137 4942 6331 29 
H(12A) 6326 1631 5279 30 
H(12B) 5530 3520 5241 30 
H(17) 5358 -888 5772 29 
H(18) 4231 -3044 6197 29 
H(20) 4129 2002 7613 29 
H(21) 5250 4141 7182 29 
H(22A) 7206 6730 3690 43 
H(22B) 7962 8669 3880 43 
H(22C) 7077 8725 4233 43 
________________________________________________________________ 
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 Table 6.  Torsion angles [°] for 007-16012. 
________________________________________________________________  
C(13)-O(1)-C(2)-C(22) -82.6(2) 
C(13)-O(1)-C(2)-C(3) 155.41(15) 
O(1)-C(2)-C(3)-C(4) -50.0(2) 
C(22)-C(2)-C(3)-C(4) -169.98(18) 
C(6)-O(5)-C(4)-C(3) 161.83(17) 
C(2)-C(3)-C(4)-O(5) -49.7(2) 
C(4)-O(5)-C(6)-O(14) 4.3(3) 
C(4)-O(5)-C(6)-C(7) -174.89(16) 
O(14)-C(6)-C(7)-C(8) -54.0(3) 
O(5)-C(6)-C(7)-C(8) 125.2(2) 
C(6)-C(7)-C(8)-C(9) -70.3(3) 
C(7)-C(8)-C(9)-C(10) 105.8(3) 
C(8)-C(9)-C(10)-C(11) -177.34(19) 
C(9)-C(10)-C(11)-C(16) -128.0(2) 
C(9)-C(10)-C(11)-C(12) 107.0(2) 
C(10)-C(11)-C(12)-C(13) -71.6(2) 
C(16)-C(11)-C(12)-C(13) 164.23(16) 
C(2)-O(1)-C(13)-O(15) 5.6(3) 
C(2)-O(1)-C(13)-C(12) -174.13(15) 
C(11)-C(12)-C(13)-O(15) -47.6(3) 
C(11)-C(12)-C(13)-O(1) 132.13(17) 
C(10)-C(11)-C(16)-C(17) -84.5(2) 
C(12)-C(11)-C(16)-C(17) 38.9(3) 
C(10)-C(11)-C(16)-C(21) 93.3(2) 
C(12)-C(11)-C(16)-C(21) -143.29(18) 
C(21)-C(16)-C(17)-C(18) -0.4(3) 
C(11)-C(16)-C(17)-C(18) 177.39(18) 
C(16)-C(17)-C(18)-C(19) -0.3(3) 
C(17)-C(18)-C(19)-C(20) 1.1(3) 
C(17)-C(18)-C(19)-Br(1) -178.45(14) 
C(18)-C(19)-C(20)-C(21) -1.0(3) 
Br(1)-C(19)-C(20)-C(21) 178.54(14) 
C(19)-C(20)-C(21)-C(16) 0.2(3) 
C(17)-C(16)-C(21)-C(20) 0.5(3) 
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C(11)-C(16)-C(21)-C(20) -177.35(18) 
________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
  
 
2.7.8 Crystallographic Data for Compound 47a 
Low-temperature diffraction data (ω-scans) were collected on a Rigaku SCX Mini 
diffractometer coupled to a Rigaku Mercury275R CCD with Mo Kα radiation (λ = 
0.71073 Å) for the structure of mini-16026. The diffraction images were 
processed and scaled using the Rigaku CrystalClear software (CrystalClear and 
CrystalStructure; Rigaku/MSC: The Woodlands, TX, 2005). The structure was 
solved with SHELXT and was refined against F2 on all data by full-matrix least 
squares with SHELXL (Sheldrick, G. M. Acta Cryst. 2008, A64, 112–122). All 
non-hydrogen atoms were refined anisotropically. Hydrogen atoms were included 
in the model at geometrically calculated positions and refined using a riding 
model. The isotropic displacement parameters of all hydrogen atoms were fixed 
to 1.2 times the U value of the atoms to which they are linked (1.5 times for 
methyl groups). The full numbering scheme of compound mini-16026 can be 
found in the full details of the X-ray structure determination (CIF), which is 
included as Supporting Information. CCDC number XXXXXX (mini-16026) 
contains the supplementary crystallographic data for this paper. These data can 
be obtained free of charge from The Cambridge Crystallographic Data Center via 
www.ccdc.cam.ac.uk/data_request/cif.  
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Figure 1. The complete numbering scheme of mini-16026 with 50% thermal 
ellipsoid probability levels.  The hydrogen atoms are shown as circles for clarity. 
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  Table 1.  Crystal data and structure refinement for mini-16026. 
Identification code  mini-16026 
Empirical formula  C18 H22 O4 
Formula weight  302.35 
Temperature  93(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  Pna21 
Unit cell dimensions a = 11.2952(8) Å a= 90°. 
 b = 20.9595(15) Å b= 90°. 
 c = 6.6840(5) Å g = 90°. 
Volume 1582.4(2) Å3 
Z 4 
Density (calculated) 1.269 Mg/m3 
Absorption coefficient 0.089 mm-1 
F(000) 648 
Crystal size 0.320 x 0.200 x 0.200 mm3 
Theta range for data collection 2.651 to 27.671°. 
Index ranges -14<=h<=14, -27<=k<=27, -8<=l<=8 
Reflections collected 26669 
Independent reflections 3664 [R(int) = 0.0447] 
Completeness to theta = 25.242° 99.8 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.000 and 0.815 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3664 / 1 / 201 
Goodness-of-fit on F2 1.149 
Final R indices [I>2sigma(I)] R1 = 0.0499, wR2 = 0.1228 
R indices (all data) R1 = 0.0545, wR2 = 0.1276 
Absolute structure parameter 0.4(5) 
Extinction coefficient 0.012(3) 
Largest diff. peak and hole 0.260 and -0.202 e.Å-3 
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 Table 2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement 
parameters (Å2x 103) for mini-16026.  U(eq) is defined as one third of  the trace 
of the orthogonalized Uij tensor. 
________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________   
O(1) 860(2) 7033(1) 6331(3) 22(1) 
O(5) 1510(2) 5682(1) 5040(3) 23(1) 
O(14) 2504(2) 7392(1) 7780(4) 34(1) 
O(16) 1382(2) 5505(1) 1764(4) 30(1) 
C(2) 719(2) 6573(1) 7937(4) 23(1) 
C(3) -51(3) 6048(1) 7118(5) 25(1) 
C(4) 263(2) 5825(1) 5055(5) 25(1) 
C(6) 1964(2) 5537(1) 3251(5) 23(1) 
C(7) 3271(2) 5440(1) 3346(5) 24(1) 
C(8) 3912(2) 5980(1) 2261(4) 22(1) 
C(9) 3778(2) 6598(1) 3371(5) 22(1) 
C(10) 3236(2) 7102(1) 2639(5) 23(1) 
C(11) 3150(3) 7724(1) 3707(5) 25(1) 
C(12) 1937(3) 7828(1) 4646(5) 24(1) 
C(13) 1814(3) 7402(1) 6434(5) 23(1) 
C(15) 176(3) 6894(2) 9724(5) 28(1) 
C(17) 5218(2) 5849(1) 1992(4) 22(1) 
C(18) 5869(2) 5459(1) 3230(5) 24(1) 
C(19) 7081(3) 5393(1) 3008(5) 26(1) 
C(20) 7656(2) 5723(1) 1494(5) 26(1) 
C(21) 7017(3) 6114(1) 255(5) 26(1) 
C(22) 5811(3) 6180(1) 487(5) 25(1) 
________________________________________________________________ 
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 Table 3.   Bond lengths [Å] and angles [°] for  mini-16026. 
_____________________________________________________  
O(1)-C(13)  1.328(3) 
O(1)-C(2)  1.452(3) 
O(5)-C(6)  1.336(4) 
O(5)-C(4)  1.440(3) 
O(14)-C(13)  1.191(4) 
O(16)-C(6)  1.194(4) 
C(2)-C(15)  1.502(4) 
C(2)-C(3)  1.506(4) 
C(2)-H(2)  1.0000 
C(3)-C(4)  1.498(4) 
C(3)-H(3A)  0.9900 
C(3)-H(3B)  0.9900 
C(4)-H(4A)  0.9900 
C(4)-H(4B)  0.9900 
C(6)-C(7)  1.491(4) 
C(7)-C(8)  1.527(4) 
C(7)-H(7A)  0.9900 
C(7)-H(7B)  0.9900 
C(8)-C(9)  1.500(4) 
C(8)-C(17)  1.512(4) 
C(8)-H(8)  1.0000 
C(9)-C(10)  1.315(4) 
C(9)-H(9)  0.9500 
C(10)-C(11)  1.490(4) 
C(10)-H(10)  0.9500 
C(11)-C(12)  1.523(4) 
C(11)-H(11A)  0.9900 
C(11)-H(11B)  0.9900 
C(12)-C(13)  1.499(4) 
C(12)-H(12A)  0.9900 
C(12)-H(12B)  0.9900 
C(15)-H(15A)  0.9800 
C(15)-H(15B)  0.9800 
C(15)-H(15C)  0.9800 
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C(17)-C(18)  1.376(4) 
C(17)-C(22)  1.394(4) 
C(18)-C(19)  1.383(4) 
C(18)-H(18)  0.9500 
C(19)-C(20)  1.388(4) 
C(19)-H(19)  0.9500 
C(20)-C(21)  1.370(4) 
C(20)-H(20)  0.9500 
C(21)-C(22)  1.378(4) 
C(21)-H(21)  0.9500 
C(22)-H(22)  0.9500 
 
C(13)-O(1)-C(2) 115.9(2) 
C(6)-O(5)-C(4) 115.4(2) 
O(1)-C(2)-C(15) 109.6(2) 
O(1)-C(2)-C(3) 106.2(2) 
C(15)-C(2)-C(3) 112.3(2) 
O(1)-C(2)-H(2) 109.5 
C(15)-C(2)-H(2) 109.5 
C(3)-C(2)-H(2) 109.5 
C(4)-C(3)-C(2) 115.2(2) 
C(4)-C(3)-H(3A) 108.5 
C(2)-C(3)-H(3A) 108.5 
C(4)-C(3)-H(3B) 108.5 
C(2)-C(3)-H(3B) 108.5 
H(3A)-C(3)-H(3B) 107.5 
O(5)-C(4)-C(3) 107.6(2) 
O(5)-C(4)-H(4A) 110.2 
C(3)-C(4)-H(4A) 110.2 
O(5)-C(4)-H(4B) 110.2 
C(3)-C(4)-H(4B) 110.2 
H(4A)-C(4)-H(4B) 108.5 
O(16)-C(6)-O(5) 123.2(3) 
O(16)-C(6)-C(7) 124.9(3) 
O(5)-C(6)-C(7) 111.9(3) 
C(6)-C(7)-C(8) 110.4(2) 
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C(6)-C(7)-H(7A) 109.6 
C(8)-C(7)-H(7A) 109.6 
C(6)-C(7)-H(7B) 109.6 
C(8)-C(7)-H(7B) 109.6 
H(7A)-C(7)-H(7B) 108.1 
C(9)-C(8)-C(17) 108.3(2) 
C(9)-C(8)-C(7) 110.9(2) 
C(17)-C(8)-C(7) 112.6(2) 
C(9)-C(8)-H(8) 108.3 
C(17)-C(8)-H(8) 108.3 
C(7)-C(8)-H(8) 108.3 
C(10)-C(9)-C(8) 123.8(3) 
C(10)-C(9)-H(9) 118.1 
C(8)-C(9)-H(9) 118.1 
C(9)-C(10)-C(11) 123.7(3) 
C(9)-C(10)-H(10) 118.1 
C(11)-C(10)-H(10) 118.1 
C(10)-C(11)-C(12) 112.5(2) 
C(10)-C(11)-H(11A) 109.1 
C(12)-C(11)-H(11A) 109.1 
C(10)-C(11)-H(11B) 109.1 
C(12)-C(11)-H(11B) 109.1 
H(11A)-C(11)-H(11B) 107.8 
C(13)-C(12)-C(11) 109.1(2) 
C(13)-C(12)-H(12A) 109.9 
C(11)-C(12)-H(12A) 109.9 
C(13)-C(12)-H(12B) 109.9 
C(11)-C(12)-H(12B) 109.9 
H(12A)-C(12)-H(12B) 108.3 
O(14)-C(13)-O(1) 124.1(3) 
O(14)-C(13)-C(12) 123.5(3) 
O(1)-C(13)-C(12) 112.4(3) 
C(2)-C(15)-H(15A) 109.5 
C(2)-C(15)-H(15B) 109.5 
H(15A)-C(15)-H(15B) 109.5 
C(2)-C(15)-H(15C) 109.5 
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H(15A)-C(15)-H(15C) 109.5 
H(15B)-C(15)-H(15C) 109.5 
C(18)-C(17)-C(22) 118.2(3) 
C(18)-C(17)-C(8) 123.9(3) 
C(22)-C(17)-C(8) 117.7(2) 
C(17)-C(18)-C(19) 121.6(3) 
C(17)-C(18)-H(18) 119.2 
C(19)-C(18)-H(18) 119.2 
C(18)-C(19)-C(20) 119.4(3) 
C(18)-C(19)-H(19) 120.3 
C(20)-C(19)-H(19) 120.3 
C(21)-C(20)-C(19) 119.5(3) 
C(21)-C(20)-H(20) 120.2 
C(19)-C(20)-H(20) 120.2 
C(20)-C(21)-C(22) 120.8(3) 
C(20)-C(21)-H(21) 119.6 
C(22)-C(21)-H(21) 119.6 
C(21)-C(22)-C(17) 120.4(3) 
C(21)-C(22)-H(22) 119.8 
C(17)-C(22)-H(22) 119.8 
_____________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
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 Table 4.   Anisotropic displacement parameters  (Å2x 103) for mini-16026.  The 
anisotropic 
displacement factor exponent takes the form:  -2p2[ h2 a*2U11 + ...  + 2 h k a* b* 
U12 ] 
________________________________________________________________
______________  
 U11 U22  U33 U23 U13 U12 
________________________________________________________________
______________  
O(1) 22(1)  23(1) 22(1)  3(1) 1(1)  -2(1) 
O(5) 20(1)  27(1) 23(1)  1(1) 2(1)  3(1) 
O(14) 32(1)  43(1) 27(1)  2(1) -6(1)  -11(1) 
O(16) 29(1)  33(1) 28(1)  -5(1) 0(1)  1(1) 
C(2) 22(1)  24(1) 22(1)  6(1) 1(1)  1(1) 
C(3) 24(1)  24(1) 26(1)  3(1) 5(1)  -1(1) 
C(4) 21(1)  27(1) 27(2)  -2(1) 3(1)  0(1) 
C(6) 24(1)  18(1) 26(1)  -1(1) 4(1)  -2(1) 
C(7) 22(1)  20(1) 29(1)  2(1) 5(1)  1(1) 
C(8) 21(1)  21(1) 24(1)  1(1) 2(1)  0(1) 
C(9) 21(1)  22(1) 22(1)  0(1) 2(1)  0(1) 
C(10) 23(1)  23(1) 22(1)  -1(1) 2(1)  0(1) 
C(11) 25(1)  20(1) 30(2)  1(1) 6(1)  0(1) 
C(12) 23(1)  21(1) 27(1)  3(1) 1(1)  2(1) 
C(13) 24(1)  21(1) 25(1)  0(1) 2(1)  -1(1) 
C(15) 31(1)  31(1) 23(1)  0(1) 4(1)  1(1) 
C(17) 22(1)  21(1) 22(1)  -2(1) 2(1)  -1(1) 
C(18) 23(1)  25(1) 23(1)  2(1) 1(1)  -1(1) 
C(19) 24(1)  26(1) 28(2)  -2(1) 1(1)  2(1) 
C(20) 20(1)  25(1) 32(2)  -6(1) 1(1)  -1(1) 
C(21) 26(1)  24(1) 28(1)  -1(1) 5(1)  -3(1) 
C(22) 26(1)  23(1) 26(1)  1(1) 4(1)  0(1) 
________________________________________________________________ 
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 Table 5.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters 
(Å2x 10 3) for mini-16026. 
________________________________________________________________ 
 x  y  z  U(eq) 
________________________________________________________________  
  
H(2) 1511 6395 8309 27 
H(3A) -9 5679 8039 30 
H(3B) -882 6199 7106 30 
H(4A) -200 5439 4709 30 
H(4B) 82 6161 4063 30 
H(7A) 3477 5027 2718 29 
H(7B) 3528 5427 4761 29 
H(8) 3547 6031 907 26 
H(9) 4104 6627 4679 26 
H(10) 2880 7067 1356 27 
H(11A) 3313 8074 2751 30 
H(11B) 3761 7740 4767 30 
H(12A) 1850 8280 5058 28 
H(12B) 1309 7730 3660 28 
H(15A) 712 7226 10218 43 
H(15B) 41 6578 10781 43 
H(15C) -581 7087 9340 43 
H(18) 5477 5230 4262 29 
H(19) 7515 5124 3885 31 
H(20) 8487 5678 1318 31 
H(21) 7411 6342 -778 31 
H(22) 5382 6454 -384 30 
________________________________________________________________ 
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 Table 6.  Torsion angles [°] for mini-16026. 
________________________________________________________________  
C(13)-O(1)-C(2)-C(15) 82.1(3) 
C(13)-O(1)-C(2)-C(3) -156.3(2) 
O(1)-C(2)-C(3)-C(4) 44.7(3) 
C(15)-C(2)-C(3)-C(4) 164.5(2) 
C(6)-O(5)-C(4)-C(3) -173.5(2) 
C(2)-C(3)-C(4)-O(5) 51.2(3) 
C(4)-O(5)-C(6)-O(16) -2.5(4) 
C(4)-O(5)-C(6)-C(7) 176.1(2) 
O(16)-C(6)-C(7)-C(8) 67.8(4) 
O(5)-C(6)-C(7)-C(8) -110.8(3) 
C(6)-C(7)-C(8)-C(9) 68.5(3) 
C(6)-C(7)-C(8)-C(17) -169.9(2) 
C(17)-C(8)-C(9)-C(10) 118.9(3) 
C(7)-C(8)-C(9)-C(10) -117.0(3) 
C(8)-C(9)-C(10)-C(11) -177.2(3) 
C(9)-C(10)-C(11)-C(12) -102.7(3) 
C(10)-C(11)-C(12)-C(13) 72.7(3) 
C(2)-O(1)-C(13)-O(14) -3.5(4) 
C(2)-O(1)-C(13)-C(12) 175.8(2) 
C(11)-C(12)-C(13)-O(14) 54.4(4) 
C(11)-C(12)-C(13)-O(1) -125.0(3) 
C(9)-C(8)-C(17)-C(18) 96.9(3) 
C(7)-C(8)-C(17)-C(18) -26.2(4) 
C(9)-C(8)-C(17)-C(22) -78.3(3) 
C(7)-C(8)-C(17)-C(22) 158.6(3) 
C(22)-C(17)-C(18)-C(19) 0.1(4) 
C(8)-C(17)-C(18)-C(19) -175.1(3) 
C(17)-C(18)-C(19)-C(20) -0.5(4) 
C(18)-C(19)-C(20)-C(21) 0.6(4) 
C(19)-C(20)-C(21)-C(22) -0.4(5) 
C(20)-C(21)-C(22)-C(17) -0.1(5) 
C(18)-C(17)-C(22)-C(21) 0.2(4) 
C(8)-C(17)-C(22)-C(21) 175.6(3) 
________________________________________________________________  
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2.7.9 Crystallographic Data for Compound 48a 
Low-temperature diffraction data (ω-scans) were collected on a Rigaku SCX Mini 
diffractometer coupled to a Rigaku Mercury275R CCD with Mo Kα radiation (λ = 
0.71073 Å) for the structure of mini-15062. The diffraction images were 
processed and scaled using the Rigaku CrystalClear software (CrystalClear and 
CrystalStructure; Rigaku/MSC: The  Woodlands, TX, 2005). The structure was 
solved with SHELXT and was refined against F2 on all data by full-matrix least 
squares with SHELXL (Sheldrick, G. M. Acta Cryst. 2008, A64, 112–122). All 
non-hydrogen atoms were refined anisotropically. Hydrogen atoms were included 
in the model at geometrically calculated positions and refined using a riding 
model. The isotropic displacement parameters of all hydrogen atoms were fixed 
to 1.2 times the U value of the atoms to which they are linked (1.5 times for 
methyl groups). The full numbering scheme of compound mini-15062 can be 
found in the Supporting Information. Full details of the X-ray structure 
determination are in the CIF included as Supporting Information. CCDC number 
XXXXXX (mini-15062) contains the supplementary crystallographic data for this 
paper. These data can be obtained free of charge from The Cambridge 
Crystallographic Data Center via www.ccdc.cam.ac.uk/data_request/cif.  
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Figure 1. The numbering scheme of 007-15093. All atoms shown are depicted 
with 50% thermal contours. Atoms C8 has R chirality; C11 has R. 
 
 
 
 
 
  Table 1.  Crystal data and structure refinement for mini-15062. 
Identification code  mini-15062 
Empirical formula  C13 H20 O4 
Formula weight  240.29 
Temperature  93(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P 21/c 
Unit cell dimensions a = 8.0547(6) Å α = 90°. 
 b = 18.7875(14) Å β = 102.530(6)°. 
 c = 8.9660(7) Å γ = 90°. 
Volume 1324.49(18) Å3 
Z 4 
Density (calculated) 1.205 Mg/m3 
Absorption coefficient 0.088 mm-1 
F(000) 520 
Crystal size 0.180 x 0.170 x 0.160 mm3 
Crystal color and habit Colorless Prism 
Diffractometer Rigaku Mercury275R CCD 
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Theta range for data collection 2.168 to 25.024°. 
Index ranges -9 ≤ h ≤ 9, -22 ≤ k ≤ 22, -10 ≤ l  ≤ 10 
Reflections collected 17742 
Independent reflections 2341 [R(int) = 0.1311] 
Observed reflections (I > 2sigma(I)) 1835 
Completeness to theta = 25.024° 99.7 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.986 and 0.695 
Solution method SHELXT-2014/5 (Sheldrick, 2014) 
Refinement method SHELXL-2014/7 (Sheldrick, 2014) 
Data / restraints / parameters 2341 / 0 / 156 
Goodness-of-fit on F2 1.092 
Final R indices [I>2sigma(I)] R1 = 0.0844, wR2 = 0.2156 
R indices (all data) R1 = 0.1009, wR2 = 0.2298 
Largest diff. peak and hole 0.524 and -0.272 e.Å-3 
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 Table 2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement 
parameters (Å2x 103) for mini-15062.  U(eq) is defined as one third of  the trace 
of the orthogonalized Uij tensor. 
________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________ 
O(1) 1156(3) 6152(1) 4056(2) 43(1) 
C(2) 1268(4) 6769(2) 3110(3) 45(1) 
C(3) 2297(4) 6557(2) 1964(3) 46(1) 
C(4) 3936(4) 6197(2) 2691(3) 46(1) 
O(5) 4791(3) 6643(1) 3951(2) 44(1) 
C(6) 6082(4) 6334(2) 4921(3) 42(1) 
C(7) 6776(4) 6785(2) 6291(3) 41(1) 
C(8) 6801(4) 6381(2) 7779(3) 39(1) 
C(9) 5008(3) 6313(2) 8031(3) 38(1) 
C(10) 4067(4) 5744(2) 7763(3) 37(1) 
C(11) 2264(4) 5674(2) 7945(3) 38(1) 
C(12) 1060(4) 5615(2) 6395(3) 40(1) 
C(13) 1002(3) 6281(2) 5484(3) 37(1) 
O(14) 843(3) 6865(1) 5953(2) 44(1) 
O(15) 6618(3) 5757(1) 4715(3) 58(1) 
C(16) 7974(4) 6755(2) 9083(4) 47(1) 
C(17) 2078(4) 5026(2) 8906(4) 50(1) 
________________________________________________________________
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 Table 3.   Bond lengths [Å] and angles [°] for  mini-15062. 
_____________________________________________________  
O(1)-C(13)  1.335(3) 
O(1)-C(2)  1.450(4) 
C(2)-C(3)  1.506(4) 
C(2)-H(2A)  0.9900 
C(2)-H(2B)  0.9900 
C(3)-C(4)  1.501(4) 
C(3)-H(3A)  0.9900 
C(3)-H(3B)  0.9900 
C(4)-O(5)  1.454(4) 
C(4)-H(4A)  0.9900 
C(4)-H(4B)  0.9900 
O(5)-C(6)  1.334(4) 
C(6)-O(15)  1.197(4) 
C(6)-C(7)  1.496(4) 
C(7)-C(8)  1.532(4) 
C(7)-H(7A)  0.9900 
C(7)-H(7B)  0.9900 
C(8)-C(16)  1.508(4) 
C(8)-C(9)  1.515(4) 
C(8)-H(8)  1.0000 
C(9)-C(10)  1.302(4) 
C(9)-H(9)  0.9500 
C(10)-C(11)  1.502(4) 
C(10)-H(10)  0.9500 
C(11)-C(12)  1.516(4) 
C(11)-C(17)  1.517(4) 
C(11)-H(11)  1.0000 
C(12)-C(13)  1.488(4) 
C(12)-H(12A)  0.9900 
C(12)-H(12B)  0.9900 
C(13)-O(14)  1.192(3) 
C(16)-H(16A)  0.9800 
C(16)-H(16B)  0.9800 
C(16)-H(16C)  0.9800 
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C(17)-H(17A)  0.9800 
C(17)-H(17B)  0.9800 
C(17)-H(17C)  0.9800 
C(13)-O(1)-C(2) 116.5(2) 
O(1)-C(2)-C(3) 107.5(2) 
O(1)-C(2)-H(2A) 110.2 
C(3)-C(2)-H(2A) 110.2 
O(1)-C(2)-H(2B) 110.2 
C(3)-C(2)-H(2B) 110.2 
H(2A)-C(2)-H(2B) 108.5 
C(4)-C(3)-C(2) 112.7(2) 
C(4)-C(3)-H(3A) 109.1 
C(2)-C(3)-H(3A) 109.1 
C(4)-C(3)-H(3B) 109.1 
C(2)-C(3)-H(3B) 109.1 
H(3A)-C(3)-H(3B) 107.8 
O(5)-C(4)-C(3) 107.5(2) 
O(5)-C(4)-H(4A) 110.2 
C(3)-C(4)-H(4A) 110.2 
O(5)-C(4)-H(4B) 110.2 
C(3)-C(4)-H(4B) 110.2 
H(4A)-C(4)-H(4B) 108.5 
C(6)-O(5)-C(4) 115.3(2) 
O(15)-C(6)-O(5) 123.3(3) 
O(15)-C(6)-C(7) 123.8(3) 
O(5)-C(6)-C(7) 112.9(3) 
C(6)-C(7)-C(8) 111.5(2) 
C(6)-C(7)-H(7A) 109.3 
C(8)-C(7)-H(7A) 109.3 
C(6)-C(7)-H(7B) 109.3 
C(8)-C(7)-H(7B) 109.3 
H(7A)-C(7)-H(7B) 108.0 
C(16)-C(8)-C(9) 112.4(2) 
C(16)-C(8)-C(7) 109.4(2) 
C(9)-C(8)-C(7) 109.8(2) 
C(16)-C(8)-H(8) 108.4 
 127 
C(9)-C(8)-H(8) 108.4 
C(7)-C(8)-H(8) 108.4 
C(10)-C(9)-C(8) 125.2(2) 
C(10)-C(9)-H(9) 117.4 
C(8)-C(9)-H(9) 117.4 
C(9)-C(10)-C(11) 126.1(3) 
C(9)-C(10)-H(10) 117.0 
C(11)-C(10)-H(10) 117.0 
C(10)-C(11)-C(12) 110.4(2) 
C(10)-C(11)-C(17) 110.4(2) 
C(12)-C(11)-C(17) 109.8(2) 
C(10)-C(11)-H(11) 108.7 
C(12)-C(11)-H(11) 108.7 
C(17)-C(11)-H(11) 108.7 
C(13)-C(12)-C(11) 112.3(2) 
C(13)-C(12)-H(12A) 109.1 
C(11)-C(12)-H(12A) 109.1 
C(13)-C(12)-H(12B) 109.1 
C(11)-C(12)-H(12B) 109.1 
H(12A)-C(12)-H(12B) 107.9 
O(14)-C(13)-O(1) 123.0(3) 
O(14)-C(13)-C(12) 124.9(3) 
O(1)-C(13)-C(12) 112.1(2) 
C(8)-C(16)-H(16A) 109.5 
C(8)-C(16)-H(16B) 109.5 
H(16A)-C(16)-H(16B) 109.5 
C(8)-C(16)-H(16C) 109.5 
H(16A)-C(16)-H(16C) 109.5 
H(16B)-C(16)-H(16C) 109.5 
C(11)-C(17)-H(17A) 109.5 
C(11)-C(17)-H(17B) 109.5 
H(17A)-C(17)-H(17B) 109.5 
C(11)-C(17)-H(17C) 109.5 
H(17A)-C(17)-H(17C) 109.5 
H(17B)-C(17)-H(17C) 109.5 
_____________________________________________________________  
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Symmetry transformations used to generate equivalent atoms:  
  
 
 Table 4.   Anisotropic displacement parameters  (Å2x 103) for mini-15062.  The 
anisotropic 
displacement factor exponent takes the form:  -2p2[ h2 a*2U11 + ...  + 2 h k a* b* 
U12 ] 
________________________________________________________________
______________  
 U11 U22  U33 U23 U13 U12 
________________________________________________________________
______________  
O(1) 48(1)  53(1) 30(1)  -4(1) 16(1)  4(1) 
C(2) 49(2)  55(2) 34(2)  2(1) 17(2)  9(1) 
C(3) 48(2)  63(2) 31(2)  -1(1) 14(1)  8(1) 
C(4) 50(2)  59(2) 32(2)  -4(1) 16(1)  5(1) 
O(5) 43(1)  57(1) 36(1)  0(1) 15(1)  5(1) 
C(6) 36(2)  59(2) 36(2)  1(1) 19(1)  4(1) 
C(7) 32(2)  56(2) 40(2)  1(1) 18(1)  0(1) 
C(8) 32(2)  51(2) 36(2)  0(1) 16(1)  0(1) 
C(9) 34(2)  54(2) 31(1)  -3(1) 18(1)  2(1) 
C(10) 39(2)  48(2) 30(1)  0(1) 18(1)  4(1) 
C(11) 35(2)  52(2) 34(2)  -3(1) 20(1)  -2(1) 
C(12) 35(2)  52(2) 39(2)  -5(1) 21(1)  -2(1) 
C(13) 25(1)  52(2) 36(2)  -5(1) 12(1)  2(1) 
O(14) 45(1)  52(1) 41(1)  -6(1) 23(1)  1(1) 
O(15) 54(1)  73(2) 48(1)  -12(1) 12(1)  20(1) 
C(16) 39(2)  63(2) 42(2)  -1(1) 16(1)  -4(1) 
C(17) 49(2)  65(2) 42(2)  3(1) 25(2)  -3(2) 
________________________________________________________________
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 Table 5.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters 
(Å2x 10 3) for mini-15062. 
________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________  
  
H(2A) 1826 7168 3748 54 
H(2B) 116 6923 2578 54 
H(3A) 1613 6232 1203 56 
H(3B) 2551 6987 1416 56 
H(4A) 3707 5720 3072 55 
H(4B) 4659 6139 1936 55 
H(7A) 6068 7218 6260 49 
H(7B) 7946 6936 6264 49 
H(8) 7257 5892 7683 46 
H(9) 4531 6718 8416 45 
H(10) 4568 5335 7420 45 
H(11) 1961 6109 8474 46 
H(12A) 1427 5216 5821 48 
H(12B) -97 5506 6540 48 
H(16A) 7569 7242 9170 70 
H(16B) 9126 6769 8891 70 
H(16C) 7989 6498 10037 70 
H(17A) 2371 4597 8398 75 
H(17B) 900 4992 9026 75 
H(17C) 2842 5072 9913 75 
________________________________________________________________ 
 130 
 Table 6.  Torsion angles [°] for mini-15062. 
________________________________________________________________  
C(13)-O(1)-C(2)-C(3) 151.1(3) 
O(1)-C(2)-C(3)-C(4) -49.6(4) 
C(2)-C(3)-C(4)-O(5) -50.5(4) 
C(3)-C(4)-O(5)-C(6) 166.3(2) 
C(4)-O(5)-C(6)-O(15) 6.6(4) 
C(4)-O(5)-C(6)-C(7) -173.1(2) 
O(15)-C(6)-C(7)-C(8) -53.8(4) 
O(5)-C(6)-C(7)-C(8) 125.8(2) 
C(6)-C(7)-C(8)-C(16) 162.7(2) 
C(6)-C(7)-C(8)-C(9) -73.6(3) 
C(16)-C(8)-C(9)-C(10) -136.5(3) 
C(7)-C(8)-C(9)-C(10) 101.5(3) 
C(8)-C(9)-C(10)-C(11) -177.4(3) 
C(9)-C(10)-C(11)-C(12) 109.7(3) 
C(9)-C(10)-C(11)-C(17) -128.7(3) 
C(10)-C(11)-C(12)-C(13) -66.3(3) 
C(17)-C(11)-C(12)-C(13) 171.8(2) 
C(2)-O(1)-C(13)-O(14) 5.1(4) 
C(2)-O(1)-C(13)-C(12) -174.7(2) 
C(11)-C(12)-C(13)-O(14) -47.6(4) 
C(11)-C(12)-C(13)-O(1) 132.2(2) 
________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
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Part II: 
Chapter 3 
Synthesis of Acinetobactin and Analogs: A Trojan Horse Strategy 
Targeted at Acinetobacter baumannii  
3  
3.1 The fascinating world of Acinetobacter baumannii  
3.1.1 The rise of a multi-drug resistant pathogen 
For 70 years antibiotics have helped treat infectious diseases, allowing 
people to fight and overcome illnesses and death.1 Unfortunately with the 
widespread use and misuse of antibiotic drugs, there has been an extreme rise in 
organism resistance and therefore reducing the number of effective therapeutics 
available. Antibiotic resistance has been a recurring topic of discussion for quite 
some time, as it drastically increases and has even been referred to as “the 
silent tsunami facing modern medicine”.2 Due to antibiotic resistance, Multi-drug 
resistant (MDR) Gram-negative bacterial pathogens, in particular, are emerging 
as a major threat worldwide.3 
In 1911, Dutch microbiologist Martinus Willem Beijerinck discovered the 
genus Acinetobacter, isolating it from soil enriched in calcium acetate.4 It was 
originally described as Micrococcus calco-aceticus by Beijerink but 43 years later 
was changed to Acinetobacter (from “akinetos” meaning non-motile in Greek) by 
Brisou and Prevot in order to distinguish it from motile organisms in the 
Achromobacter genus. Acinetobacter is a Gram-negative, encapsulated, aerobic, 
pleomorphic, nonmotile, and non-fermentative bacteria which became known as 
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a hospital pathogen in the 1970’s.4,5 During this time it was easily cured by 
common antibiotics and it wasn’t until 1986 that four new species of the bacteria, 
which included Acinetobacter baumannii (A. baumannii), were discovered as 
antimicrobial resistant pathogens. Of these four, three species are closely 
related, which also cannot be differentiated by routine testing. Since then more 
species have been discovered that are also closely related to A. baumannii. They 
are known as the A. baumannii complex or Acb complex and is comprised of five 
pathogenic species, which entails A. baumanni6,7, Acinetobacter pittii6,8, 
Acinetobacter seifertii6,9, Acinetobacter nosocomialis6,8 and Acinetobacter 
dijkshoorniae6,10, as well as the nonpathogenic species Acinetobacter 
calcoaceticus. It is very difficult to phenotypically distinguish A. baumannii from 
others in the Acb complex6, which can be a major factor in A. baumannii being 
the most well characterized species, as well as it accounting for 80% of all 
Acinetobacter infections.11 Since it is very difficult to distinguish A. baumannii 
from the 5 other species, the complex is and will be referred to as A. baumannii.  
A. baumannii, also known as “Iraqibacter”, is part of the most common and 
serious “ESKAPE” pathogens (Enteroccus faecium, Staphylococcus aureus, 
Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and 
Enterobacter spp). It has dramatically increased in the U.S. since infected troops 
have returned from Iraq, where the bacterium is found in the soil.4 A.baumannii 
typically occurs in intensive care units and the healthcare setting where patients 
are very sick. It poses little risk to healthy people, but can still (although rarely) 
colonize in open wounds without causing any symptoms. It is, however, a very 
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big threat to people with weakened immune systems and who are more 
susceptible to infections.11 This particular type of bacterium is known to cause 
illnesses such as nosocomial pneumonia and bacteremia, urinary tract infections, 
respiratory tract infections, wound infections and bloodstream infections.12,13 It 
has always been known to be transmitted through direct contact of patients and 
surfaces, but it has recently been reported to spread through aerosolized or 
airborne bacteria as well.14  
Once being a low-grade pathogen, A. baumannii is now a large threat to 
society. A list of the world’s most dangerous superbugs was recently released by 
the WHO, which reported three bacteria that are considered critical to find new 
antibiotics. The top priority bacteria consist of Pseudomonas aeruginosa, 
Enterobacteriaceae, and A. baumannii.15 A. baumannii is mostly persistent in 
hospital settings for three main factors: resistance to desiccation, resistance to 
antimicrobial drugs, and resistance to disinfectants.16 The spread has been 
linked to different variables, but the lack of implementation of infection control 
guidelines, as well as the use of broad-spectrum antibiotics are the two most 
important.17,18 There are currently isolates of A. baumannii that are resistant to a 
wide variety of therapies including monobactams, carbapenems, 
aminoglycosides, fluoroquinolones, and third-generation beta-lactam 
cephalosporins.19 There have even been bacteria isolated that are resistant to all 
treatments including polymixins,20 which are toxic and only used as a last resort 
option. Due to bacterial resistance among various antibiotics, there are three 
types that the European Centre for Disease Control and Centre for Disease 
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Control & Preventions (Atlanta) have defined, which are multidrug-resistant 
(MDR), extensively drug-resistant (XDR) and pandrug resistant (PDR) bacteria, 
with PDR being the most resistant and MDR being the least resistant.21 MDR 
bacteria are resistant to at least one agent from three or more antimicrobial 
categories, whereas XDR bacteria remain resistant to all but one or two 
categories. Pandrug resistant on the other hand are bacteria that are resistant to 
all antimicrobial category of agents. There are many various types of categories, 
but the major ones are penicillin, carbapenams, cephalosporins, 
aminoglycosides, monobactams, macrolides, polymyxins and 
fluoroquinolones.21,22  
MDR A. baumannii is mainly resistant to the three classes: beta-lactams 
(penicillins and cephalosporins), fluoroquinolones, and aminoglycosides. XDR 
strains are not only resistant to the three classes just stated, but they are also 
usually resistant to carbapenams. These strains have been referred to as 
“CRAB” for carbapenam resistant A. baumannii. Lastly, PDR A. baumannii is 
usually resistant to all classes including polymyxins and tigecyclines.23 
3.1.2 Mechanism of Virulence 
Gram-negative bacteria are much more difficult to kill using antibiotics 
than Gram-positive bacteria. The main difference between the two is that Gram-
negative bacteria have an additional outer membrane that makes it harder for 
antibiotics to penetrate. The exterior of Gram-negative bacterial cell consists of 
three main components: the outer membrane, periplasmic space, and inner 
membrane (Figure 3.1). The outer membrane contains two leaflets: an outer and 
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inner. Associated with (or traversing) that membrane are receptor proteins and 
porins. The inner leaflet usually contains phospholipids and lipoproteins, while 
the outer leaf consists of lipopolysaccharides (LPS) jutting out. The inner 
membrane (IM; also known as cytoplasm or plasma membrane), is composed of 
phospholipid bilayers and binds the bacterial protoplasm. The third component is 
the periplasmic space, which is a gel-like peptidoglycan layer that separates the 
outer membrane from the plasma membrane through various protein-protein 
interactions.24  
 
Figure 3.1 A. baumannii  surface-exposed glycoconjugates (Image reproduced 
with permission of the rights holder, Nature Reviews Microbioology)6 
 
A.baumannii also has virulence factors, which are proteins, peptides, and 
small molecules produced by bacteria. Virulence factors do three main things: 
invade host, cause disease, and avoid host defenses.25 Some identified virulence 
factors for A. baumannii consist of phospholipases, the outer membrane protein 
OmpA, membrane (capsular) polysaccharide components (Figure 3.1), penicillin 
binding proteins and outer membrane vesicles.26 Others include extracellular 
components with hemolytic, protease and iron chelating properties. There are 
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also complex phenotypes, which include surface motility, stress resistance, and 
biofilm formation. Through the use of virulence factors, bacteria have the ability 
to adapt to various environments such as nutrient starvation, desiccation and 
antimicrobial treatments and enhance both its bacterial toxicity, as well as 
pathogenicity.17,27  
A. baumanni bacterial cells contain glycans that form a network between 
the pathogen and its surroundings. The glycoconjugates are the bacteria’s first 
line of defense for stresses and immune invasion, and play a huge role in the 
virulence factors. Glycoconjugates include glycosylated proteins, peptidoglycans, 
lipopolysaccharide (LPS), and polysaccharides (Figure 3.1).6 The LPS, in 
particular, is an essential structural component found on the outer membrane 
and is very important for the bacteria’s vitality. In most Gram-negative bacteria 
the LPS consists of lipid A, which contains a core oligosaccharide and a 
polysaccharide O antigen in the outer leaflet. A. baumannii, though, does not 
consist of an O antigen, and is therefore referred to as the LOS. The LOS can be 
polymerized into a polyssacharide by the Wzy polymerase, which is then 
transported to the outer membrane for capsule formation. The capsular 
polysaccharide that is formed helps protect the bacteria from complement-
mediated-killing (hosts defense). It has even been considered to be one of the 
main virulence factors for A. baumannii since strains that lack it are more easily 
killed.6,28 Many clinical isolates have shown desiccation resistance, which could 
be related to the robustness of the capsular polysaccharide. With its ability to 
survive under dry, water limited conditions, some isolates of A. baumannii have 
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sustained life for more than 100 days.6,27,29 Even though it is still not fully 
understood as to how the bacteria obtains desiccation resistance, recent studies 
have linked resistance to the composition of the outer membrane (Figure 3.1).6,30 
It’s believed that the ability to form biofilms plays a huge role in its survival of 
these harsh conditions, which are usually enhanced by the glycoproteins.31 A 
biofilm is a structural arrangement of cells (outer membrane) that are encased in 
an extracellular matrix and is almost impossible to permeate using current 
antibiotics.32 Through the formation of the biofilm, the bacteria can actually attach 
themselves to both abiotic and biotic surfaces. In addition to biofilm formation, it 
is also thought that the LOS, which consists of a core glycan and hepta-acylated 
lipid A, assists in drug and desiccation resistance.6,30   
 MDR A. baumanni has also acquired various mechanisms responsible for 
antimicrobial drug resistance. There are currently strains that are resistant to 
cephalasporins, and carbapenams, which go through β lactam hydrolysis, and 
resistance to aminoglycosides uses aminoglycoside-modifying enzymes. There 
have also been reported cases of polymyxin resistance. Polymyxin is an 
“antibiotic of last resort” for difficult Gram-negative infections. It is however, very 
toxic. As mentioned earlier, the LOS is found on the outer membrane. The lipid A 
is the anchor of the LOS and is responsible for resistance to colistin (polymyxin 
E). Lipid A is the target for the antibiotic colisitin and it is this component that is 
modifying/mutating to become resistant. The bacteria can mutate the design of 
the lipid, which prohibits the binding of the polymyxin (Figure 3.1).6  
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3.1.3 Siderophores and sideromycins 
 Iron is a very important, but limited, micronutrient in various types of hosts. 
In mammalian hosts, extracellular iron is tightly bound to various biomolecules, 
including heme, as well as transferrin family proteins, which transport the iron to 
cells throughout the body.33,34 Not only is iron important for the host, but it is also 
vital for the survival and growth of bacteria. It is required for maintaining cellular, 
metabolic and biosynthetic processes. Some include, but are not limited to, DNA 
synthesis, electron transport, formation of heme, a cofactor for enzymes, oxygen 
transport, synthesis of ATP, and nitrite reduction in the nitrogen cycle.33 In order 
to adapt to iron-limited environments, bacteria have iron acquisition mechanisms. 
One main mechanism is the production of siderophores. Siderophores are low 
molecular weight compounds that bind iron, and whose association constants 
can exceed 1050, allowing it to compete with host proteins.35 Under iron-limiting 
conditions, different types of siderophores are secreted by the bacteria and 
compete against the host to chelate to iron. In Gram-negative bacteria, ferric-
siderophores (Fe+3) are recognized and transported by an outer membrane 
receptor (OMR). The iron is then moved to the inner membrane by the 
periplasmic binding protein (PBP), which can then progress into the cytoplasm or 
it can be released and the siderophore is exported out of the bacteria to be 
recycled.36 There are different types of siderophores that bacteria can produce, 
falling into four categories. Each category is dependent upon the moiety that 
chelates to the iron: catecholates, hydroxymates, carboxylates, and phenolate. 
There also ones that contain a mixture of moieties called mixed siderophores 
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(Figure 3.2). 
Not only do bacteria secrete their own siderophores, but they can also 
secrete the same siderophores as other bacteria. For instance, enterobactin 
(Figure 3.2), has been isolated from various enteric bacteria (Enterobacteriaceae 
family) including both Salmonella typhimurium and E. coli 37. In addition, even 
though bacteria may not produce a particular siderophore, they can still contain 
membrane receptors that recognize and transport them. The receptors have 
certain selectivities for particular siderophores, many depending on the chirality 
which allows coordination to the chelating moiety to occur.37 This can allow 
sideromycin-producing bacteria to have increased pathogenicity.  
 
Figure 3.2 Siderophores from various bacteria containing four different chelating 
moieties catecholate: 60 (Enterobactin from enteric bacteria), hydroxamate 61 
(Ferrichrome from Ustilago sphaerogena), carboxylate 62 (Staphyloferrin A from 
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Staphylococcus spp.), and phenolate 63 (Pyochelin from P. aerugenosa). 64 is mixed 
hydroxamate/ carboxylate (Aerobactin from Enterobactin spp.) 
 
Siderophores that are recognized by other bacteria membranes can be 
used against an organism through the production of sideromycins. Sideromycins 
are naturally occurring siderophores that are covalently linked to an antibiotic, 
which utilize other bacteria outer membranes to deliver the antibiotic payload, 
also known as the Trojan Horse Approach (THA).38 An example of these is 
albomycin 65, which is produced by Streptomyces griseus (Figure 3.3). It is a 
derivative of ferrichrome with a thionucleoside as the “warhead”. Albomycin has 
been proven to have activity against most Gram-negative Enterobacteriaceae 
species, as well as Gram-positive Staphylococcus aureus and Streptococcus 
pneumonia, by inhibiting the seryl-t-RNA synthetase.39–41 In order for the 
sideromycin to be effective and be transported into the cytoplasm, though, it must 
be released, through cleavage, from the siderophore after transport, where it can 
then be recognized and inhibit its target.42 Cleavage is essential for the 
siderophore to have activity, otherwise the warhead cannot be release and 
inhibition cannot occur. 
  
Figure 3.3 Natural sideromycin, albomycin, produced by Streptomyces griseus. 
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 Through the use of siderophores and sideromycins, bacteria cannot only 
live in harsh, iron depleted environments, but can also use it as protection 
against others. It is with this feature of bacteria that scientists can use to their 
advantage in the development of new antibiotics.    
3.2 Trojan Horse approach in the literature 
Due to the rise in MDR and XDR bacterial pathogens, there have been 
many different strategies for fighting this epidemic. Many scientists have found 
ways to treat drug resistant Gram-negative bacteria, such as prevention of biofilm 
formation, discovery of new classes of antibiotics, and combination drugs, to 
name a few. Another strategy that is gaining in popularity is the Trojan Horse 
approach.  
During the Bronze Age, there was a war between the peoples of Troy and 
Mycenaen Greece. After ten years of back-and-forth battle, the Greek armies 
were in retreat. The Greek hero Oddyseus, however, left the present of a large 
wooden horse outside Troy’s gates. Little did the Trojans know but the horse was 
fashioned so that the interior of the horse concealed a number of Greek soldiers 
hidden inside. The Trojans gladly brought the horse into the gates of the city, and 
then at nightfall the Greek army escaped from the horse and proceeded to defeat 
them from inside the city walls.43,44 
Similar to this historic war story, many scientists have proven that a similar 
approach can be taken when trying to defeat Gram-negative bacteria. Since 
MDR and XDR bacteria tend to change its outer membranes and porins, it is very 
difficult for antibiotics to penetrate. Because one cannot fight from the outside, 
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one must fight from within. The Trojan Horse approach, also known less 
figuratively as the siderophore-antibiotic conjugate (SAC) strategy, consists of 
synthesizing siderophores that are naturally produced from the bacteria and 
attaching an antibiotic warhead that can be smuggled inside the cell through 
siderophore receptors.45 Once inside the cell, the antibiotic is then released to 
engage its target, compromising the bacteria. That is, as long as it is active 
against the intracellular target. Through this strategy, it is possible to overcome 
resistance, since it is independent of the porin-mediated pathway and may even 
have increased potency. 
There have been various bacterial siderophores that have been proven to 
smuggle in antibiotics. One siderophore in particular, pyoverdine, was coupled 
with a quinolone and showed activity against P. aeruginosa (Figure 3.4). It was 
shown to have higher activity with a more labile linker, such as an ester versus 
an amide.46 In addition to pyoverdine, the Miller group recently published a 
synthetic mixed ligand-daptomycin conjugate that is potent against MDR A. 
baumannii strains both in vitro and in vivo. Daptomycin (68) is a Gram-positive 
antibiotic that binds to bacterial cell membranes, disrupting their function. It 
causes rapid depolarization of the membrane, subsequent ion efflux, and 
disruption of DNA, RNA, and protein synthesis ultimately leading to cell death.42 
Because of its large molecular weight and polyanionic character, it cannot 
permeate Gram-negative bacteria and get inside the cells. However, by attaching 
it to a fimsbactin-like mixed siderophore (one that A. baumannii naturally 
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produces), they were able to smuggle the antibiotic inside the bacteria to the 
target inside the cell wall (and not the cytoplasm).  
a.    
 
b       
 
Figure 3.4 a) Pyoverdine-linker-antibiotics 66 and 67 b) mixed-ligand-daptomycin 
conjugate 68 
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As of 2016-2017 there were three main Trojan Horse complexes in clinical 
development. These siderophore-based compounds are: Pfizer agent MC-1 - 
siderophore-conjugated monocarbam, Basilea agent BAL30072 - siderophore 
monosulfactam, and Shionogi Pharmeceuticals S-649266 - a catechol-
cephalasporin drug (Figure 3.5). There is currently no clinical trial information on 
MC-1 available, but S-649266 is in Phase three clinical trials with patients having 
carbapenem- resistant pathogens, regardless of the primary infection area.44,47,48 
Basilea’s BAL30072 unfortunately was abandoned after years of early stage 
development due to elevated liver enzyme levels in Phase 1 as well as the 
company claiming the drug to be “lacking overall”.49  
 
 
Figure 3.5 Trojan Horse complexes that are/were in clinical trials 
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3.3 Pre-acinetobactin as a Trojan Horse 
Because of the rise in MDR A. baumanii, it is important to explore new ways 
to kill the bacteria and avoid resistance. The Trojan Horse strategy is becoming 
popular among chemists as seen in the various complexes that are in 
development.44 Through this method, the bacteria’s iron transportation pathway 
is utilized by attaching a warhead onto a siderophore, like that of sideromycins. 
This warhead is usually an already known antibiotic (that bacteria is currently 
resistant to), which in turn is smuggled into the bacterial cells. Just like other 
bacteria, Acinetobacter baumannii secretes various siderophores, which consist 
of fimsbactins A-F, (pre)acinetobactin, and baumannoferrin A-B (Figure 3.6).50  
 
Figure 3.6 A few siderophores secreted by A. baumannii 
 
It is thought that bacteria make multiple siderophores for different reasons such 
as scavenging ability for iron bound by different types of proteins or so the 
bacteria can evade the host immune respons.51 It wasn’t until 2009 when Walsh 
and co-workers concluded that there are two forms of acinetobactin, pre-
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acinetobactin (72) and acinetobactin (75) (Figure 3.7).52 They are mixed 
siderophores containing a catecholate and hydroxamate moiety. They are unique 
and unlike many other siderophores, in that they isomerize nonenzymatically into 
each other when pH levels change, proven by Wencewicz’s group, allowing them 
to be more versatile iron chelators and in turn be transported down the BauA 
pathway.53 At a pH of 5.5-7.5, pre-acinetobactin serves as the favored 
siderophore, but at a pH of 7.5 or greater, it is acinetobactin.  
 
Figure 3.7 Proposed mechanism for the isomerization of pre-acinetobactin to 
acinetobactin.53  
 
 It was shown that if acinetobactin-(Fe III) complex was in a more acidic solution 
(pH=5.7), the complex was not stable and reverted back to pre-acinetobactin 
(72). 53 The exact mechanism of where isomerization occurs is still not fully 
understood, but has been proven to isomerize in the extracellular space and 
could possibly isomerize in the cytoplasm as well. What we do know is that either 
pre-acintobactin is biosynthesized inside the cytoplasm and excreted through the 
BarAB efflux pump (Figure 3.8). The siderophore (which is dependent on the 
acidic or neutral conditions) then sequesters iron(III) and makes its way down the 
BauA outer membrane receptor and TonB/ExbB/ExbD complex into the cell. It is 
then transported down the BauB periplasmic siderophore binding protein and 
then the BauCDE inner membrane transporter to end up in the cytoplasm. From 
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there it is thought that the hydrolase BauF aids in the release of the iron (Figure 
3.8).53 It is still not fully understood how BauF works or what exactly happends to 
the isomers intracellularly, but it has been found to be similar to V. cholera ViuB, 
which is proposed to be an esterase needed to release iron from the siderophore 
intracellularly in the cytoplasm.54 Some have even proposed that in bacteria, 
once Fe(III) is reduced to Fe(II), the siderophore no longer has the high affinity 
for the Fe(II) resulting in dissociation from the complex.55 
 
Figure 3.8 Model of pre-acinetobactin 1a (72) and acinetobactin 1b (75) siderophores 
being secreted, sequestering iron, and being smuggled back into the bacterial cells. 
(Reprinted (adapted) with permission from Shapiro, J. A.; Wencewicz, T. A. 
Acinetobactin Isomerization Enables Adaptive Iron Acquisition in Acinetobacter 
Baumannii through pH-Triggered Siderophore Swapping. ACS Infect. Dis. 2016, 2 (2), 
157–168. Copyright 2016 American chemical society)53 
 
Three groups have previously synthesized pre-acinetobactin, but currently 
there are no published results of an attachment of a warhead, nor a crystal 
structure of it bound to iron to aid in SAR studies.53,56,57 The closest thing to pre-
 153 
acinetobactin bound to iron is anguibactin chelating to Ga+3 where instead of an 
oxazoline ring like that of pre-acinetobactin, there is a thiazole ring (Figure 3.9). It 
is noticeable that one of the nitrogens on the imidazole ring is away from the site 
of chelation. This could imply that by adding an R group there, the iron binding 
affinity would not be affected. It has also been reported that the addition of a 
methyl group at the N1 position of pre-acinetobactin does not affect the iron 
binding affinity.45 Using this, as well as previous studies on key elements 
affecting iron binding, we are able to speculate the best placement of substituent 
centers.  
 
 
Figure 3.9 Chemdraw of Anguibactin 76 and its crystal structure  (in methanol) bound to 
Ga+3 
 
 The overall goal of this project is to synthesize pre-acinetobactin analogs 
that connect the siderophore and a warhead through a covalent linker (Figure 
3.10). We posit that the analogs will inhibit A. baumanii bacterial cells, thus killing 
the bacteria. The stages of the project are as follows: synthesize linker-
containing pre-acinetobactin analogs, perform iron binding studies and A. 
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baumannii growth promotion assays, synthesize the warhead containing pre-
acinetobactin analogs, and then finally test inhibition into the bacterial cells.  
      
 
Figure 3.10 Siderophore-Linker-Warhead for the Trojan Horse strategy 
 
3.3.1 Synthesis of linker-containing pre-acinetobactin analogs 
The first step is to synthesize pre-acinetobactin analogs, which include a 
linker on the imidazole ring. Two different types of analogs are to be made, one 
with the linker of choice on the C2 atom of the imidazole ring and one with the 
linker of choice on the N1 of the imidazole ring (Figure 3.7). As stated previously, 
groups have recently shown that substitution (methyl group) on each of these 
atoms do not affect the iron binding and do not affect its growth promotion.45 To 
stay consistent with accomplished studies, the succinyl linker will be used, similar 
to that of Wencewicz et. al, which allowed iron binding to still occur.58  
 The retrosynthesis begins with the pre-acinetobactin analog, which is 
obtained from coupling two major fragments, the oxazoline ring 80 and imidazole 
(86 or 87). Oxazoline 80 is acquired through a cyclization with benzyl protected 
L-threonine and imidate 79. The imidate comes from nitrile 78 using acetyl 
chloride in methanol, which is previously obtained from 2,3-
dihydroxybenzaldehyde 77. The imidazole fragment can have two pathways, 
depending on the desired analog. For substitution at the N1 (86), the pre-
acinetobactin will be obtained from aldehyde 84, whereas substitution at the C2 
Linker WarheadSiderophore
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(87) will be obtained from an α-hydroxyketone 85. From there, they can both be 
synthesized from tert-Butyl-N-(benzyloxy)-N-(but-3-enyl)carbamate 83 and then 
tert-butyl-benzyloxycarbamate 82.  
 
 
Figure 3.11 Retrosynthesis of pre-acinetobactin analogs 
 Three groups have recently reported the forward synthesis of pre-
acinetobactin. However, two of these three groups do not protect the 1,2-
dihydroxybenzaldehyde, lowering the number of steps that are needed to 
complete the synthesis. Therefore, conditions were adopted and put forth in the 
synthesis. Unfortunately most of the conditions were not optimized, so time was 
spent on improvement of the reactions, specifically for the oxazoline ring. The 
oxazoline fragment was synthesized starting from 2,3-dihyroxybenzaldehyde as 
seen in Scheme 3.1. In formic acid, 2,3-dihydroxybenzaldehye (77), sodium 
formate, and hydroxylamine hydrochloride were reacted under reflux. 
Unfortunately, the literature did not give equivalents for the procedures, so 
optimization was necessary. For the first trial, a 0.5M concentration of 
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benzaldehyde 77 in formic acid was used, but upon workup it was found to be 
very difficult to neutralize. A decent crude yield was obtained (65%), but 
conditions were altered. Second trial consisted of just added enough formic acid 
to dissolve benzaldehyde 77, which proved to be a much better approach (94% 
crude yield). Workup was much easier in the end to obtain the nitrile (78). Once 
nitrile was in hand, the imidate (79) was synthesized using acetyl chloride in dry 
methanol. Many attempts were done to find the best conditions, especially if dry 
methanol was necessary. When regular methanol was used, it was found to have 
a very low yield (36% crude) when compared to that of dry methanol (56% and 
74%). Also, since the reaction generates HCl gas in situ, it was found that using 
a nitrogen filled balloon fitted to a septa was best in collecting the gas during the 
48 hour time period. After it was proven that the imidate was obtained, the last 
step of the synthesis for the oxazoline ring was performed. Through a benzyl 
protected L-threonine:oxalic acid in dichloroethane the ring (80) is formed with 
the correct stereochemistry in a low 21% pure yield.  
Scheme 3.1 Synthesis of oxazoline (80) fragment 
 
 
 Once the oxazoline fragment is obtained, the substituted imidazole (86) 
was synthesized (Scheme 3.2). Most of this synthesis was followed by previous 
literature procedures, but since we are trying to obtain a substituted imidazole, 
the last two steps will be different, depending on which substitution we will need. 
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Both types of analogs begin with the synthesis of tert-butyl benzyloxycarbamate 
82 in large quantities. O-benzylhydroxylamine hydrochloride (81), di-tert-butyl 
dicarbonate, and sodium bicarbonate in dioxane were reacted to give the 
Boc/benzyl protected hydroxylamine 82 in a 72% pure yield. The hydroxylamine 
was then subjected to 4-bromo-1-butene in sodium hydride in DMF to yield tert-
butyl-N-(benzyloxy)-N-(but-3-enyl)carbamate (83) in 86%. 
Scheme 3.2 Synthesis of 83 
 
After obtaining about a gram of the butenyl carbamate 83, a portion of the 
material (500 mg) was used to attempt in synthesizing the imidazole fragment 86 
with substitution at the N1 position (Scheme 3.3). Aldehyde 84 was obtained (in 
very poor yield, 22%) after alkene 83 was subjected to oxidation using osmium 
tetroxide and sodium periodate in water and dioxane. The low yield could be due 
to various reasons such as concentration of catalyst, scale size, and time. After 
doing this reaction on various scales, 50mg (crude 70%), 200mg (crude 57%), 
and 500mg (22%), it seems that the smaller the scale, the better the yield. Future 
studies could consist of trying to find a different method to obtain the aldehyde, 
such as ozonoloysis, in order to improve yield. Even though ozonolysis has been 
done in our lab numerous times, it was not done to obtain this molecule, simply 
because we wanted to stay consistent with the literature. Although it was low 
yielding, we were still able to obtain the aldehyde and attempt the imidazole 
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formation through the use of TosMic and a desired amine. In the end we 
ultimately would love to be able to use an amine where the succinyl linker is 
implemented, but before doing so we wanted to make sure we were able to get 
the reaction to work. We decided to use beta-alanine methyl ester, because it 
has a two carbon chain away from the imidazole ring and has a carboxylic acid 
functionality at the tail end, which will be needed to couple the antibiotic warhead. 
Unfortunately, the first attempt at making the ring was unsuccessful. The 
literature that was followed used methylamine (which is in a liquid form), whereas 
the beta-alanine methyl ester is a hydrochloride salt (Scheme 3.3). We believe 
that the amine needs to be activated so that the imine can be formed and react 
with the TosMic. It has also been proven in literature other than the one we were 
following, that a weak base is necessary to activate the TosMic and allow it to 
react with the imine to form the imidate. So, the second attempt we reacted one 
equivalence of potassium carbonate with the beta-alanine methyl ester in 
methanol and then after a half hour slowly added the TosMic. It is still 
undetermined if the product was formed, since there was no purification done 
due to time restraints and TLC does not seem to have changed. If we can get 
this reaction to work and obtain the substituted imidazole, we could then move 
forward to perform deprotections and coupling of the two fragments.  
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Scheme 3.3 Synthesis of substituted imidazoles 
 
 
 The milestone attained for this project was completing the synthesis of the 
oxazoline fragment, as well as attempting to synthesize imidazole 86. Although 
86 needs to be optimized and it was not actually obtained, it is safe to say that up 
to this point has been successful. Goals to follow obtaining the imidazole 86, are 
to complete the pre-acinetobactin synthesis (containing linker). First, obtaining 
the methyl ester linker on 86 is priority. Once that reaction is optimized, obtaining 
the imidazole with a succinyl linker for the desired conjugates are to follow. Once 
the imidazole is in hand, the imidazole fragment would be deprotected using TFA 
to give the benzyl protected amine 89 and the oxazoline fragment would be 
deprotected using hydrogen and palladium to give free carboxylic acid 90. Once 
deprotected, the two fragments would then be coupled using EDC and HOBt with 
triethyl amine in DMF (Scheme 3.4). The methyl ester then needs to be 
hydrolyzed into the carboxylic acid so it can coupled to the antibiotic warhead 
giving you the amide. Depending on the warhead being used, a global 
deprotection can then be done to give you the unmasked pre-acinetobactin 
analogs.  
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Scheme 3.4 Deprotection and coupling to obtain pre-acinetobactin analogs 
 
 
3.4 Strategies for testing 
There are many steps that need to be taken once the analogs are in hand. 
Before the warhead is even coupled to the linker, there needs to be preliminary 
tests first. For instance, it is necessary to explore whether or not the linker of 
choice is impeding on the siderophores chelation properties. In order to do that, 
though, iron-binding studies must be performed first. If the iron binding studies 
are successful, then growth promotion assays need to be done. If the affinity for 
iron has not changed, then the bacteria should still grow when the siderophore is 
present. It is at this point that the warhead can be coupled to the linker and 
tested for inhibition against A. baumannii.  
3.4.1 Iron binding studies 
Because iron-binding affinity of sideromycins is critical in the transportation 
of the warhead into the cell, it is important to do iron-binding studies before 
attaching the warhead onto the compounds. This will allow us to see if the linker 
is obstructing the chelating moieties from functioning properly. To remain 
consistent, we plan to follow recent literature.58,59 Wencewicz et al., as well as 
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others, has performed specific iron binding studies, which utilize optical 
absorbing spectroscopy and chromeazurol (CAS) colorimetric agar diffusion 
assay.58,60,61 This particular test uses Chrome Azurol S as an indicator, which 
when metal complexes are formed, gives off color. The assay is based on 
competitive exchange of iron(III). Therefore, chelators are detected based on 
their affinity for the metal; if it is a strong chelator then it will act in a 1:1 ratio, 
whereas the weaker chelators will need to be present in excess (needing higher 
concentrations).61 Ultimately for our studies, if color is observed, then the 
substrate is chelating to iron to form iron(III) complexes and can be used in 
further assays. If no color is observed, then the siderophore is not chelating to 
the iron, which could be due to the linker, since we are comparing to pre-
acinetobactin. 
3.4.2 Growth promotion assays 
If a siderophore has significant iron binding, then it will have a higher 
chance to promote growth (due to utilization of the iron transportation pathway). 
Taking the analogs that proved to have iron binding affinity (observed color), we 
will then test for growth promotion in A. baumanii. Assays using UV-Vis for 
optical absorbance of the bacterial growth will allow us to detect which pre-
acinetobactin analogs are being utilized by A. baumannii to promote growth.58 If 
growth is promoted, which will be visualized using growth curves, then that 
means the molecule is getting inside the bacterial cells and there is possibility 
that we can attach the warheads and smuggle antibiotics in for cell death.  
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3.4.3 Synthesis of warhead-containing pre-acinetobactin analogs 
Once growth-promoting analogs are determined, we will then need to 
synthesize the warhead containing pre-acinetobactin analogs. Derivatives of pre-
acinetobactin will contain either periplasmic or cytoplasmic warheads on either 
the C2 or N1 position of the imidazole (Figure 3.12). Ultimately, we expect the 
periplasmic warheads to have activity, since we know from previous studies that 
they are able to achieve cell death.58 Cytoplasmic antibiotics, on the other hand, 
have been proven to not be effective, due to the molecule not making it into the 
cytoplasmic space (which could also be due to the nature of the linker). This 
could be due to the fact that the study was done on a mixed-ligand siderophore 
that mimics the fimsbactin-iron(III) complex, not acinetobactin-iron(III) complex. 
Because pre-acinetobactin has yet to be tested using a warhead, we will develop 
both types of Trojan horse analogs to see which has the best outcome. 
 
Figure 3.12 Pre-acinetobactin Trojan Horse analogs 92 containing loracarbef in blue 
(periplasmic antibiotic) and 93 containing ciprofloxain in red (cytoplasmic antibiotic) 
 
3.4.4 Inhibition studies 
With warhead analogs in hand we will then test its potency. We will find the 
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then find the antibiotic susceptibility by performing a modified Kirby-Bauer 
Diffusion assay, also developed by Wenciwiec et al.58 
3.5 Summary 
Due to the rise in antibiotic resistance, it is imperative that new alternative 
options are explored. MDR A. baumannii is becoming more prominent and is now 
a large threat to our society. By developing new antibiotics that use the bacteria 
against themselves, we may be able to overcome resistance and save many 
innocent lives. Although acinetobactin analogs have not yet been attained in our 
lab, we are eager to see where the project leads us. Once analogs are in hand, 
testing can be done to see just how potent the sideromycins may be. We are 
hopeful that our acinetobactin analogs can help in the antibiotic crisis that our 
world is currently in.
3.6  Experimental 
3.6.1 2,3-dihydroxybenzene-nitrile (78) 
 
A stir bar, formic acid (6 mL) and 2,3-dihydroxybenzaldehyde (1.00 g, 7.25 
mmol) were added in a 100 mL RBF. Sodium formate (0.641g, 9.43 mmol, 1.3 
eq) and hydroxylamine hydrochloride (0.655 g, 9.43 mmol, 1.3 eq) were then 
added and the mixture was refluxed for 5 h, over which time the solution turned 
eventually turned purple (opaque). It was then diluted with ice water (50 mL) and 
neutralized to 7 (using pH paper) with solid sodium bicarbonate. The mixture was 
extracted with Et2O (3 x 50 mL), dried using sodium sulfate, and concentrated 
under reduced pressure to yield a dark orange/red solid in 94% (923.3 mg) crude 
yield. The 1H NMR of the isolated material was similar to that reported in the 
literature.53 Rf 0.24 (hexanes:EtOAc, 60:40); 1HNMR 400 MHz, (DMSO-d6)  
(ppm) 10.5-9.75 (br.s, 2H), 7.04 (dd, J = 7.9, 1.6 Hz, 1H ), 7.00 (dd, J = 7.8, 1.4 
Hz, 1H) 6.75 (dd, J = 7.9, 7.9 Hz, 1H), 13C (100 MHz)  (ppm) 149.2, 145.9, 
122.6, 120.0, 119.7, 117.1, 99.4 
  
OHHO
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3.6.2 2,3-dihydroxybenzeneimidate (79) 
 
 In an 8 dram vial, pure nitrile (1 eq., 0.137 g, 1.0 mmol) and a stir bar were 
added. The vial was equipped with a septum and methanol that had been dried 
over sieves, (48 eq, 1.96 mL) was added with a syringe. Nitrogen was flushed 
through the flask, followed by an addition of a nitrogen filled balloon using a 
needle. Acetyl chloride (36 eq., d= 1.1 g/mL, 2.85 g, 2.6 mL, 36.35 mmol) was 
then slowly added dropwise using a 3 mL syringe, and using an ice bath to 
control the exothermic reaction. The ice bath was removed after the addition of 
acetyl chloride. After 1.5 hours, the balloon deflated and reaction mixture turned 
from tan to peach/orange. The reaction was allowed to stir and after 48 h at room 
temperature, the solution was a milky peach color. 10 mL of water was added to 
mixture and it was, transferred to a 125 mL Erlenmeyer flask, where the solution 
was neutralized by the addition of solid sodium bicarbonate (went from milky 
peach to green to purple when adding solid NaHCO3 (pH paper indicated neutral 
when solution turned purple). After, the solution was extracted with ether (3 x 20 
mL), the organic layers were pooled together, washed with brine (20 mL) and 
dried over sodium sulfate and evaporated under reduced pressure to yield a 
crude tan powder in 74% (124.6mg). Rf 0.15 (hexanes:EtOAc, 60:40); 1HNMR 
(400 MHz, DMSO-d6)  (ppm) 9.04 (s, 1H), 8.70 (s, 1H), 7.12 (dd, J = 8.1, 1.2 
Hz, 1H), 6.84 (dd, J = 7.6, 1.5 Hz, 1H), 6.55 (dd, J = 7.8, 7.8 Hz, 1H), 3.87 (s, 
3H); 13C (100 MHz)  (ppm) 165.9, 149.2, 145.9, 122.6, 120.0, 119.7, 99.4, 53.2  
OHHO
OMe
NH
 166 
3.6.3 Benzyl protected oxazoline (80) 
 
 In a 100 mL RBF equipped with a stir bar, pure imidate 75 (1 eq., 0.108g, 
0.647 mmol) was refluxed in 1,2-dichloroethane (15 mL) with O-benzyl-L-
threonine: oxalate (1 eq., 0.194 g, 0.647 mmol) for 12 hours. The reaction 
mixture was cooled and the solvent was concentrated under reduced pressure. 
Then, to the mixture was added a 5% citric acid solution (15mL) that was 
extracted with ethyl acetate (3 x 30 mL). The combined organic layers were 
washed with water (30 mL) and brine (30 mL) and dried over sodium sulfate. The 
solvent was then removed under reduced pressure to deliver a yellow/brown 
oil/solid that was subsequently purified using column chromatography (0% à 
40%, EtOAc/Hexanes) to give an oil in 21% yield (44.7 mg). Rf 0.61 
(hexanes:EtOAc, 50:50); 1HNMR (400 MHz, CDCl3)  (ppm) 7.36-7.39 (m, 5H), 
7.22 (dd, J = 7.9, 7.9 Hz, 1H), 7.08 (dd, J = 7.6, 7.6 Hz, 1H), 6.8 (m, 1H), 5.24 (d, 
J = 1.48 Hz, 2H), 4.99 (ddd, J = 12.8, 6.3, 6.3 Hz, 1H), 4.54 (d, J = 7.2 Hz, 1H), 
1.16 (d, J = 6.6 Hz, 3H); 13C (100 MHz)  (ppm) 170.2, 167.3, 147.6, 144.9, 
135.2, 128.8, 128.7, 128.2, 119.1, 118.9, 118.4, 78.8, 73.5, 67.4, 52.4, 18.2 
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3.6.4 tert-butyl benzyloxycarbamate (82) 
 
 
To a 25 mL flask equipped with a stir bar, O-benzylhydroxylamine 
hydrochloride 81 (1.00 g, 6.23 mmol, 1 eq.) was added followed by the addition 
of dioxane (7 mL). Thawed/melted di-tert-butyldicarbonate (1.33 mL, 6.23 mmol, 
1 eq.) was then added through a 3 mL syringe followed by a 1M solution of 
sodium bicarbonate (6.23 mL, 6.23 mmol). Gas evolution was observed and the 
mixture was left to stir overnight. A 1 M solution of citric acid was added until pH 
was approximately around 4 to pH paper. The solution was then extracted with 
DCM (3 x 30 mL), the combined organic layers were pooled, dried over sodium 
sulfate, and the solvent was evaporated. To the residue was added 20 mL of 
hexanes, which was then evaporated under reduce pressure. Then the residue 
was left on the high vacuum and finally put in refrigerator (1 day). A white solid 
was obtained in 72% yield (1.00 g). Rf 0.3 (hexanes:EtOAc, 90:10); 1HNMR (400 
MHz, DMSO-d6)  (ppm) 7.34-7.38 (m, 5H), 4.73 (s, 2H), 1.41 (s, 9H); 13C (100 
MHz)  (ppm) 156.1, 136.1, 128.6, 128.2, 128.0, 79.6, 77.1, 28.0   
 
  
Boc NH
OBn
 168 
3.6.5 tert-Butyl N-(benzyloxy)-N-(but-3-enyl)carbamate (83) 
 
 
 
To a 25 mL dry 2-necked flask equipped with a stir bar and carbamate 82  
(1 eq, 0.438g, 1.96 mmol), dry DMF (5mL) was added with a syringe. The flask 
was fitted with two septums and purged with nitrogen for a few minutes. NaH (2 
eq., 60% dispersion, 0.157g, 3.92 mmol) was added at 0 °C in two portions  at 
which point evolution of gas was observed. The solution was stirred for 30 
minutes and then 4-bromo-but-1-ene was slowly added dropwise (at this point 
solution turned milky grey from clear). The solution was slowly raised to rt and 
stirred for another 2 h. The reaction mixture was then quenched slowly with cold 
water (10mL) and diluted with 30 extra mL of water. It was extracted with diethyl 
ether (3 x 20 mL), washed with brine and dried over sodium sulfate. The solvent 
was evaporated under reduced pressure and purified using column 
chromatography (5% EtOAc/Hexanes) to yield 84-86% of a clear oil (456.8 mg). 
Rf 0.61 (hexanes:EtOAc, 90:10); 1HNMR (400 MHz, CDCl3)  (ppm) 7.39 (m, 
5H), 5.8 (dddd, J = 17.5, 10.5, 7.0, 7.0 Hz, 1H), 5.10 (dd, J = 17.3,1.5 Hz, 1H), 
5.05 (dd, J = 10.4,1.3 Hz, 1H), 4.87 (s, 2H), 3.51 (ddd, J = 7.2, 7.2, 0 Hz, 2H), 
2.38 (dddd, J= 7.2, 7.2, 7.2, 7.2 Hz, 2H), 1.53 (d, 9H); 13C (100 MHz)  (ppm) 
156.6, 135.7, 135.3, 129.4, 128.5, 128.4, 116.7, 81.2, 76.9, 49.3, 31.5, 28.3 
 
  
BocN
OBn
 169 
3.6.6 tert-Butyl benzyloxy(3-oxopropyl)carbamate (84) 
 
 
 
In a 100 mL round bottom flask containing tert-Butyl N-(benzyloxy)-N-(but-
3-enyl)carbamate 83 (1 eq., 0.533 g, 1.92 mmol) and a stir bar, 1,4-dioxane/H2O 
(7 mL/ 2.4 mL) was added. Osmium tetroxide in H2O (4% in H2O, 1 mol %, 0.13 
mL) was added at rt, which at this point the mixture turns from clear to brown. 
After 30 minutes NaIO4 (3.5 eq, 1.44 g, 6.73 mmol) was added slowly (turns 
milky brown/purple) and stirred for 2 hours. The reaction mixture was quenched 
with a 0.2M sodium thiosulfate solution (50 mL) and extracted with EtOAc (3 x 25 
mL). Organic layers were combined, washed with brine, and dried using sodium 
sulfate. Solvent was evaporated under reduced pressure to yield 70% (364.5mg) 
grey/brown crude material. It was then purified using column chromatography 
(0%-30% EtOAc/Hexanes) to yield 22% (118.2 mg) as a grey oil. Rf 0.42 
(hexanes:EtOAc, 70:30); 1HNMR (400 MHz, CDCl3)  (ppm) 9.76 (s, 1H), 7.37 
(m, 5H), 4.83 (d, 2H), 3.78 (ddd, J = 6.3, 6.3, 0 Hz, 2H), 2.67 (ddd, J = 6.7, 6.7, 
1.8 Hz, 2H), 1.52 (s, 3H); 13C (100 MHz)  (ppm) 200.6, 156.6, 135.3, 129.6, 
128.7, 128.5, 81.9, 77.0, 43.8, 41.5, 28.7 
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